var title_f33_17_34064="Tetrahydrozoline: Drug information";
var content_f33_17_34064=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"10\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Tetrahydrozoline: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block inc\" id=\"F12618096\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12618097\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/18/24867?source=see_link\">",
"       Tetrahydrozoline (nasal): Drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/21/19795?source=see_link\">",
"       Tetrahydrozoline (ophthalmic): Drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10280 Version 26.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-221.179.173.170-9A4DD99832-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_17_34064=[""].join("\n");
var outline_f33_17_34064=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?24/18/24867?source=related_link\">",
"      Tetrahydrozoline (nasal): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?19/21/19795?source=related_link\">",
"      Tetrahydrozoline (ophthalmic): Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_17_34065="Ruptured papillary muscle post myocardial infarction long axis";
var content_f33_17_34065=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/77752/papmuscr_conv.mp4?title=Ruptured+papillary+muscle+post+myocardial+infarction+long+axis\" style=\"width:320px;height:256px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ruptured papillary muscle after a myocardial infarction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 287px; height: 431px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGvAR8DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5hnGJ5QQQQ5zTABU18f8ATJ/98/zpkEUk80cUEbySuwVEQEsxPQAdzSAaQKMCt3VvCWu6TYNeajps0FspAZyQdpPQEA5HXvWFUwnGorwaa8ipwlB2krAQPSgAVNZWs99dRW1nE89xKdqRoMlj6AVFIjxSPHKpV0JVgeoI6iqur2JtpcTA9KML6VdstKvb2xvry1h8y2sVV7h9yjYGOBwTk8+mao54pJptpPYbi1ZvqBA9KXAxSd6M1QgwKXA9KQ0dO9ABgelAA9KKKADANGBR1ooAXApMD0pVUsyqoJY8AAZJp4hkNx5GxhNnbsIwc+lICPA9KNozUtxby2wUzLtDdOQc/lUXWgAIFLhfSkoNMAIHQClAHpSUUALgYpMCiigBcD0owDSUUALgUED0pB6UtIAwKNopB9aM0ALgYoCr6UmaKYAQADUZ+9Uh6VEfvUAW9YAh1W8iVt4SVgGxjOD1xV7wbdXFt4o02azltYbiOYNG9222IH0Y9gemfeqXiBSut36sMMJ3BH41QqZx54uPcqEuWSl2PYvGD6Xb6RcazdabZaV4hF1HIlvb6gtzHfjeGYuikgL1PI64qx4pi0LSpdJaxtLKdPEN9FqPlz7Y1jt9qnyyxHyBnLe2BjHFeK1e1fVr7V54ptRuGnkiiWCMkABUXooAGABk156wDTiubRX7+Vlu3o1fc7njU0/d107fP71pse4ajf2Gn+K/DN491aWxa9ZWtZ0tS1vGVIyJIeNmTgbue+eDWSrXf2rxF5aaGvinfGbLd9m2tbb3yUz8m8jrnnGK8XopRy1RXxfh5377dH3HLHtvb8fK339ux7JrN3o0Nt4zitZrJJJbGyE6WrqEecPmURAcHHt3zWh4ufR28Paomm2thPoxtA1nMk9sgicKCNo/1xcnIIOc814XRTWXWafNt/kl38vxF9fumuXf/Nv9R/mH0o8w+lMor0jzx/me1HmH0plFAD/M9qPMPpTKACe1AD/MPpTkYscAVHtPpVi0XEnzigDo/Dgj0+5FwUWe7HEY34VCe57k/pUOvAx6ol2sSx3JbeV35Vsfr+dJatsZRE6qSM9s/TirkMVsoikvjHHCSRhcbuvXvSA5+9vZLuNEkVFCnPy55qsAM1dvIFd3kiwBnAXAGfpVLvTAOaKKSgApe1Nk3BNw6Zxmt+TwX4hTwNH4vay/4kEk/wBnW43rndkrnbnOMgjOOtAGD1oqeXTdThs7e7lsbuO1uTtgmaFgkp9FbGCfpWlp3hHxJqNlqN3Z6TdyQacgkuWKbSgLbeAcFjnjABIoAxqKsz6Tq0Gmx6jPp17HYSY2XL27CJs9MORg/nVDe3rQBP2opO9HSgAooooA0NF0e/1u7a20u3a4nVS5RSAdo6nk1c1LwtrOmWkl1e2ZjgjOHfzEbB/An1rq/gL/AMjvN/15Tf8AoNdF8SWd/B196rIgbaT04/8ArUAeLEgjIqM/epyfdNNP3+aANDxOSfEOpFl2sbiTIznHzGsytXxV/wAjLqn/AF8yf+hGsqgAooooAKKKKACiiniPIzmgBlFP8s+tHl+9ADKKf5fvR5Z9aAGU+PpR5fvUiKqxsCGLnG0g8D6jvQBOiJ5asrF5T1QL0Hrn/wCtSAhhwpBHvmolJB604vk+9AFiCVoyCV75DNnirQlDgB5FGefkXmswE1IzLkHv+FIC00AY4Vwe/WqssLKSdvFPjnZHBBOPU81JPdGaIKQgwc7gMGgClQakdQRkZz3xUdMBsrERbexYE/hn/Gvb5fi34Uk8P3vhU6HqK+Hn0SPTIrkMPPM0fzrK0O/yx++Z2yGzjH0rxKtFoY7KyzcIHup1+RD/AMs0P8R9z2/P0pN2NKdJzu9kt3/Xfoeq638XNGvtMuRFbasbjUH0zzrOXZ9lsBaFcm3+bJL7cYIXG48mmP8AGKO+17x2dR1LxMmk62hTTjDKGlsgJQ6qEMgVQRkHa3Ge+a8copmZ7FffE/w03wrvvDVja6tHdXemW1oY5Y0kjWaJ1Zn80yFypC8LtAXoB6eKVZooAMUCiigA70UGjvQB6H8DJkg8ZTvK21BZyjOM8kYH6mrnjaeN/DV2BwSydcjdz/n8q5n4dSyQa5M8TEMIG/GtLxQ6yeHpz5i5DrjJ6+w/OkBwS/d56U0/e9qcv3ab/HTA9c+D2jaZrPxb1HSNb0i21SzkW5YmbzAY2jVmUqUYYyQAc546Y61b8IfDXw/4ni8Mzald6hpmo+KrjUI7W1soFNvaPA2cNvYvtwQAOT6kYyeFXUPEln4z1ePwjd6xBezTSB10uSRZJFDE8iM5IFV4rzxrLeNcxXHiN7rS5ZZ2lV5y9pJKcyOT1RnOSx4J75oA9LT4ZeG9euPh1YaSdQsLnWdMN3eXDL5iy7FlZtoLf6wmPAUYGOeuRVa9+F3hSC31PUhr2pnSrHT47uVIYEmmSQziNo8kor9QQQRjPPTnzZbjxWujWoWXXBpNiyz2+Gl8i3Zidrp/CpJzgjGea1fGQ+IFhd3Fr4qu9feWa1RpxcXck6vAcOoZgxBUEqcE8Hrg0AdDJ8M9JfwCfGNtqtyNGayIj85UVxfef5QhbsF2/OSOcZrpNa+CehWGt6fosev3h1I6lbWVyGiXDxy8GWMAfJgkYDE5BzntXj0EXiO408aNbx6vLYmVLkWKCRo/MYbVk8scbiOA2MnpV281zxpZWFgt5qniK3sreU/YxLcTJHFJGcHy8nAZTxxyKAPXPBfwt8F3uv6FIZtY1HTrm71HTZ7a5RYi89vA0gdTG+QuASBknIAPGa5qz8EeG7fT/CWpte6uJ9d1KS2s7WeziZAI7iNMzZcY+V+gDZPHA6+aQeIdatzCbfV9RiME7XURS5dfLmbhpFweHI6sOTU914g1m9ktpbvVtQuJbaVriF5bl3MUrMGZ1JPysWAJI5JANAHp+t/DzSLJtY1DUm1e583xBe6VawaLaIRD5Tn5nXtnIxGMcDg0l98JYtNl1u4ea9ey06wsL6GWSHEdw07Rhkz0wNzdPSvNrTxRr9nJfSWmuapA98zPdtFdyKbgtncZCD8xOTknOc0r+KfED6etg+u6s1isYiW2N5IYwgIIULnGAQCB6gUAe4z/AAm0TXviH4kinS60rTRrP9mWTWnlrEshjVtgTBYkZB6KMfxenm/jbwXo3hbwtpd1LqWoT6zqCStFCtuggAjnaNizltwyFyAFPPeuatfGHia0uLqe18RazBNdSCW4kjvpVaZx0ZyGyxHYnmqVzrGpXX2c3eoXk/2cMIfMnZvKDEs23J4ySScdSaAKSMVjdcL84wcqD+RPT8KYBSnBOe5pR1oASkqVBk4f7v61Gw5OAcUAIKX60h/SgUgF9aXnIxzinRxs/IHy9CavaRaQ3F08dzdJbRgHDsDyewxQA6zEYgIKl5ieDngVTmt5N7YXOOTgVuqdlpJLJbzSWyMUjcgonbBPUdD0963fAsJYXFy7BkQeWpwAPU/0rOrU9lFyO7LcDLH4mOHi7X69kjjrGJLaH7bdoGXOIYm/5aMO5/2R39enrVKeV55nlmcvI5yzHua6TxqLO5vUlsJd+1djqo+QY6bf16cVzHfHpTpvmXO+oY6Cw9R4aDTUeq6vv/wOnrdtKKIxJLL5cMTyPzhVGSfwqPzfb9a0OEkoqPzfb9aniguZrWe5htZntrcqJpVQlI9xwu44wM4OM9cUAMo71H5v+zR5vtQBJRT7OC5vpvJsraa4l2l9kSF2wBknAHQAZNRqdyg0AdL4BwNYmB7wP/KrGvkHRpEI6MGBzWV4WkMWrq4yMIw468jFXdVcPpM3zMWwOD9aQHMr0ppxu5p69KYfv9qYHqfgfxpY+DfGvieTVGu/s16XgeOC1ScSDzNxDAyRsOnBVwR711uj/G3QrM3a21nq+lKmqS39rJEq3rujoq7ZPMkXDYXg5YAHGDjnxLxOM+JNU/6+ZP8A0I1mhFoA9+8T/EPRNJ8LabFZX15fX954OTShY28kZs7Z5Hfc8hDZWZABhdvHy8iqOofFfw5rGp38urHxI9pqugrpdzGojc2syiL54dz4ZWMZLE7Tz0NeIeWKNgoA9q1L4u6VHFro0Aa5Zy3em6VY2k3yJIn2WQGTcyvwGQEDHXOCADWb8VfijZeM9A1mwh/tVnuPEC6nafa9pWG2Fu0fl/fO07jnaOMd815PsWjYtAE8WqX0UaxpdS+WowqsdwA9ADVkarcEfOts/wDvW0ZP57c1n7BnpTqnkj2N1iqyVlN/ey//AGgjf6yws3/4Cy/+gsKPtVkzAPp6rk/8s5WH881RpWAXbhg2RzjPFHIh/WanWz+Sf6GzqEWk29zst01ABVBLOyqQT6KVzj3zzW94N0/Tr1r1nVrn5VUidQcZz0OevHWuHBOKliuJokdYpXRW+8FYgNj19azqUnKPLF2OvAZhDD141atNSSvpZLo16fgdT4j8OWFnuktL+GFh/wAsJX5/A9fz/OuVRtobIHI6+lTR+UyrnAbvnpVhbS3lJVZQnuTkfoKqnGUVaTuYY3EUsRU56NNQXZO/9fIhtlHliVyDHuCso+8fcVo3+ieR5YtpRdmYfuzBkg+xyAf51SurU2wMfmIUPK89ffFWLc38AEEdxtRTuwJQAKs4yCOyVZNt2PLIOCPT61bbRFmmBtJS1ucZfacJ9T1/Sr9jHqLNLILkh40LDe6nA+pOO9ZV5qL3MrzNOXdsfMRjPPTigB2t2celtFbxSidnUOZNuAPYZ5/lWXE+1wzc85ww3A/hV9r43CLDcJEIyeXVBu+vGCavDTZY2lttPshPPnPmTY3he3yZwvfkk9aG0tWVCEpyUYq7ZV1HWLvVLVILueWUK25dzcA47DtUX9o3AsEsY5fLthksFGNxJ/iPf+VdDpvgmdome+nWNyDtjj5IPbJ6flXOnSr7+K0df975f51kqtKbsnselUy7H4OKlKDjzprTe2m9tvmMgC+UxYszZwoHT6morlDjzMY7GrUemXSnDG3T/euY1/m1Elg5PzXdn/3+B/lmr549zj+q1usGvVWPSvgDrWieC4NZ8Vatq9tZ6gJYbCzhCCeUqXEkzeUCGClE2B+gLnnNdPFpfgO18Va+bG98KagtzrFvch9Suk8mPS5VLyrES2PNVjtx98ADA5rwY6ZDkltTs1z7SH+SU37BZj72pKf92Fj/ADxT51/SD6tPuv8AwKP+Z6udV8FeHdL0a80TTtEv5JNeuwZb0u9xb2aTIYXKK4IJXOCwPQ4710Pi668Jahr/AI+udbvNENndanpckD6ZeK7z2puZDO4Cud0mzBbAyOOBmvA57azSImG6mkk7KYAo/Pcf5VV8r3/SmncynBwdn+DT/I9E+MMVnHdJ/ZkXhFNO+1TCyOiTLJMbf5dnnbSccYxuw2d3aurlh+Hsvhjw9qEMmi2+p63LYWt1BJ840wwuwuZmjDAhZMR8HGQWwR1rxDyvf9KPK9/0pkH1DJL4I0nxDoV7p134bs7sW2rW11JZ3lvsdfs5ELMI22KWJIUdecZJFcF/xQX/AAqyx1mSOwGuXEEGlTWETAzQukzGW72ZyC0QUA9NzV435Xv+lPUbRjNAHv3xLh8GJpIPhS30QGO5U2dzY3cRle3MbZSSIEyHkKS0gBB4zg141qbv9hcfw5Gao6c5Sc46lSKmvHLWjD3HekBnjpUeMtUlRn79MDS15nfXNReZPKlNw5aPO7acnjPeqI9q0fE3/Ix6p/18yf8AoRrOFACg0lFAoAWiikoAKKUU7KeWcq3mZ4bdx+WP60ADCPyVKs5lzypXAA+uf6UyjpRQAUU6JDJIiLjcxAGTiuvs/A1ywzd3UUQ7hAXP9KzqVYU/idjtweXYnHNrDw5rb/0zjs4NO3HPWrWqx2kN7JFYyPLCny+Y5HzHuRjtVT8KtO6uctSDpycG727C7s9TTslsbjkfyplApkDs4z78YFGc9/1oUZ7HHtViKEq26WGXyx7Y/WkBNpoV3JmBwB8p68/kaS4ur5NQluFlnSVjw4c5wPelTVruE7beaSKNTlFDdPf68CpptZuLna1yEmYEHEnzLke2efxotfccZOLvF2Z0fhnUPEV+XFuv2qGJdzvJEflH1XqfbmsO60pLKdY7klFOQGf5fXqO3Toeanm8X6tcQLBJclIUTywsahfl6Y4xxjtVIXpvGImJ3gYXAHP4VMacYXcVY6K+Mr4mMY1puSjtfXf/AIYrrZmeaRLJXmVOcgH8/YVHLbiPhmBcdQK147lY/Kt438mPd+8dsEAHrhe5rIumUM3lMWBY4J6/jVHMVSM89qTFLk9KO9MBKSlNFACCilpKACiiigCWAhZQc4qadsxkZqsnWpJGO2gCGoz94VJ71GfvUAanib/kZNV/6+ZP/QjWeKv+IUaPX9SSR2kdbhwzsoUscnkgcD8KoUAFFKaKAD60lLTo3MbhgASP7ygj8jQAseATlQ2RjnPH5Uwjng8UDjpT87jk+lADAM0AEnAHNWrSylunPkgBFGXdjhUHqTV1bq1tMx2THz+92y/og/h+vX6VLl0W5vCjdc83aP5+i6/l3ZCLSGyUPqWTL1W1U4b/AIGf4R7dfp1rXvPFlzd6KbUIqTsdryKcfJ6AHv2rmpAdxYktk8nrmmCodJSs5a2OinmFXDxlDDvljJWfd+r/AMrW6dQpKdjHWhQCcdK1OASjkjIqVYSyEgg+w6/lV/QtJutSvligDIqkGSQg4Qf4+1TKSirs0o0Z15qnTV5PZFdLNQgd7iEcZwGyRSXDlUAjbjoSDXaeI9MtbeC0toSFK7jgrkuTjkn/AIDXJ2Vhc6rfNbWiZlGflAJ6fSppz9pFSRvjsJLB15UJu7Vr/cn+Gxmd6K09U0W601Ea6V0LEgB0ZM49CwGfwrMI9x+daHIT2NpPfXCwWyhpW+6pcLn8yK0W8MayhObF+PRlP8jWQrFWDISrA5BB5BruNG8ZKmnyJqQZriNcowH+s9AfQ+9c9aVWOsFc9jKqGX4huGMm4Po7q3ptv+ZycSyidrdoXacMUKDsRwc1FcFo2KMACOoBq67Wt7M80dw9pcyMWYSnKMT1ww5H4j8ap3dlcWoDTxEI33ZAdyt9GHBrVST0e559XDuN5Q1j3X69vnYrZoooFWc4AZzR24qRct8uMD6UFAo759KAI6KVvfrSUAJS0UUAAODQSKO1BoATsajP3ualqI/foA2fEoe68W6msMbvJLeOqIoyxJY4AHc1SvrK6068ls9Qtp7W7hO2SGeMo6H0KnkGthp4rb4hG4uHCQxamJHY9lEmSfyr2C+1PwPF8ZdR8UXuv6Zqmn6l5/2dVt5XNlMUHlyyK8RBAIPQNgkHHFAHivh3w7q/iS6kttD0+e9miQyyLEudiggZJ6AZIHNUbmzurWWOK6tp4ZZFV0SSMqWVhlSAeoPY96941jx/o1pZ+MU0660NLq+0W1gU2lt5qXNysxDEmSCMFvLIJ+ULnBHzDjkfjp4jg8SzeGry21CyuUXTYo5LeKz+zywTBEEm8+WoKlh8oBYDacBQeQDzBg8UuGDJIp6Hgg/0pGJdyzEsx5JJyTXuOoeLvAR0jw5eNY2s99qd1Yvr9rHaAfZ4rYbZAnAH704YhTyAQetdBqnjLwS+qi5aXw5crDa3/wBkkW0Z2O+P9ykkbW0aDDAbV+bGTzigD50tbS5uxMbW3mmEMZml8tC2xBjLNjooyOTxzU2i6fdarqlvY6fbvc3MrYSFCAXwMkAn2Br3rQviFohu1nOpaNp+p6n4Teyurl9NUQi/EuU8xViIxsznClT8oIOABnaT4v8ACkPi74fW1wuhtodvp0TavOdNTcblVnBDts3EfMhwMjJHpwAtDxp7ifUZYbS2jCqzhYrePpuJwPqT6mmalYXOlajc2OowPBeW7mKaJ/vIwOCCK9a8P+ItCt/CPh2LT9X0bS1tI2/tezutOMtzdTGTKukgjbPG3B3qUx0PSus0zxx4I/tjxTcibSGvbnXZroy6lC/lXlmwAVdwglbGdx2YUnOc+iSS0Rc6kqj5pO7PneLkfJhh/dPBqxFaW1yoZp/IbOCGX9aZdS241G5a3IW3MreWEyBtycdeemOtWYI0njw7gN/DvyOPXIzTIINU0maxhSUyRzQv0ZGrP+THVs+mK6K3tpWRkgmJPT7pK4+o/wAKzxpu2QpcLJA2MqQu4H/61AGX05rf8MalcactzPG3+jxrloz0dzwo9vX6A1Xt9Ga6mKW91AWH/PQ7M/j0q5f6NdW1lb2mxOCZZcSKcueAOuOB/M1nUSkuV9TswVSdCbxEHZx29Xsv1fdJj9X8V3t+hiikntIHTZJFFIcOe5PT2/KsKyvJ9Pld7Y7GYYJx2qzbWDNPtctn0XB/kaZe2jqw3LsHuMZqoxUVyrYxr16mIqOrVd5PdmnpqXHiSOa1e4CzwoJIVZRtI6EZ6jqKw720nsrhoLuJo5V7MOvuPWtHwvdrp2u28srhYiSjtnjBH+ODW5401a31HT0Fikc0aSbXmK8ocZAGecHnn2rFznGry2un+B6tLCYSvlzrc3LVg3pvzLfb577aanFUdqKK6DxBasWl5cWpP2eQqrfeQ8q31U8H8argE09EyQF5NJpPRlQnKD5ouzL3m2NyP9IhNrKf+WkA3IfqhPH4H8KR9LmEbSwstxABkyRHOB7jqv4iqkmF+Xgmn28rwzB4nZHHQoSCPxqeVrZm/toT/ix+a0f+T+5PzDOz7o59TXoni3wFDBr3gPSNAaRrzxFo9jdubh8qJ52YMcgcIMD1P1rjI7yO8JF9brLt5MsfyOPqeh/EZ966m/8AiH4jn0azsRrkMun2McEVuotIIrmBYWUxBZAm8bSqnIYng56mmpdGiZUU1zU5XX3P7v8AK52vh/4L6ZD440Sy1rXIb3TrprlZYYlaKUvDGX24ySEYAkNxwpHBIrlviN4R8Nab4N0XxHoWpOsuqXF2iWm2Ro2SKRVBjLLuXAOTvJJ3DGMGsu7+JniqbV7bU1v4Yry3aRopI7GBDmRDG7OQg3sVZhlsnnI5rCm8TavJ4Yh8Ovcq+kwytNFC8KM0bMcttcrvUEgEgHB9KowOs8LfCu48Q+DJtci1IW06W1xdR209syrMkOdwSQn5jgHlVIHQkHpsat8JdJa906DRvEipv8NjXrt7yFyqIEDMw2pnacnC4ZhjnPFcbpnxF8VaXoaaRZamq2CQy2yK1rDI6xS53oHZC4U5PAP0qP8A4WH4n/s+Gz/tJTBFp0mlITbQl/srqFaIvs3EYGBk5XtigDqR8NItR0DR59JvrJ0ng1W5+3KJR9pS0KnlGxtyDxwDzzVLSPhbLew2txc61a2drLoT6/JK8Lv5UKSiMqQoJLc54rn9G8eeJdFTR00zU2gXSfP+xgQxkRibHmg5U7w2Bw2RxxiptQ+I/irUJZnu9U3tLp76U+LaJQbV33tGAEAA3AcjkdAQOKAOg8Z/Cn/hHNE1nULfxDaai+ltatPAlvJGRDcjMT5YYyccqM4HftXlv8VdTqfjfxDqdpqdtfah5sOpJbR3S+TGvmLbjEI4XjaD2xnvmuW/i/CgDV8TqU8SaqrDDC5kBH/AjWcK0fE7F/EmqsxyTcuSf+BGs4UALU13dTXjo1w+8ogRTgDCjtxUNFACUUUUAH0oopaAHDBwDwfWlK7Rnrn0pmenNLnigB4IbgnFSI3lsGA5HbsfwqEEAcHBoJLdSDQBehvmRsqSpz0HI/I11Gl+I4jHJFqNvFJbPjcu3OQPUE1xSsMAcU+JypyPunjmgD0G1stH1O+ik0vZGYiJMB2U5z93DcBfoRUc3hHUbiR5rS5tb0FiWcSAEn6gkVhLc/YbW3hEiid8TSBhkYI+VT+HP/AqmTU5UlEtvcyROP4ozg/ooqI6vmOmt+7iqXbV+r/yX3O5ZPhzXLKcubKYHGd0ZBOPrTxoGuSzKfsd1I/YOAf5mm2Hiq+s2fF3MwYkkFQxJ9TmtiLxldygfvMA/wDTPn+RqjmOen8Jav8AagbyznRD/dUevoKnsvDd/FK2zT7hraUbJFIzuX169QeR7ir58TzRTbxdznBwUYll9/l6fpS3PiiWRncTyoMDASbyh+CrxQ1dWZdOcqclKO6OauPDc1uXMk0ewcq2R8y+uKoSWiodqjcfVjgGtqDUTfxtaMB5xy0JIIyx6rz69vf61gSylWIywYdRSi3s9zStBK1SHwv8O6+X5WGiCWRwsa5PYDnP+NXLjSbmylVLvakrDJjB3FR744H0JzVSO7kQ/K7L7jirURjeMlpHaQ84HQn3qjAqTxbeh6d6jVf9rmrfldWkzntjpVWUDPXGaAFL7QQDyewqPpzSHABxz7039aAHbycUmTn0oBGPem0ALupKKD1oAKO9FFACnpUP8X4VNUJ+8KANHXQ39uajvzu+0PnP1NUxV7xESfEGpFl2n7Q+R6fMao0ALSUveigBKKKWgBKXBPSijJFAC59eD616Ponwi17XPD3hfWNPktZLbXrp7VAC2bYq0gLyccLiJ2yM8D1rzpCpPz5HuBmvRdN+Kur6P4Y0DRNKjNvb6fFPBdssoYXkclx52MFf3eOVyCTgn1xQA2f4T6tHrT6RDOk2oLrSaLvETC23tGX3mTqMAEldpOAT7Vl6j8NPF1ldarH/AGNc3EemyvFczwLvjTau8tnsu35snHBHfiuk1b4vPe3sl1FoqwynxNB4kUPc7wDEmwQn5RkHru49Md6xvF/j211vw9quk6foslhDf63/AG0zSXnnlWMTIyfcXILOWB7DAwetADdH+F/iO71LRob+zaxstSu4rMXeUlWJpPu71VsqcdjisC20C9ufEF5plhbPfzWTStIkYwXSInefpgE16l/wvS3RLRLTwqLaKG9s737PFfBYEMHVIkEXyK3XksQe5rznw14un0L4hQeKLW2DPHeNctbl+HRyd8ZbHQqxXOO/TtQNOzuWrbwX4n1m+Rk0xjNdQJexrIyRhopCQjDcwGDg4HXitMfDrXf7FtJ4Ip21SfUZ9O/ssRFZUeGMOxznngnj2rYsPizAnifXNUn8PKEvYre3skguhHLp8UIAWOOQxn5SAA2ACfUVY174snU9Qsr+ysPsN1a64+toTchwSyopiPyjjCcnuGxiklYJScm5PdnFaT4Q8Q6i1oINKupxdwNdQscKphVtpkLMQFXPGSQM1S1rT7vQ9SudN1O0ks763IWSCb7yZAI9sEEHPcEV6C/xkceL9S1CLRok0a7sI9NTTorjBt4kIZSkuwjO/c3KEHdyD1rifGuvv4n16bUxHLEsiRoqz3IncBVCjLbVz07KAPSmI5+Rxt46+x/+vURlOc5Off8A/XUzwHacuT+Bqs64Pt7UAM3sGDZII6YNaN9m+tftyLiVSFuV/wBo9H+h7+/1qpbMI3yNufcZroNHubOJvMu2mkdgVZBgIVIxjGPpUyXVbm9GcVenP4X+HZ/L8rnLkHpitCwQHqNx/Ot3VILczxmBGWBlyhTkN9c557Hnt0qqYGAKxgDPc+3vTTurozqQdOTjLdFW8dI+3mt3J4ArLlbdg+9WruM5/wBYHx3HSqbHHHUimQNJz34ptKaSgApKWkoAKO1FAoAKKKUUAIelR/xCpexqI/eFAGp4mAHiPVAGVh9pflTkH5jWeKu+IE8vXdSXOcXDjP8AwI1SHSgBaKKKAEpRSCloASilpKAA0oJByDikooAeXLDBH4ikI7g03vRQAtGaSigB24/w8fSl3tjrTKWgCRJJAcqxFSfaWB5wT781XpcgjgUASPJv5I/Ko8+gpuaUEg8UAOBJYc4q7AoUZKsR3JBx+dUQxVtwJB9RSE5OT1PU0AbcWpCK0MD+WVDbkxyUPfHXr7+1fSvwou9Jn+HPhiK5+wS312up7NPuoItmoOudkUkjZMfXII64P0PydXV6X8PvFGq6NFqthpbTWU0Ms8TCaMNKkRKyFELbm2kHIAJ4pJWKlOUrX6aHpfgj4a6Trdl4Mvb+BGikXU4tdD3ojeOePzPITYWDA/Kpwo6cniptU8C+GdM8EJqN7oyQQN4as9Ti1J79w81+4Um3WPdghwWJwvHYivKm8CeIv+Ef/tpLGOTTtsbs8V1C7xrIQELxq5dASRyyjrXSap4F8bajqmiw+KbW5WGOWDQ43iME8luFH7uIxq4wdvTeVz60yT0Px74M0XxF4l8Uro+j2NtdHSLa70doLxY47tsRCRlUsFG0Fl9yM9TmsfxV4P8ABvhnT/E13NpZv20/+zUghj1FlBaaAmU7l3bhu54/A4rmdP8AhQbzTLC8OrtCbq31WfymtBmP7EQNpw/V8/8AAcfxVyx8CeIv+Ee/ttLKOTTgsbs8V1DI8ayEBC8auXQEkYLAdaAPXrvwB4CHhTTJEWcQTpYu+vRTqUQvIiz+Zul2jAZgEEYZSvORmqnxg0200T4VvptjpMGk20Xiqb7PDHdtcGeEW4VZ2LMxBYDoMDgYHPPmerfDjxbpEV2+o6LPALSJppgXQskYYKW2hskZZeR656Vm3PhXW7bxSnhuawddbeRIRaF13b3AKrnOAcEd+O9AGGKD7V3dx8JPHFvbyTy6FIIkge4JFxC2UTO8AB+WXByg+YelYg8Ha+2zGnSfNph1lfnXmzGcy9enynjrx0oAwKK6+8+G/iy0msoJ9JP2q7mS3itkuInnEjqWVXiVi6ZUE/MBwKvSfDHVrTwxruq6k8cM+nG0ENtbvHdC58+R4+JI3IBUxnjk544oA4HtUZ+9+FdR4n8EeIfDFlFda3p/2e3klMAdZo5QkgGTG+xjsfHO1sH2rlz96gC5qj+bql5IVZN0zHa4ww5PBHrUA6Vb1wg63qBUYH2h+M5xyapigBaKKKAE6UtSW0EtzMIoEZ5D0AH51rp4Y1giOb+z7p7JmwbuGMyw4HU+YmVOO+DxQBiUVo/2TdXerT2WjW8+osmSotozKzKOrYXPFP8A+Ee1oEg6RqII/wCnZ/8ACgDLorVXw5rbE7dH1I/S1f8Awo/4RzW8Z/sbUsHofsr/AOFAGV2pO1a//CNa7/0BdT/8BZP8KJ/DesQQPK+nXBWP/W7F3mHgkeYBkoSASA2MgZHFAGRRWzr+jDSbHTJTMJJrqMvInH7s9hjr+eOaig8Pa3cW6zwaPqUkDAESJauVOeRyBigDMFHatQ+HtaBx/ZGogjt9mf8AwoHh3WicDR9SJ9rZ/wDCgDKFFareHdbU4bR9SX62r/4VNH4W1dyqfY2W4f8A1dqzqLiT2WInefwWgDEFLW5qHh2fTtD+134ltr3zdn2SZNjhf72Cc9eOlRSeF/EEaK8uhaqiOMqzWcgDD1BxzQBkAHkiirt1p17YIGvrS4tlY4BmjKZP41ZXw3rskMU8ei6m0My745FtZCrr6qcYI+lAGTXr2n/ErTNA8DeDotMsVvPEulWuoQCeV3RLMzyv8wXGJCUc98A15r/wj2tE4/sjUcn/AKdn/wAKmj8La3KQkOnTzT7Sxt4sPOoHUtEpLqPcgUAd+PjC0ng8eHf7GS2t5LW3tJHiunES+U6t5qwY2h22/Mep9e1aviv4xWFv4zu7vwtpMb2UusxarcXEkzh70xD5F2kfuxyc8E5/KvI9S0qWws7U3CSx3srsJLd0KtGONuQecnk/TFSzeGNft32XGh6pE+MhXtJFJHryKAO2tfixPb2NpbDSY2EEOqwhvPPzfbiCT93+DHHr7Vak+MUreCm8PR6JHDG9nBaMYrt1hzE6t5ghxtDtt+Y9T69q88/4R7WsE/2RqOB/07P/AIUn/CP6z/0CNR/8Bn/woA9I8FfEmzX406h4v15FtNM1CO4F3ZhDOJVaPiLpzlwhycDjmuM0/wAZXcHxHh8Y3cQurxdQ/tB4i5UM2/dtzzgdh6CsweG9cYZXRtSI9rV/8Kp32n3unsq39pc2rMMqJ4mQn6ZFAHolh8WJ7T+yMaTG39nf2pj9+Rv+29f4eNn6+1PtfiwkXh6Oym8OWsupJoMvh4agLmRW+zuGC/u/u5G4knv7V5hg0mOnFAHsd58dL9p9Gms9Gt1l064MwkvLh7qQq0TRNEsjYdUKu3Usc454rnoPiHaaTpGpaf4Z8Ox6Wt5LZ3HmNePOVkt5XkVjuHIO4DHGAvfNee0UAeh/En4mTeN9N+zzWE1q8l2LyX/T5ZYd+1gdkTcIDvJ7kdAQMivN/wCL8KlPSov4qALurzfadWvbgDaJZmcA9sk1WFSXJDXEp9XPH41GKAFooooAAaMCig0AXrvWNQurcW813L9mAAEKnbHx/sjiqGAPSl70UAFFFFABSqzIwZGIYdCDyKbS0AX7LWtSsYGisb2e2Rn3sYW2Mxxjlhyfz71Uubia6mMt1NJNKeryMWJ/E1FS0AIKWikoAXpSd80Uo/WgC5p2p3mnJMllcNCJhh9oGSPr2/CqcjGSRnclnY5ZmOST6mkpaAFU4pppaSgBaKKSgC7aapfWds0FpdTQRM29hE20k4x1HPSqbEu7MxLMTkk8kmigUAFFFFAAKKSloAKO1FFABRR9KD0oAOxqP+P8KkPSourfhQB2Vx8OfGz3UxXwf4iILkj/AIlk3r/u1H/wrrxt/wBCd4j/APBXP/8AE11HxT8deLrL4l+KrWz8Va/b20Op3EccMOozIkaiRgFVQ2AAOwrlx8RPG3/Q4+JP/BpP/wDFUAH/AArrxt/0J3iP/wAFk/8A8TS/8K68bf8AQn+I/wDwWT//ABNIPiH42/6HHxJ/4NJ//iqX/hYfjX/ocfEn/g0n/wDiqAE/4V1426/8Id4j/wDBXP8A/E0f8K68bf8AQneI/wDwWT//ABNH/Cw/G3/Q4+JP/BpP/wDFUv8AwsPxr/0OPiT/AMGk/wD8VQAg+HXjb/oTvEf/AILJ/wD4mg/Drxt/0J3iP/wWT/8AxNH/AAsPxt/0OXiT/wAGk/8A8VS/8LE8a/8AQ4+JP/BpP/8AFUAJ/wAK68bf9Cd4j/8ABZP/APE0f8K68bY/5E7xH/4LJ/8A4mj/AIWH41/6HHxJ/wCDSf8A+KoPxD8bf9Dj4k/8Gk//AMVQAf8ACuvG2P8AkTvEf/grn/8AiaP+FdeNv+hO8R/+Cuf/AOJo/wCFh+Nv+hx8Sf8Ag0n/APiqB8Q/Gv8A0OPiT/waT/8AxVIAPw68bf8AQn+I/wDwWT//ABNB+HXjb/oTvEf/AILJ/wD4mj/hYfjX/ocfEn/g0n/+Ko/4WH42/wChx8Sf+DSf/wCKpgH/AArrxt/0J3iP/wAFk/8A8TR/wrrxtj/kT/Ef/gsn/wDiaP8AhYnjX/ocfEn/AINJ/wD4qj/hYfjX/ocfEn/g0n/+KoAP+FdeNv8AoTvEf/gsn/8AiaB8OvG3/QneJP8AwWT/APxNH/CxPGv/AEOXiT/waT//ABVH/Cw/Gv8A0OPiT/waT/8AxVIA/wCFd+Nv+hO8Sf8Agsn/APiaP+FdeNv+hO8R/wDgsn/+Jo/4WJ41/wChx8Sf+DSf/wCKo/4WJ41/6HLxJ/4NJ/8A4qmAf8K68bD/AJk/xH/4LJ//AImpn+GnjNYo3XwvrzswyY10u53J7HMePyJqEfETxr/0OXiT/wAGk/8A8VR/wsTxr/0OPiT/AMGk/wD8VQAp+HPjYf8AMoeIj/3C5/8A4ig/Drxt/wBCf4j/APBZP/8AE0n/AAsPxt/0OPiT/wAGk/8A8VR/wsPxt/0OPiT/AMGk/wD8VQAf8K68bf8AQn+I/wDwWT//ABNH/CuvG2P+RO8R/wDgsn/+Jpf+FieNf+hx8Sf+DSf/AOKpP+FieNf+hx8S/wDg0n/+KoAP+FdeNv8AoTvEf/grn/8AiaP+FdeNv+hO8R/+Cyf/AOJo/wCFieNf+hx8Sf8Ag0n/APiqB8RPGv8A0OPiT/waT/8AxVAB/wAK68bf9Cd4k/8ABZP/APE0v/CuvG3H/FHeI/8AwWT/APxNJ/wsPxt/0OPiT/waT/8AxVL/AMLD8a5/5HHxJ/4NJ/8A4qkAn/CuvG2P+RP8R/8Agsn/APiaP+FdeNv+hP8AEf8A4K5//iaX/hYfjY/8zl4k/wDBpP8A/FUf8LD8bf8AQ4+JP/BpP/8AFUwE/wCFdeNv+hP8R/8Agsn/APiaB8OvG3/QneI//BZP/wDE0v8AwsPxt/0OPiT/AMGk/wD8VR/wsPxr/wBDj4k/8Gk//wAVQAh+HXjb/oTvEf8A4K5//iaavw38bFx/xSHiID1OmT//ABFO/wCFieNf+hx8Sf8Ag0n/APiqY3xG8bBh/wAVj4k/8Gk//wAVQBa+MKgfFfxfg5zqlyT/AN/G4rj1BZgqglicADvXYfGmNrf4s+LVfBLanO4x6FyR/OuZ0Jx/bmn/APXxH/6EKUnZNjiruw24sru2UNc208KngGSMqCfxFJcWlzbRwSXFvNFHOu+J5EKiRfVSeo+lfQOpHWIfGniCTxGzjwQYGEguXUxsNgwIwTnduz0/niuP0rw/DfDwu0FpbzsdHmu5o7kSSh9r4+WNWBZuRhQRmvKp5mpR5pLz0d+jdvVW1PSqZe07Rf36dUr+jueT05EZ9xVSQoycDoK9kvfDWhp4r0V20W6MNzp0k81tFayDbIrYDNBvLgDPKBienvWhZabHpWr6/aW2k2FxJc6D9oS2t4pojL85G0xM29C2VBXOflHQkiqlmkLXjF9/xsSsune0pL+lc8KNTPaXKWcd29vMtrIxRJihCMw6gN0Jr1jQvD9rLbaEY/Ckd6NSvZ4tUZvNzp4WTb5Yw37vauTluTin2Gk6Re6d4c0m5uN+kHXbyFZN2PNVQdgz/tEKP+BU5ZlFPRbb/K/+Qo4CT3e/62/zPHqSvR/iVpNhZ+H4bmHRp9PvY7zyGdbOS3heMqxA+dm3MCv3hwR+FeaeYPSuzD11XhzpWOWvRdGXIySio/M9jR5g9DW5iSfhRUfmD0o8z60ASdaM1H5g9DShwTQA+itXRbOL7SJbwEqmGSMDO8+h9BVvxMDNex36RsjkgsrDhj146/lSAw54JoB+/ikj/wB9SKjyBWhqOpfbIGi8rZufeSWye/HSs/AHSgApfrSUlMBaWkooAUmkoo7UAFFFFABRSfSgUALRR3o70AFA4zU9nZ3N7KY7O3muJANxWJC5A9cDtU9zo+p2sRludOvIYh1eSBlA/EigCiaiY8ipM5HFRt1FAHc/HZAnxc8VBRgG/lPXuWJNcGCQQQcGu++PP/JXvFP/AF/SfzrgaAHyzSygebI746bmJxTo7iaN43jmkR4/uMrEFfp6VFRSsth3ZKl1cJIsiTyrIn3WDkEfQ0ou7kXJuBcTC4PWUOd359ahoosguydbu5UShbiYCX/WYcjf9fX8aiLsUCFm2jkLngU2iiyC7Jri7uLkKLieaUJwokctj6ZqGiihJLYTd9wooopgFFFOj6mgBuKntF/fKSOBzzT403KSCMjouDk/SnLnIG0+9AG/pspjllMSwkEjAZAc/wDfQP6VbSwa6iIlZIUT5iW7n6VzkMvlyLuBYDtnitE3kEqFDBtOOSTjn2pAVb+yUyTNbsCqc5Py7h7A1mg+tav2XzBsE0bA87QT/OqZtpJZJBGhLKMkCgCsaKSg/SmBFI7BiAeKTe3rRJ980ygB29vWl3t6/pTKKAHb29acjsWAJqOnx/fFAE1FFFABRRRQB1/wj/5KPon/AF2FeneN59/h/XIZYzIDHgfNjocg/ga8w+EzKnxD0VpGCosuSWPAGD1ru/FN0RZa3+8dhsdVGcrgkg/pUvcDxOPpSPwwpY/u0j9aoDuvjx/yV7xV/wBf0n866uT4caHrun/Du18OxXdhqvilZpHnu7sTRQiHcGXaI1J3EA5zx0wc5rlPjz/yV7xV/wBf0n86iX4q+MEGjeXqVtH/AGM2+wMenWymAlWU4Ij5BDHIOQTgnkA0Adf4a+EOi3xsru68Urc6Pf6Zf3dvcWtvJGwltdu8MrqSUG4HoCwBxg4rL0z4Pz3/AITGtjXrKJbiK4uLGOSMqJ44mZcsxI2M+07Rg9s4rk9H8e+JdGh0qHTtS8qLS1uFtUMETqiz480MGU7w2Bw2QMcYq9pnjPxk2iXttYyPcaZbmSeX/iXxTJZ+a3zMrGM+QGZv4SoyeKANyf4SlNdj0KLxLp82uzWLXsVksEoZv3AmVCxULuYZAwT05xVrTfgreXF9ew3utW1rHYW9o94whZ2hmuF3LDtyMlV5Y5GOwPSuEk8Z6/J4ps/Ebagw1q0EQhuVjRSojUKg2gbSAoA5Bz3zVq0+IPie11jVtTj1Pfdas2++E1vFLFcHJILROpQ4JOPl47YoA7LS/gx9ouo4L/xTpto9xq0uj2pjhknW4mRVKkMvAVgw5JGP5WY/g9Y3tl4HtbDXtmu69JdQzxyxM0StC7qxQhRgLs2nJO4nI4rhB8QfEwms5V1JVezvzqdvttogI7ggDeAFxjCqNv3eOlXNM+JfizT4tPFrqir9guZbu1ZrWF2hkkLFypZCQrF2JX7uTnGQKANzTvhqmseHbUaBfadqVzda9BpUd+nnxKC9u0jDa6j5FIOW27jjjis68+H1i+l6/faH4lt9STRYfMuV+ySQnPmrHhc8EEtkH2OQK5/TvFGtabpMWm2F/Jb2kN8mpxrGqhkuVUqsgfG4EAkYzj2reT4q+MUvXuo9VijleJ4ZAljbqkiuQWLoI9rMSoO4gtx1oA6C8+F0Gl+F9cS7f7VrEN1pcdtPCHIVLpCxXyxyx5UdCeOKnu/gTdpd6bHba/amG7N0kj3EDRtbvBF5jK6KWIyB9R3FcdffEjxZfT3E1zrEjTXE1tcSSLDGjGS3GIWBVQQV9sZ75q1dfFbxlcypJJq0QZHmkXy7G3jG6ZCkjYWMAllJyT65680AcfrFlb2WpT29hqEWo2yEBLqKN41k4BOFcBhg5HIHSq0SAZ3EjjjAzzUkTBH3NGsgwRtbIH14IpnfvQA5GKkEZBHvTvMYs7Fjubr70mz3HrmmA80ALnkYqQOVxhuKipcjHQ5oAlEhB9unWn+cyqFVuP7vaoM+/HpSZoAkmIdtwAH9TUVOHU46e9TTQgqrRZ6fNnj8qAKjJuJOf0pPK9/0qQHivZv2fdN0uwi1bxd4kTSjp9rJDp9uuqD9zJLIwaTHB+ZYlcjjqwoA8V8r3/Sk8v3/AEr6Pi+E2i23ijXraTTpdZ/4nFvHBbwXXki102dS/wBryPvBchc/dBU5rnD4d8FeHdL0bULmzn1pbrXbqxiuTeiKFoIZkCyMuwhgVOeoHNAHihi9/wBKUJtYHOa+mX+HGjal8T/Fq3XhcQaXazwiO1gmcO0ckjjz4o4woEZAHJO1QP4s8eFfETRrbw9471/SLEyG1sr2WCIyHLbFYgZPc4oA56gUUUABo60ZoNAHR/Dw48X2R9A//oJrp/EM0kmj6kXbJZeeB61yPgu4S18S2ssqsyAMCqjJOVI6fjW5rlyrabeqseGIwM5zyee9IDhE6UjfeHpTkPyjpTW60wO7+PH/ACV3xT/1/Sfzr0y68f8AgP8AsHw3FfyRXi2VzZmbTrC0ZYGjQfvGkjljAVs84SRt568E15l8eP8Akrvir/r+k/nXBUAfU9j4i8P+KNX1L7FqGjXUljoGqyrffYJS0CERsjSiSIbthBIVQ+BkAnOKwW+JXh/z/ENlZ67Bbz3mg2lo+rvprGO9vYny8hjCFhuQ7QWUcrk44r52ooA9y1TxF4En8Pape2+pwDUrzwxb6amnHTpFaK6jKbj5m3bk7SdwPc5I79FffFjw5Fqeof2dfWC2kOp6XJp5GkjKQCJVvGBMWQc7gSfmI4XivmuigDa8cXGn3fjTX7nRdn9lTahcSWmxCi+SZGKYUgFRtI4IGKr2+pXccCR+aHjUYVJUWQAemGBrNqZPuik0nuXCrOm7wbXoaH2+N/8AX2Fq/uoaM/8AjpA/Sjfpr/eguoT6rIHH5ED+dUKDS5F0NfrM38ST9Uvztf8AEvi2spP9VqGw+k8JX/0HdSrpsu4NBLaTEdAsy/8AoLYJ/Kor22htobaSK6iuDKhZkTIMRz0bt71VZt5zgA+wAos+4e1pP4ofc3+ty5dafexsZJ7WVAeciPC/hgY/Kl0nT5tSvFtrcKXZScscAYHeobaeWA5jmkiPqjEV0fhfXJLe/ka9ea5zGQvRmzkdzzjANRNzjFuOrOjCU8JVrxjVk4xvrs9PXT8jDuLGewnaG8R4ZOwIyGHt2NV7qERbSrhw3bBBH512GreKoLtWt5tMV4s8tK2ce4wP5Gubga0mEq3Ksn/PIq3Q++c8flRSlOS99WYZhQwtGpbC1eePo01+Fn8jMFHerMlsyHPyspGcxnIFMEDMMoCw9a1PPIepqZLWZwCInIPQ44qf7FPbQpc3VvIkJOFLLgMfxpTeTTzRIWCohwgAGEBoAt2+lSJCk0pCKe7DA46gHpWr4iS0Z7BEha0ik5ZmBZj9B17+uK2vD4020skkvL6GS4bg+ZMpAGeAF6+lV/GWp2whgksp4Gu1bbkKHZVIPIz05A5rmdf95yRVz3KeTr6m8VWqKL3UdG2vS6+SOZu9JeR3mhT7PaA8SXLgAj19/oAarE6dbrhfMvJMdTmOMfh94/pUbzS3JZpneaU/xMxY1BKuMZBzW3K3uzzPa04fw4/N6/ht99/UhZgvWml19f0r0rwp8Ln8R/DrUvEJ1H7PqEK3E1hYGLJvI4AhmYNnjG/AGDkisKP4b69J4a/tlfsWDYtqYsjcAXLWittM4T+4CD3zgZxVnMclvX1o3r616fofwV1S81KWz1bWdG02VdPe/RDdxyylRGJF3RhgyKQRlj05ODWZF8M9Qv8ATdDl03ys3cF7dXN5Ndp9lSG2mMbShgMqg45Oc5GKAOD3r60b19a24/Cl1P4utPDtle6bd3V28ccE8FyGgdnA2jfjg5IGCAQeDWxafDDXprnToLl7GxlvxceSlzKQ58iTynBVQWzuyAADnBPQGgDjN6+tKDu6c16VP8Jb3T9N16HVplg1yw1CwsoUEq/Z3FyCQ7NjIGNvPGOciqFr8J/FT3sFmbWCO4mu7q0CyTBcG3/10h/2F/vd+2c0AcnofOs2YJ2gyDnpjmug1IL5N3slB4YLz978c03xF4S1PwZ4h0+21YQt9ohW6gmgfdHLGSRkEgEcqQQQCKo3dwfIuSoGGB/I0Ac+nQU1+CKenSmP1FAHefHYZ+L3ir2vpP51wYQetd18b38z4ueLDtZcahKuGGDwxGfpXEigBnlj1o8setSCkoAZ5Y9aPLHrT6WgCPyx6mnAYA9KdSUAFOZSFVjjDdORn8qXaPL3b1znG3nP+FM/CgB8kkku3zHZ9owu45wPSm0mKDQAoJ7/AIU7c2Qc4I7imUEUAWjfXLQeS0paLj5W56dKgVxuBIxz1AplLQBq2xWSVEtJHKk8xvgFj6e9aYZIIUupNPhit0bDMVJ3nPpn2x6Vy9P3NtADHaOgoA2dWuL3VVXAaSAHKJGOF49PwrFwVYg8MDgg9amtZ5YZA0EjIx4O0kZ9jW5Fqdrp11G89jb3bAZ3L8mCfY9fqRUybS0VzWjCNSajOXKu7u/yuzOh06/eze8SBvs8YyXYY/L1/Cq1wdy+a7AseMV3E/jCwutMukVZYZ2iYIroGBbBx69/WuOGq6hj5JynpsUJ/IVjSqVJX5o2PUzDB4HD8nsKznda2Sev3q3oQwJM/wDqopGz/dBqX+zdRl+b7FdY9TGwFJJe37nM13csP9qVj/Wqswk8z96GBxwD1xWvvHnfuF3f3L/M9Q0T4n+NPD8ehw6b/Z1rp+kW5gWxbaIbjJYu0oZ8lmLc7SoyBgCsKT4m6w2gyaalnpkbtYvpa3qQt9ojsmcsbdWLFdnJAJUtg4zXEEc4pvaqV+pnNwfwJr1d/wBEdvH8SdXXxmfEjWunSXL2I06W2eNzBLD5IiIYb92SoGSGHPtxUlj8TtXsbbTbS3sdLGn2VveWf2RoXaOeC5l82SKQF8lQ2NuCCNo5J5rhKO1MzNLVNWa81xNTsrKz0mSMxmGGwQpHEUAwRuLEnIySSSTXc3vxl8RXviu8127tNKkku9POmy2vlSJD5RfecbXDhi2WJDckmvNKOlAHc+KfiZrHiS01i2vLbT4Y9Te0eX7PG6lDboUj2Zc44POc+2Kval8ZPFN94q0vXpTYpd2Fq1osSQkRTK+fMMiljln3fMQRyARjFecfWjvQB0+v+Jp/E+t2dzPZWln5MflrHamUg8k5Jkd2JyfXFZty7NBNnPQ5NZ0HEyHpzVqRxsbJFAFAdKY/UVIB/Ko37UAd78dP+Sv+K/8Ar+k/9CrhhXcfHMg/F7xWRgj7dIP/AB41w4oAWikpaACiiigAp6+WVbezBv4QFzn9aam0MPMBK+gODSd6AAZ70lFH1oAKK1LTRrmfTp7+QeTaxIWDuPvnsAPr3rLqVJS0RrUoVKSjKatzarzXcKDRSg46VRkFKu0MN4JXPIBxmuo0vU7SbTItOl0qylnbgXB2pJnt82B9OSc1Pquj6jPDGsGlFAoA/wBah5/A/wCFRKpGOknY6KOExFdOVKm5Jdk3+RgRT2a4zZ7l75c5/Co5Usmb90065PVsED8sVBd201ncvBcoY5kxuXjjIz/I1DuJ4NUmnqjGUZQbjJWaNWCyspACb8g55Hl9B68nmrFxYWLwIYLtpJCxX94Ao/mcVhdKUNt6ZpknU2WlaZYi1vL66S4B+Y2u37xyeODkjjrx1rRvH0bU7i4uImFjHsxHEka5BHqBgDP1Jrh0mZO2frQGONxG7BHWkB0cGnzG1W5uCVkzmFSob5f7xNY9wAkrEOZMnlhzk1dl1qe6SONtrbQAOP61VlAlGWJQE9vT2pgUt3JwOfUmmGlbg4/rmmn1oAOlFdF4U8K3XiWz16e1nghXSLB9QmEucuikAquB1570nhvwV4i8S201xoWlXF5DE/ll0wAXxu2Lkjc2OdoycdqAOepO9es6P8D9d1XRdAuYLqGK/wBZSSeG2mjYJHEqs255BnDEKMKFP3hkjnHnlr4d1W68QtocFozaorOjQM6rtKAs2STgYCkk57UAZXakNd9pfwk8X6hPq1uNOWC5060S8eOVxmaN2ITyyuVbOGwcgfKec1X0X4beIr2bTHvtL1C007UF3W92tt5okzC8y7RkbsrGT14HJoA4tD8wqVz8prVXwrrvy40y4+bTzqo4HNoM5m/3eD+Vbdt8LfG93aW9zb+HL54LjZ5bgAAhxuVuvCkfxHj3zQBxIqJ+oq/qmn3elajc2Go28lteWzmKWJxhkYHBBqg/WgDufjarL8W/FgkCZ/tCYjYMDBc4/HHX3rihXd/Hfb/wt/xVt6fbXz9c1wgoAWiikHWgBadEyrIrMiyAHlWzg/kQaaaWRi7liBk+gA/QUAPdSQXAwhPboPaozxU9rMIJclA6EYKk9afcxxtmS3bKsfudGX8KAKtanhkQHWIBd2/nwnOQTwoHO4+w6ms4xsOa05Nun2BgIxdXCgynuidQv1PBP4e9RU1XL3OrCe5UVZ7R19ey+f8Am+h1PjfVLabQYY7KaORZ3H3D/CvPTtziuAqVoGCb+qnuOajKn61NGkqUeVG+Z5jPMa/tpq2iVvQFBY4Aye1G05IwcijkdRSHJ55rU84K7Lwx4rNtF9m1R2eJR8ko5Yex9a43P51LHKEXBRST3rOpSjVVpHbgMwr4Cr7Wg7P8H6mnqN3Zatey3ExltJ5Gzk/vEPpnuOPTNU59NuIozKgWeAf8tYTvUfXuPxxWhbWWmXEDMbp1k9GH+c1mKxtLkvBO8bKTteMkGhR5VaJM8RGvJyrLV9Vo/mtvy9SrRWib+K4OL+2SUn/lrF+7f9Bg/iPxoFhFcH/QLlJGP/LKX92/4Z4P4HPtT5rfET9X5/4T5vLZ/d1+Vy14ft9GlcNq128ZzxEFIB+rD/61ddr39lDwvOLRYJLeMowSBwOdwGcjPPNedTwy28hjnjeOQdVcYNRjpWU6HPJS5melhc2+qUJ4f2MbtNX66973+7RGgt5aIcpp0Z9PMlc/yIp76qCBss7RcdPkLf8AoRNZlLW3IjzPrNTpZeiS/JF7+1LkfcW2T/ctowfz25pkmp3ssbRtcyeWwwVBwCPTAqsEJ+lSpAznAIHuelHJHsJ4qs1Zzf3s674ZeMLXwnJrkeo6U2qWerWDWEsSXX2dlVmBJDbG9MdK6jw58VrPw7p8+mWGh3UWmLe/brNINR2z27lFVlaUxEOp25+6CPWvLvJWMZOTgdu5/pUbHKkAAA9TVGB6TZfFZrXX/Ceqf2OJP7CiuoXia6P+krcGTdzt+UgSkA/NyM+1cz4R8Taf4a8ZnV49EW7sAJVisricM8YZSFYSFCN65BDbMZ7DtzQX5vlGcUkseOcjce1AHrGpfGG31PVZpb7w/PNp8+groU0Lal++dVmMgl83y+vOCNv49qyrH4n/AGXxn4X1/wDsjf8A2JoyaR5H2nHnbbeSHzN2z5f9Zu24PTGe9eb9aKAPVLX4r2kfh6O0n8NCTVk8PTeHBfrfMo8hw21vK2EZBYk88+1Qal8VPtumaraf2Ns+3afpljv+1Z2fY3Vt2NnO/bjHGM9TXmVIKAN/x74i/wCEt8Y6tr32X7J9umM3keZ5mzgDG7Az09BXOP1FS1E3WgR3vx2Ur8X/ABVuGM3sh/WuGFd38d93/C3/ABVv/wCfx8fTNcIOlAxacY2VFclcN0wwJ/LrTatXV9Jc2VrauqCK3zt25ycnqeaAIJZZJn3Su0jYxljk4pgpAAKKAFzz9Kcpwcg4NN69asWlrJdTpDFjLdWJ4UDqT7Ac0m7K7KjFzkoxV2y/YFFWS+njXyo8KsZ6SSdhj0HU/wD16ozs9xM0krlpHJZmPUk1JqNykrpFb5FpANkWeCfVj7k8/kO1VQzAcEGpivtM2rySSpQ2X4vv6dF5a9WWMuoAI4HfHFSw+VJ98FWHXHSoUnJGD19anQh9uZF3D324qznG3NuWw0e1kPcHr+FVJUaPAdSp68961YQ9rIJEJdTwdpB/+tUeoyC4U7UIOeflxn8utAGWMeldh4N0IXUE99OnysjRwqe5IwW/p+dcvFbhm271B/2uK9A0zV7i20yBZbWJtpES7H2jAA56e4rnxPPyWp9T28h+qRxDqYx2jFXWl1fzt2/M85jZ4ydpIzUssEjJ5hVznnJFa95Zr5pI8pWyTsDEnr9BSyQzMiKzSDOBsJ/TrW54r30Oe60cVvTeHrpUEiROVPcAnH6VVfRrhfvIwPpjmgRBBqNxFGImZZoB0imG9R9M9PwxUmNPue72UnvmSM/+zD/x6rUPhjVp1RobC4ZH+6wjOG/HpUFxol5aymK6UQuP4XOD+XWp5F00OiOJnbln7y8/8918mQXGnXEMZlCrNAP+WsR3qPqR0/HFVo1Zj8oJx1q9awzW0paGVkkXo0bHP6f1rUidLmNxdQxqccSoNrMf91eCPc8+9P3lvqDVGavF8r89V961/D5mOsG9d0zqiqOFXksf8+tAYccAL6VNcxKGYRgBV59fxNV0BYZAGB61RzloIsibzgAcAsf5CqeEXkHIp0kjbfm/lUGdx5HFAE3mgL8oqJSWbP3jQdowDz/SnM+0Yjyo7nuaAI3x2OaZQTRQAUlLRQAVE3UVKaibqKAPQfj2wb4v+KMHOLxx+tcdpWlX+qfa/wCzbOe6+yW73Vx5SFvKhTG52x0UZGT711fxyYN8XfFmO1/KP/Hqv/BPWtG0e/8AFcPiHUl0y31Xw/d6ZFcPDJKBLKYwuVRScYBPTtQB5yK6Gx8F+I7/AEi21Ox0i6ubS6kaG3MS7nnZfvCNB8z4wckAgYNes/DjxR4N8IaPe6XHq2m3F4l+Jmv7mwn8i/t2iUeWQI2cBW3jYwCnqDVrw18V9I0u5+GsT6iqafpUt8NRjjsj+4RpJBBglckeWwJ2kn1yaAPnulruvDfiK00f4r2+ratc22saYbkx3k6WpSOeFxsdhGVUjCkkDaDkCvRNJ8c+CNO8Vaha2MsUOn2ek2+naPq0lo4+dCGlkcKhdWkJYbgpIA9DQB4BWwYbiy0CK6W2uFivnaP7U0TLGwTGY0bGCeQTjpwK9xj+JnhvT9Qhn0+50qF7jxTFcXxttMYobA28KzMvmR7gpdZMgYYnJAGaisPH/hk6foVlJq9rb6ZpniSa4ksn052Etk06vGUIjOAoySpwx6YPFJq5pTqOndx6q39fkeEQ6bdT6bcahGim1t3SORt6ghmzjC5yeh6CptJ0e/1YXx0+1a4WxtXvLjBA8uFSAz8nkAsOnPNemw+ONAvbDWz4hjtLonWbGS2tYLBYfNsYpZGkQbEVRlWA+YgnPOcVvaj450Ut4ueXxZbX9pqOkX9rptpFpUkBtfMeExwltg7IRjJUbM7smmZngZAz8p4p4bb1r274ieNvCer/AA7m07Qn0+NWgtPs2nyWkontJUKiTYwTyxkb8tvJbPTPNeHpkDrQBYimkjJXI8tuoIDA/hW3oN/Yx3IW6EkcZOWePHA47HNc4uAecj6DNTA85DYx7UAeoQ6loM1nifSvPUg/O8aMQP8AZbgj8Knii8OXKp5w8iALuRBKwIzjtz/PtXmcEpLoepHQjP8ASti6vnj1GaEljHHiPIIPKgL3+lQ/iR0U/dpTl3sv1/Q6e+0Dw45jEV7dI3OWZd4/kP61H/wj/huJQ7ajcvtORxtOR7bTXLPegzoMyyegMn+FWbm+bbjYMn1Oce/3qo5zr7BvC6Mdz3Up/vSOfl/75weelS6h4qhty0OmrbKjdPLj5zjqRxXBPcSAqHmKr7jH8xmqbyBARFnJ74xQBta54o1C6MsE0oaI4BDqMHGO2K5u7uZJ5GeaVnZjuzz1/Go3Y7jlVJPXJqJ9xPA49QKYFqyUySgtIgQd3JI/Kvp74XeE/DWo/DrRb2/0mx1O7uEv5JE2stzciLO1YCDt3g7eCemfQ4+WrfCnIBLetdlosXjCTTIb2xh1w2ForzRzw+b5cIyQ7qw4UZBBIIoA7Xwt8KB4hs/B9zM2p/ZNXiv5NQkhiHl2rwF/LGduF3FV+91zxTbv4Y6JB4Ze9kl1xJY/DttrzXbeWLXc+3dbj5c7zuO35u3INcbqEXjPTdKj1KMeIINOuJPNS6TzlgZ3yC2/ozNnGc85q1r7eNvEX9gaZrlvqGm6eI4NKthNbXEdsxiG1SygNucDrtUn2oA7fx/8MtHn1/xbH4Y07V4JNL021u7a1jXzEuGcRbvLGCzABiTyfmz24rL8QfDLw94btPEF1rF3rYj0sWCiKFI/ML3EJdlbdjGGGPp2NYun+EPGV1a6dqNv4h2iW01D7OxvJ1eOGzx5qfdyoORtXoe+2uU1Cy8XyaL/AGhf2uvtpF35f+kzxzGCbHyx/OflbHRefpQB6ld/BzQotH02Ma1errF3HYyrcNEz2rrcOiueIwFVA+dxkOSMYXNUvih4V0Xw78MJI9L0u+t7i28UTWRu9SRPtE6JABlWVFIiLDIXnnPJrze6g8WWujy2d1FrsOlQ/NJBIsqwphgMlT8o+Yj8ai1W48S393HpWrS6xc3JdWSzuWldy5UbSEbnJUjHHTFAGFQa25vCXiOCOSSbw/q8cccH2l2aykAWL/noTt4Xg/N0ql/ZOpHGNPvObc3Y/ctzAOsvT7nB+bpxQBRorXuvDGvWttZ3N1omqQ294wS2lktJFSdiMgISMMT2ArTPgHX4dF13UtRspdMXSIoJpoL6KSGaRZpfLQopXkbupJHHr0oA5UVG/WtbVdB1fR4beXVtKv7GK4G6F7q3eISj1UsBkcjpWS/WgDvPjp/yV7xX/wBf0n/oVcOK7r47KV+L3irIxm9kP61wg6UALRRR3oABRRS0ABooooAOKKQ0UALSH2o7UCgB6ZHt9RTi5J6Age9Rj2pVJU+hoA1NDjD6lbllyiuHbnsOT+gNRzuZLlnUuN7Eknjkn603TrlbZp5HzvMLKg9SeD+hNNF0SMhf1qV8TZvKSVKMet2/yS/JkxzH0fcffmkaVR7EjuKg+1DeGVT9C3BrRW7tmjwSFJHO2MZ/Mk0zAqGQbiQajMgEo3IGX6YqwVWQ5gnAH+2MVVlDpJ80iH6GmBpwSCQY2xKOPlVcFvyFTXESKdu+NTwME8/X2rLidd4XzQT6KpzWnE9mmHLSKc8gn+ftQAssDIii3iYt1Llc/wA+tez6X400nwx4A8GzmW5utWsbTUohZQyoIg80jgeeOuNrbgAOcV49c6pEYdsSiNRgZ6Z+hrGnv1ZcRpz2LHcfzNAHtEPxH0H/AIQabQ7PTrq1luLO1tpWZImjWSKRGaRpf9YQQpwpOF7DvWl4v+K/h/SvG12dLN/qtu+v2+qXFx5qPCEhGAtuM988kkdAPevneSVpPvNn2phoA9isvirpdvptjbtY3paCDWomI2YJvSDGRz/Djn9M1MPin4eh8AT6FZaVfW889ja28g2RMnmxSIzOZT+8YMF4UnC9AO9eL0lAHu3hf4j2ev8Axq1bUNfu5E8Ianb3EU9tqU52xwFAwRRkgNvRMBa4Gz8cmX4wQ+NdVjllUamL54oyCwQNkIucDhQAPpXEdqQUAe22fxmhjj0hLoatMlqNXFyplDCYXX+p4Lc7Oc56dqq2nxN8Or4eiW403VhrieFpvDQZJIzb7WDbJMEbs5bnnj3rxylNAHvd98bdG/tbRdTh0W8vdQtLvz57q58uGV08l4sHy/ldwHyHKjBXgDJrmbP4g6Joui61Y6Umu6gbwWTxNq0iOFeG789lIB4QgAcZySTxXlNFAHq3xY+JVj4z0d7XT49Qt/P1H+0ZLeaKARxuUZWw6KHc/MBk44HIJwR5KwGRUtRN1FAHffHYbfi94r5BzeyHg+9cIOldx8cJI5fi34saF96i/lQnBGGDEEfgQa4gdKAFFJS0negBc0lFHWgBaSlo60AFFFFAH2LoF34Fb4peH7Wezszrv9nx2PkmAeS0JtftH2gnG3eGVo/XDe3HC+D7HSJI9Etryzi1i4u/BNy1vbXd0SPPDviKPJ+Qt2xgjkjFfOdFAHtJ8K+FzqPgTSU0q3hv9bjSe7uLrUpBDERLIGiIHOSFC5DDnGMZzXZ3Hhnw/wCG/wC0LrRbX+zpNQ8IaylzbO5wJI8KpCtLKVJB6bz24ByB8x0UAem/BfwvoHjOfU9K1mRLW+jMF3BcvMY18hJQLhCM4J8tsjvla7r4d+BfBviXTLm9l06D7BfXd8lpJHcyGayjjQmISkyqqk4BAMchbPO0cj54zRQB9AXOh6P4w1HwfoN/LFFf3Pgi3GnXJl2rDcpJK21hnBBUMOfarHhfwf8ADzU7/wASTWWnzalDaasLKKxS6YyLaKgBuE/exkl3DHJ3KvHy1870dKAL+uQx2etX9tbbzBBcSRxlypbaGIGSpIJwOxx6VURwHywJHoDioxS0AT/anClVAUdiCQR+tRtNIxJLtz15xTKSgBSSTzyaKKKACiiigApKWigBKWkoFABS0Ud6AEopaKACon6ipaib71AHbfGlnb4teLjIQSNSnAx6bzj9K40V2XxodZPiz4uaMEAanOpz6iQg/qK40UAFL3oIooADU1xa3Fs6pcQSxO2CFkQqTnkcH6j86ZBNLbzLNBI8UqHKujFSp9iKuw61qsMJih1O+jiOcok7gcnJ4z3zQA3XtNl0fU5LKcq0qKrNtOQMgHH61QHIrWtNfv7CVJdNkWxuFj8vz7ZQkpB6neOQT6g0n/CR65kk61qZPqbuT/GgDLFFaY8QayDxq+oZHf7S/wDjTv8AhJNc/wCgzqX/AIFSf40AZNTy2lzHaR3UlvMtrIxVJmQhGI6gN0Jq/wD8JJrn/QZ1L/wKk/xplvr2sW97JeQarfx3UqeXJMlw4d14+VjnJHA4PpQAl1pFxbaLa6lNgRXMhSNe5AHWs0Hn3rUt9cvIUkD+RcFmDA3MKzBMZ+6rgqOvpU0virXpEjiGrXkMEQxHDbymGJB1+VEwo/AUAY1IPetRfEGtA5XV9RB9ftL/AONKfEWtsMNrGon63L/40AZVPP3fatNfEeuIRt1nUlxyMXTjH61Slu557o3NxK09wTkvMfMJPvnOaALmraNNpmmabeTH5L1Syj0xjr+YrK61sx+I75Y5FmW1upGIIku7dJygxjChwQBjjAFJP4m1yZ8nVbyNcBRHBKYo1A6BUTCgewFAGPRWp/wkGs4IGr6iAf8Ap5f/ABobxDrTHLavqJPvcuf60AZdW10y/ax+2rZXRs+f34iby+OvzYx2NWx4j1wDA1nUgP8Ar6k/xqJNc1WO9F5Hqd8t3jaJxcOHxxxuznsPyoAjOnyrov8AaZI8kzeQBjqcZzVIHkjFaia7feZLLdOt7NIAvmXq+eVwc8b8j9Kln8U6/MwL61qWFG1VW5dVUdgqg4Uew4oAx6StRvEOtHrq+ok473L/AONC+IdaT7usakM+l0/+NAGXS9q1f+Ek1z/oM6l/4FP/AI1Vv9Tv9QCC/vbq6CZKieVn2564yaAKlFKCfWkPSgAopKXvQAYqJjyKlFRN94UAdl8Xjn4q+MDjj+1rof8AkVq5EV1/xgUj4reL89Tqtyf/ACK1chmgBaKKBQACjNHf3oFABRQRRQAUUUUAFHeiigApKWgUAFFFFACUtFA56UAGKKOlFABSUtH1oAKKK1ND0DUtc+0/2Vbef9mTzJf3irtX1+YjP4UAZfaip5LSeJmV0wVODyOtRmNxnjp70AMopcH0pDx1oAQUGnUlABQaXH86SgAo70UdKACom+8Kl61GykkHFAH/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Long axis view from a two-dimensional echocardiogram shows a flail anterior mitral valve leaflet resulting in mitral regurgitation. Part of the papillary muscle is attached to the leaflet, seen as an echo dense mobile mass.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_17_34065=[""].join("\n");
var outline_f33_17_34065=null;
var title_f33_17_34066="Patient information: Jaundice in adults (The Basics)";
var content_f33_17_34066=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"14\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/16983\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?39/54/40804\">",
"         Organs inside the abdomen (belly)",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?24/25/24979\">",
"         Patient information: Cirrhosis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?1/56/1923\">",
"         Patient information: Gallbladder removal (cholecystectomy) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?8/29/8658\">",
"         Patient information: Gallstones (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?40/46/41698\">",
"         Patient information: Hepatitis A (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?25/41/26258\">",
"         Patient information: Hepatitis B (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?31/39/32370\">",
"         Patient information: Hepatitis C (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?43/42/44706\">",
"         Patient information: Liver cancer (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?1/45/1746\">",
"         Patient information: Vaccines when you have hepatitis C (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?30/9/30865\">",
"         Patient information: ERCP (endoscopic retrograde cholangiopancreatography) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?7/21/7507\">",
"         Patient information: Gallstones (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?3/16/3328\">",
"         Patient information: Gilbert's syndrome (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?4/39/4721\">",
"         Patient information: Liver biopsy (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Jaundice in adults (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/jaundice-in-adults-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H31814361\">",
"      <span class=\"h1\">",
"       What is jaundice?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Jaundice is a condition that causes the skin or the whites of your eyes to turn yellow. It happens when you have too much of a certain substance in your blood. This substance is called &ldquo;bilirubin.&rdquo;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H31814376\">",
"      <span class=\"h1\">",
"       What causes jaundice?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Jaundice is usually caused by problems with your liver. The liver is a big organ in the upper right side of the belly (",
"      <a class=\"graphic graphic_figure graphicRef64960 \" href=\"mobipreview.htm?39/54/40804\">",
"       figure 1",
"      </a>",
"      ).",
"     </p>",
"     <p>",
"      Problems with the gallbladder or pancreas can also cause jaundice. Rarely, problems with the blood can cause jaundice.",
"     </p>",
"     <p>",
"      Problems with the liver, gallbladder or pancreas can be caused by:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Small stones that form inside the gallbladder, called gallstones",
"       </li>",
"       <li>",
"        Infections",
"       </li>",
"       <li>",
"        Heavy alcohol use",
"       </li>",
"       <li>",
"        Damage from medicines, herbal supplements, or illegal drugs",
"       </li>",
"       <li>",
"        Cancer",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      You can also get jaundice after surgery, if you have certain blood disorders or if you have a condition called Gilbert&rsquo;s syndrome.",
"     </p>",
"     <p>",
"      Gilbert&rsquo;s syndrome is a common, harmless condition that can run in families. People with this syndrome sometimes get jaundice when they are under stress, take certain medicines, or have an infection. Women with Gilbert&rsquo;s syndrome might get jaundice around their periods.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H31814391\">",
"      <span class=\"h1\">",
"       Is there a test for jaundice?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Your doctor will give you a blood test to measure the level of bilirubin in your blood. Your doctor",
"      <strong>",
"      </strong>",
"      might also give you tests to see what&rsquo;s causing your jaundice.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H31814408\">",
"      <span class=\"h1\">",
"       Will I need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Your doctor or nurse will decide which tests you should have based on your age, other symptoms, and individual situation.",
"     </p>",
"     <p>",
"      Tests doctors use to find the cause of jaundice usually include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Blood tests",
"       </li>",
"       <li>",
"        An ultrasound &ndash; This test uses sound waves to take pictures of the organs inside your belly.",
"       </li>",
"       <li>",
"        A CT scan &ndash; This is a special kind of x-ray.",
"       </li>",
"       <li>",
"        An ERCP &ndash; This test involves putting a flexible tube down your throat and taking x-rays.",
"       </li>",
"       <li>",
"        A biopsy &ndash; For this test, a doctor takes a small sample of tissue from your liver. Then another doctor will look at the sample under a microscope.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H31814423\">",
"      <span class=\"h1\">",
"       How is jaundice treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatments depend on what&rsquo;s causing the jaundice. Your doctor or nurse might recommend that you:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Get plenty of rest - Ask your doctor or nurse when it is OK to go back to work or school",
"       </li>",
"       <li>",
"        Avoid alcohol.",
"       </li>",
"       <li>",
"        Avoid certain medicines - Your doctor or nurse will talk with you about the medicines you take and will tell you which ones to avoid.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If your jaundice was caused by gallstones, you might also need to take medicines or have surgery to remove your gallbladder.",
"     </p>",
"     <p>",
"      If you have Gilbert&rsquo;s syndrome, you will not need to do anything extra to treat your jaundice. Gilbert&rsquo;s syndrome does not cause long-term problems on its own.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H31814438\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?8/29/8658?source=see_link\">",
"       Patient information: Gallstones (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?1/56/1923?source=see_link\">",
"       Patient information: Gallbladder removal (cholecystectomy) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?40/46/41698?source=see_link\">",
"       Patient information: Hepatitis A (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?25/41/26258?source=see_link\">",
"       Patient information: Hepatitis B (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?31/39/32370?source=see_link\">",
"       Patient information: Hepatitis C (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?1/45/1746?source=see_link\">",
"       Patient information: Vaccines when you have hepatitis C (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/25/24979?source=see_link\">",
"       Patient information: Cirrhosis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?43/42/44706?source=see_link\">",
"       Patient information: Liver cancer (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?7/21/7507?source=see_link\">",
"       Patient information: Gallstones (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?3/16/3328?source=see_link\">",
"       Patient information: Gilbert's syndrome (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?30/9/30865?source=see_link\">",
"       Patient information: ERCP (endoscopic retrograde cholangiopancreatography) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?4/39/4721?source=see_link\">",
"       Patient information: Liver biopsy (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?33/17/34066?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16983 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.66.252.144-6720EAAD2F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_17_34066=[""].join("\n");
var outline_f33_17_34066=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31814361\">",
"      What is jaundice?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31814376\">",
"      What causes jaundice?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31814391\">",
"      Is there a test for jaundice?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31814408\">",
"      Will I need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31814423\">",
"      How is jaundice treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31814438\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/16983\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?39/54/40804\">",
"      Organs inside the abdomen (belly)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/25/24979?source=related_link\">",
"      Patient information: Cirrhosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?30/9/30865?source=related_link\">",
"      Patient information: ERCP (endoscopic retrograde cholangiopancreatography) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?1/56/1923?source=related_link\">",
"      Patient information: Gallbladder removal (cholecystectomy) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?7/21/7507?source=related_link\">",
"      Patient information: Gallstones (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?8/29/8658?source=related_link\">",
"      Patient information: Gallstones (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?3/16/3328?source=related_link\">",
"      Patient information: Gilbert's syndrome (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?40/46/41698?source=related_link\">",
"      Patient information: Hepatitis A (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?25/41/26258?source=related_link\">",
"      Patient information: Hepatitis B (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?31/39/32370?source=related_link\">",
"      Patient information: Hepatitis C (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?4/39/4721?source=related_link\">",
"      Patient information: Liver biopsy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?43/42/44706?source=related_link\">",
"      Patient information: Liver cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?1/45/1746?source=related_link\">",
"      Patient information: Vaccines when you have hepatitis C (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_17_34067="Perifollicular abnormality";
var content_f33_17_34067=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F64172&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F64172&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Perifollicular abnormalities in scurvy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 428px; height: 271px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In this example, the perifollicular hyperkeratotic papules are quite prominent, with surrounding hemorrhage. These lesions have been misinterpreted as \"palpable purpura,\" leading to the mistaken clinical diagnosis of vasculitis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Hirschmann JV, Raugi GJ. Adult scurvy. J Am Acad Dermatol 1999; 41:895. Copyright &copy; 1999 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_17_34067=[""].join("\n");
var outline_f33_17_34067=null;
var title_f33_17_34068="Quinupristin and dalfopristin: Drug information";
var content_f33_17_34068=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Quinupristin and dalfopristin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?16/36/16964?source=see_link\">",
"    see \"Quinupristin and dalfopristin: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?1/11/1205?source=see_link\">",
"    see \"Quinupristin and dalfopristin: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F216636\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Synercid&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F216637\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Synercid&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F216659\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antibiotic, Streptogramin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F216639\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Complicated skin and skin structure infection:",
"     </b>",
"     I.V.: 7.5 mg/kg every 12 hours for at least 7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Bacteremia, MRSA (persistent, vancomycin failure) (unlabeled use):",
"     </b>",
"     I.V.: 7.5 mg/kg every 8 hours (Liu, 2011)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F216652\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?1/11/1205?source=see_link\">",
"      see \"Quinupristin and dalfopristin: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F216640\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F216641\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No adjustment is necessary in renal failure, hemodialysis, or peritoneal dialysis.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F216642\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pharmacokinetic data suggest dosage adjustment may be necessary; however, specific recommendations have not been proposed.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F216618\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection, powder for reconstitution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Synercid&reg;: 500 mg: Quinupristin 150 mg and dalfopristin 350 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F216604\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F216620\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Line should be flushed with 5% dextrose in water prior to and following administration.  Infusion should be completed over 60 minutes (toxicity may be increased with shorter infusion).  If severe venous irritation occurs following peripheral administration, quinupristin/dalfopristin may be further diluted (to 500 mL or 750 mL), infusion site changed, or infused by a peripherally-inserted central catheter (PICC) or a central venous catheter.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F4117676\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W;",
"     <b>",
"      incompatible",
"     </b>",
"     with saline.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Anidulafungin, aztreonam, caspofungin, ciprofloxacin, fenoldopam, fluconazole (used as undiluted solution), haloperidol, metoclopramide (undiluted), or potassium chloride when admixed in D",
"     <sub>",
"      5",
"     </sub>",
"     W.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F216619\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of complicated skin and skin structure infections caused by methicillin-susceptible",
"     <i>",
"      Staphylococcus aureus",
"     </i>",
"     or",
"     <i>",
"      Streptococcus pyogenes",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F13856040\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of persistent MRSA bacteremia associated with vancomycin failure",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F216657\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Hyperbilirubinemia (3% to 35%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Local pain (40% to 44%), inflammation at infusion site (38% to 42%), local edema (17% to 18%), infusion site reaction (12% to 13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia (up to 47%), myalgia (up to 47%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Pain (2% to 3%), headache (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (3%), pruritus (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyperglycemia (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (3% to 5%), vomiting (3% to 4%), diarrhea (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Anemia (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: GGT increased (2%), LDH increased (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Thrombophlebitis (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: CPK increased (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Allergic reaction, anaphylactoid reaction, angina, apnea, arrhythmia, cardiac arrest, coagulation disorder, dysautonomia, dyspnea, encephalopathy, gout, hematuria, hemolytic anemia, hepatitis, hyperkalemia, hypotension, maculopapular rash, mesenteric artery occlusion, myasthenia, neuropathy, pancreatitis, pancytopenia, paraplegia, paresthesia, pericarditis, pleural effusion, pseudomembranous colitis, respiratory distress, seizure, shock, stomatitis, syncope, thrombocytopenia, urticaria",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F216623\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to quinupristin, dalfopristin, pristinamycin, or virginiamycin, or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F216608\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Arthralgias/myalgias: May cause arthralgias and/or myalgias with use; reduction of dosing frequency may improve.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperbilirubinemia: May cause hyperbilirubinemia (&gt;5 times ULN) possibly through competition for excretory pathways.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Phlebitis: May cause pain and phlebitis when infused through a peripheral line (not relieved by hydrocortisone or diphenhydramine).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cisapride: Concurrent therapy with cisapride (which may prolong QT",
"     <sub>",
"      c",
"     </sub>",
"     interval and lead to arrhythmias) should be avoided.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drugs metabolized by CYP3A4: May inhibit the metabolism of many drugs metabolized by CYP3A4.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F216654\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F216613\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Quinupristin may increase the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F216615\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F216625\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Because adverse effects were not observed in animal reproduction studies, quinupristin/dalfopristin is classified pregnancy category B. There are no adequate and well-controlled studies of quinupristin/dalfopristin in pregnant women.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F216646\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F6055734\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if quinupristin/dalfopristin is excreted in human milk. The manufacturer recommends caution if administering quinupristin/dalfopristin to a nursing woman. The increased molecular weight of quinupristin/dalfopristin may minimize excretion into human milk. Nondose-related effects could include modification of bowel flora.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323773\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Synercid Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150-350 mg (1): $247.45",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F13493234\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Culture and sensitivity",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038795\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Pyostacine (BE, LU);",
"     </li>",
"     <li>",
"      Synercid (AU, CZ, FR, GR, HN, IT, KP, PL)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F216607\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Quinupristin/dalfopristin inhibits bacterial protein synthesis by binding to different sites on the 50S bacterial ribosomal subunit thereby inhibiting protein synthesis",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F216622\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Quinupristin: 0.45 L/kg; Dalfopristin: 0.24 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: To active metabolites via nonenzymatic reactions",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Quinupristin: 0.85 hour; Dalfopristin: 0.7 hour (mean elimination half-lives, including metabolites: 3 and 1 hours, respectively)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces (75% to 77% as unchanged drug and metabolites); urine (15% to 19%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bryson HM and Spencer CM, &ldquo;Quinupristin/Dalfopristin,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1996, 52(3):406-15.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/17/34068/abstract-text/8875130/pubmed\" id=\"8875130\" target=\"_blank\">",
"        8875130",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chant C and Rybak MH, &ldquo;Quinupristin/Dalfopristin (RP 59500): A New Streptogramin Antibiotic,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1995, 29(10):1022-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/17/34068/abstract-text/8845540/pubmed\" id=\"8845540\" target=\"_blank\">",
"        8845540",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Griswold MW, Lomaestro BM, and Briceland LL, &ldquo;Quinupristin-Dalfopristin (RP 59500): An Injectable Streptogramin Combination,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 1996, 53:2045-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/17/34068/abstract-text/8870891/pubmed\" id=\"8870891\" target=\"_blank\">",
"        8870891",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Liu C, Bayer A, Cosgrove SE, et al, &ldquo;Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant",
"      <i>",
"       Staphylococcus aureus",
"      </i>",
"      Infections in Adults and Children: Executive Summary,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2011, 52(3):285-92.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/17/34068/abstract-text/21217178/pubmed\" id=\"21217178\" target=\"_blank\">",
"        21217178",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Olsen KM, Rebuck JA, and Rupp ME, &ldquo;Arthralgias and Myalgias Related to Quinupristin-Dalfopristin Administration,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2001, 32(4):e83-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/17/34068/abstract-text/11181142/pubmed\" id=\"11181142\" target=\"_blank\">",
"        11181142",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9515 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-61.234.146.186-EA4EE1DDAC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_17_34068=[""].join("\n");
var outline_f33_17_34068=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216636\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216637\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216659\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216639\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216652\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216640\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216641\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216642\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216618\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216604\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216620\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4117676\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216619\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13856040\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216657\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216623\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216608\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216654\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216613\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216615\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216625\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216646\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6055734\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323773\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13493234\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038795\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216607\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216622\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9515\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9515|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?16/36/16964?source=related_link\">",
"      Quinupristin and dalfopristin: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?1/11/1205?source=related_link\">",
"      Quinupristin and dalfopristin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_17_34069="Itraconazole: Patient drug information";
var content_f33_17_34069=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Itraconazole: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"     see \"Itraconazole: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?5/59/6074?source=see_link\">",
"     see \"Itraconazole: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F185420\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Onmel&trade;;",
"     </li>",
"     <li>",
"      Sporanox&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F185421\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Sporanox&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10027619\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700808",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use this drug to treat nail fungus in patients with weak hearts.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10027621\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691491",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat yeast infections.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691248",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It may take 3 months to see the full effect.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10027620\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to itraconazole or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701390",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a weak heart or are pregnant and are being treated for a nail infection.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701350",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you had liver problems while taking some other drug in the past.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10027625\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697148",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a weak heart, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700986",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change from the capsule to the oral solution unless the doctor knows of this change.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696829",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take antacids or sucralfate within 2 hours of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4128402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink grapefruit juice or eat grapefruit often, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10027626\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3796248",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hearing loss. This can be long-lasting.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698201",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Harm to the liver may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10027628\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698616",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in hearing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699087",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698988",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Numbness or tingling in your hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699062",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3434950",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling on legs or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10027623\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695748",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take capsule with a full meal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2696421",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Liquid:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695764",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take liquid (solution) on an empty stomach. Take 1 hour before or 2 hours after meals.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696377",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Yeast infections in mouth and swallowing tube (esophagus): Swish and swallow.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10027624\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10027629\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10027630\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10780 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-115.25.216.6-1A240FD273-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_17_34069=[""].join("\n");
var outline_f33_17_34069=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185420\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185421\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027619\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027621\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027620\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027625\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027626\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027628\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027623\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027624\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027629\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027630\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=related_link\">",
"      Itraconazole: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?5/59/6074?source=related_link\">",
"      Itraconazole: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_17_34070="Global maternal mortality";
var content_f33_17_34070=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F71683&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F71683&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 617px\">",
"   <div class=\"ttl\">",
"    Maternal mortality ratio per 100,000 livebirths, 2008",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 597px; height: 289px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Based on data from: Hogan, MC, Foreman, KJ, Naghavi, M, Ahn, SY, et al. Maternal mortality for 181 countries, 1980-2008: a systematic analysis of progress towards Millennium Development Goal 5. Lancet 2010; 375:1609.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_17_34070=[""].join("\n");
var outline_f33_17_34070=null;
var title_f33_17_34071="Idiopathic anaphylaxis";
var content_f33_17_34071=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Idiopathic anaphylaxis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/17/34071/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/17/34071/contributors\">",
"     Leslie C Grammer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/17/34071/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/17/34071/contributors\">",
"     F Estelle R Simons, MD, FRCPC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/17/34071/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/17/34071/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/17/34071/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anaphylaxis is often associated with an identifiable trigger, such as a food, medication, or insect sting. Idiopathic anaphylaxis is diagnosed when no specific trigger can be identified after an appropriate evaluation, and when conditions such as mastocytosis and C1-esterase inhibitor",
"    <span class=\"nowrap\">",
"     deficiency/dysfunction",
"    </span>",
"    have been ruled out. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/11/9401?source=see_link\">",
"     \"Anaphylaxis: Confirming the diagnosis and determining the trigger(s)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic will review the pathogenesis, diagnosis, treatment, and prognosis of idiopathic anaphylaxis. Other aspects of anaphylaxis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/29/35290?source=see_link\">",
"     \"Anaphylaxis: Rapid recognition and treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/62/38888?source=see_link\">",
"     \"Differential diagnosis of anaphylaxis in children and adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anaphylaxis is defined as a serious allergic reaction that is rapid in onset and may cause death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/17/34071/abstract/1\">",
"     1",
"    </a>",
"    ]. Symptoms of anaphylaxis involve multiple body organ systems (",
"    <a class=\"graphic graphic_table graphicRef66333 \" href=\"mobipreview.htm?20/36/21068\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/29/35290?source=see_link&amp;anchor=H2#H2\">",
"     \"Anaphylaxis: Rapid recognition and treatment\", section on 'Definition and diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis of anaphylaxis is based upon a detailed description of the acute episode, including antecedent activities and events. The diagnosis of idiopathic anaphylaxis is made when a patient has signs and symptoms consistent with anaphylaxis, but no specific trigger can be identified, and other diseases have been ruled out.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Idiopathic anaphylaxis is more common in adults, although it also occurs in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/17/34071/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. In several series, up to 70 percent of patients with idiopathic anaphylaxis were female and approximately 50 percent of patients were atopic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/17/34071/abstract/2,5,6\">",
"     2,5,6",
"    </a>",
"    ]. Patients with idiopathic anaphylaxis may also have episodes of anaphylaxis caused by known triggers, such as food, medications, and exercise [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/17/34071/abstract/2\">",
"     2",
"    </a>",
"    ]. The prevalence of idiopathic anaphylaxis in the United States (US) is estimated at approximately 1 in 10,000 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/17/34071/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Idiopathic anaphylaxis is associated with increased activation of mast cells, as is anaphylaxis with a known trigger. Patients with idiopathic anaphylaxis also have increased activation of lymphocytes, although the significance of this is not clear. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/29/35290?source=see_link&amp;anchor=H12#H12\">",
"     \"Anaphylaxis: Rapid recognition and treatment\", section on 'Triggers and mechanisms'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Mast cell activation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with idiopathic anaphylaxis have elevated levels of mast cell mediators, including plasma and urinary histamine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/17/34071/abstract/4\">",
"     4",
"    </a>",
"    ] and serum or plasma total tryptase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/17/34071/abstract/4,8\">",
"     4,8",
"    </a>",
"    ], during an acute episode. In contrast, patients with mastocytosis have elevations of serum total tryptase levels that are persistent and are detectable even after resolution of an acute episode [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/17/34071/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. In one study, a subset of patients with idiopathic anaphylaxis was identified that had a clonal mast cell population secondary to a c-KIT mutation, and this disorder should be excluded before making the diagnosis of idiopathic anaphylaxis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/17/34071/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/29/35290?source=see_link&amp;anchor=H16#H16\">",
"     \"Anaphylaxis: Rapid recognition and treatment\", section on 'Laboratory tests'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/54/40809?source=see_link\">",
"     \"Laboratory tests to support the clinical diagnosis of anaphylaxis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/13/18650?source=see_link\">",
"     \"Evaluation and diagnosis of mastocytosis (cutaneous and systemic)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Lymphocyte and basophil activation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with idiopathic anaphylaxis have an increased percentage of activated T cells in their peripheral blood during acute episodes compared to during remission. In addition, they have more activated B cells, both during acute episodes and in remission, than in the general population or in patients with chronic idiopathic urticaria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/17/34071/abstract/12\">",
"     12",
"    </a>",
"    ]. In microarray analyses, cells from patients with IA differentially express genes that strongly correlate with the level of CD203c, a marker of basophil activation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/17/34071/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The signs and symptoms of idiopathic anaphylaxis are the same as in anaphylaxis resulting from known triggers (",
"    <a class=\"graphic graphic_table graphicRef66333 \" href=\"mobipreview.htm?20/36/21068\">",
"     table 1",
"    </a>",
"    ). The severity spectrum is also similar. Fatal and near fatal cases of idiopathic anaphylaxis have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/17/34071/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/29/35290?source=see_link&amp;anchor=H2#H2\">",
"     \"Anaphylaxis: Rapid recognition and treatment\", section on 'Definition and diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Idiopathic anaphylaxis is classified into subgroups based upon frequency of episodes and clinical manifestations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/17/34071/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Criteria for frequent idiopathic anaphylaxis are defined as at least two episodes in the preceding two months or at least six episodes in the preceding year. Patients with idiopathic anaphylaxis who do not meet one of these criteria are categorized as having infrequent idiopathic anaphylaxis.",
"   </p>",
"   <p>",
"    Generalized idiopathic anaphylaxis is characterized by urticaria",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    angioedema plus severe systemic symptoms (cardiovascular, respiratory symptoms,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    gastrointestinal). Occasional patients have idiopathic anaphylaxis-angioedema characterized by marked upper airway obstruction due to severe angioedema of the tongue, pharynx,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    larynx.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     DIAGNOSIS AND REFERRAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Idiopathic anaphylaxis is a diagnosis of exclusion, by definition. Patients suspected of having idiopathic anaphylaxis should be referred to an allergy specialist. All possible triggers of anaphylaxis and disorders that mimic anaphylaxis should be considered and ruled out before making the diagnosis. Idiopathic anaphylaxis is established only after performing a comprehensive history, physical examination, review of medical records, and appropriate laboratory tests. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/62/38888?source=see_link\">",
"     \"Differential diagnosis of anaphylaxis in children and adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Unsuspected triggers",
"    </span>",
"    &nbsp;&mdash;&nbsp;On occasion, patients who were thought to have idiopathic anaphylaxis are found to have unusual triggers of anaphylaxis that were initially overlooked.",
"   </p>",
"   <p>",
"    Food-associated triggers that should be considered before labeling a patient with idiopathic anaphylaxis include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Spices, especially members of the Apiaceae (Umbelliferae) family, which include caraway, coriander, and fennel [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/17/34071/abstract/14\">",
"       14",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Foods contaminated with aeroallergens (eg, \"bee pollen\") which often contains ragweed pollen [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/17/34071/abstract/15\">",
"       15",
"      </a>",
"      ], or flour contaminated with mite allergen [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/17/34071/abstract/16\">",
"       16",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Undeclared or mislabeled food allergens, or \"hidden\" food allergens, such as peanut in egg rolls or tree nuts in salad dressing [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/17/34071/abstract/17\">",
"       17",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Mammalian meat, which can cause delayed anaphylaxis in patients sensitized to the carbohydrate allergen, alpha-gal [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/17/34071/abstract/18\">",
"       18",
"      </a>",
"      ] (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/14/36072?source=see_link\">",
"       \"Allergy to meats\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Food additives, such as carmine powder [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/17/34071/abstract/19\">",
"       19",
"      </a>",
"      ] and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/26/8614?source=see_link\">",
"       psyllium",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/17/34071/abstract/20\">",
"       20",
"      </a>",
"      ] (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/46/40681?source=see_link&amp;anchor=H14#H14\">",
"       \"Allergic and asthmatic reactions to food additives\", section on 'Anaphylaxis'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Symptoms of scombroid poisoning (histamine ingestion in dark meat fish such as tuna and mackerel) resemble an IgE-mediated allergic reaction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/17/34071/abstract/21\">",
"     21",
"    </a>",
"    ]. This diagnosis should be considered in patients who have had a suspected episode of anaphylaxis after ingestion of fish, but a thorough workup for fish allergy is negative. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/41/19096?source=see_link\">",
"     \"Marine toxins\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/61/16346?source=see_link\">",
"     \"Seafood allergies: Fish and shellfish\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Medication triggers that should be considered before labeling a patient with idiopathic anaphylaxis include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ingestion of over-the-counter medications containing nonsteroidal anti-inflammatory drugs that the consumer did not recognize (eg, Alka-Seltzer contains",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Ingestion of angiotensin converting enzyme inhibitors that can cause angioedema [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/17/34071/abstract/22\">",
"       22",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other potential triggers include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Exercise (alone",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      in combination with prior ingestion of food or medication) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/17/34071/abstract/23,24\">",
"       23,24",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Latex exposure [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/17/34071/abstract/4\">",
"       4",
"      </a>",
"      ] (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/35/9785?source=see_link\">",
"       \"Latex allergy: Epidemiology, clinical manifestations, and diagnosis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Hydatid cysts (ruptured or unruptured) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/17/34071/abstract/25\">",
"       25",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Undetected insect bites and stings [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/17/34071/abstract/26,27\">",
"       26,27",
"      </a>",
"      ] (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/48/36615?source=see_link&amp;anchor=H13#H13\">",
"       \"Reactions to bites from kissing bugs (Triatoma)\", section on 'Allergic reactions'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Other disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other disorders should be considered in the differential diagnosis, in addition to ruling out triggers that cause IgE-mediated and non-IgE-mediated anaphylaxis. These include hereditary or acquired (nonallergic) angioedema, mastocytosis, disorders that cause flushing, severe acute asthma exacerbations, and somatoform and Munchausen disorders. The differential diagnosis of anaphylaxis is discussed extensively in another topic. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/62/38888?source=see_link\">",
"     \"Differential diagnosis of anaphylaxis in children and adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Idiopathic anaphylaxis is a diagnosis of exclusion. The patient&rsquo;s episodes should include signs and symptoms that fulfill the diagnostic criteria for anaphylaxis (",
"    <a class=\"graphic graphic_table graphicRef72225 \" href=\"mobipreview.htm?22/43/23228\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    An anaphylaxis episode can be confirmed, in some cases, by acute measurement of histamine and tryptase, indicating mast cell activation (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/54/40809?source=see_link\">",
"     \"Laboratory tests to support the clinical diagnosis of anaphylaxis\"",
"    </a>",
"    ). A total tryptase level that is persistently elevated at baseline, rather than only acutely, strongly suggests systemic mastocytosis or a clonal mast cell disorder, and further evaluation for primary mast cell disease should be pursued. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/13/18650?source=see_link\">",
"     \"Evaluation and diagnosis of mastocytosis (cutaneous and systemic)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Further testing should focus on ruling out specific triggers of anaphylaxis or conditions with similar symptoms. Testing should be limited to the evaluation of specific triggers or disorders that are suspected based upon the patient's history and examination, and measurement of a baseline serum total tryptase level [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/17/34071/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/29/35290?source=see_link\">",
"     \"Anaphylaxis: Rapid recognition and treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/62/38888?source=see_link\">",
"     \"Differential diagnosis of anaphylaxis in children and adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/13/18650?source=see_link\">",
"     \"Evaluation and diagnosis of mastocytosis (cutaneous and systemic)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/17/15641?source=see_link\">",
"     \"An overview of angioedema: Clinical features, diagnosis, and management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/41/19096?source=see_link\">",
"     \"Marine toxins\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/35/12857?source=see_link\">",
"     \"Approach to flushing in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Alternative diagnoses, including functional disorders, should be considered in patients with:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Atypical signs and symptoms",
"     </li>",
"     <li>",
"      Symptoms compatible with anaphylaxis, but signs not documented",
"     </li>",
"     <li>",
"      Symptoms compatible with anaphylaxis, but signs documented to be absent during a purported episode (undifferentiated somatoform idiopathic anaphylaxis) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/17/34071/abstract/4\">",
"       4",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13912230\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of idiopathic anaphylaxis includes systemic mastocytosis, monoclonal mast cell activation syndrome, and mast cell activation syndrome (",
"    <a class=\"graphic graphic_table graphicRef74166 \" href=\"mobipreview.htm?39/31/40443\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef74223 \" href=\"mobipreview.htm?33/15/34044\">",
"     table 4",
"    </a>",
"    ). The clinical and laboratory features that distinguish these disorders from each other are reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/13/18650?source=see_link&amp;anchor=H30#H30\">",
"     \"Evaluation and diagnosis of mastocytosis (cutaneous and systemic)\", section on 'Differential diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/28/20937?source=see_link\">",
"     \"Mast cell activation disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment can be divided into acute treatment of idiopathic anaphylaxis episodes and long term therapy to prevent attacks.",
"   </p>",
"   <p>",
"    There are no randomized controlled trials of interventions either in the acute treatment of anaphylaxis or in the long term management of idiopathic anaphylaxis. Recommendations for acute treatment are based upon data from animal models of anaphylaxis, studies in humans not currently experiencing anaphylaxis, data from observational studies and case",
"    <span class=\"nowrap\">",
"     reports/series",
"    </span>",
"    of patients actually experiencing acute anaphylaxis, and clinical experience. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/29/35290?source=see_link&amp;anchor=H18#H18\">",
"     \"Anaphylaxis: Rapid recognition and treatment\", section on 'Immediate management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Acute management",
"    </span>",
"    &nbsp;&mdash;&nbsp;The emergency treatment of idiopathic anaphylaxis is identical to the emergency treatment of anaphylaxis with a known trigger.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"     Epinephrine",
"    </a>",
"    is the drug of choice for acute treatment of anaphylaxis. The pharmacologic actions of this agent address the pathophysiologic changes that occur in anaphylaxis better than any other single drug. It is the only drug that prevents or reverses bronchospasm and cardiovascular collapse. Failure to administer epinephrine early in the course of treatment has been repeatedly implicated in anaphylaxis fatalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/17/34071/abstract/28-31\">",
"     28-31",
"    </a>",
"    ]. The acute treatment of anaphylaxis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/29/35290?source=see_link&amp;anchor=H18#H18\">",
"     \"Anaphylaxis: Rapid recognition and treatment\", section on 'Immediate management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Long term management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recommendations for the management of patients with idiopathic anaphylaxis are based upon data from observational studies, case",
"    <span class=\"nowrap\">",
"     reports/series,",
"    </span>",
"    and clinical experience.",
"   </p>",
"   <p>",
"    Long term management is based upon the frequency of episodes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/17/34071/abstract/4,32\">",
"     4,32",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Classification'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Frequent - Patients with frequent idiopathic anaphylaxis are sometimes treated with a combination of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      and an H1-antihistamine, usually for a minimum of three months.",
"     </li>",
"     <li>",
"      Infrequent - Patients with infrequent idiopathic anaphylaxis are not treated prophylactically.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Combination therapy with glucocorticoids and antihistamines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prophylactic treatment to prevent additional episodes of idiopathic anaphylaxis is usually indicated in patients with frequent episodes. The use of a combination of glucocorticoids and H1-antihistamines is based upon case reports and observational studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/17/34071/abstract/2,32\">",
"     2,32",
"    </a>",
"    ]. All studies examining efficacy of glucocorticoids have included concomitant therapy with an H1-antihistamine. As an example, in one series, 22 patients were treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/24/391?source=see_link\">",
"     hydroxyzine",
"    </a>",
"    , and some received an oral sympathomimetic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/17/34071/abstract/4\">",
"     4",
"    </a>",
"    ]. Nineteen of 22 patients had fewer attacks after the initiation of treatment. After completing this therapy, approximately 50 percent of patients went into remission (ie, no episodes and no prednisone treatment in the past year). Some of these patients remained on an H1-antihistamine.",
"   </p>",
"   <p>",
"    The combination of a glucocorticoid and an antihistamine to prevent subsequent attacks can be started at the time of an acute episode or as soon as the diagnosis has been reached:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       Prednisone",
"      </a>",
"      - A typical empirical regimen is initiated with 40 to 60 mg orally per day for one week, or until the patient's symptoms cease. The same dose (40 to 60 mg) is then given on alternate days for two more weeks. The dose is then further reduced by 5 to 10 mg (still on alternate days) every two weeks, assuming there are no breakthrough symptoms. Patients usually stop having episodes after the first week of treatment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/17/34071/abstract/4\">",
"       4",
"      </a>",
"      ]. The glucocorticoid dose is increased if a patient has breakthrough symptoms during the taper. The dose is decreased again once attacks are under control. If this subsequent taper is not tolerated, adjunctive medications are considered. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Glucocorticoid-dependent idiopathic anaphylaxis'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      An H1-antihistamine is usually administered concomitantly with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      . Although only first-generation antihistamines have been studied for the treatment of idiopathic anaphylaxis, second-generation antihistamines, such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/34/36390?source=see_link\">",
"       cetirizine",
"      </a>",
"      (10 mg orally per day), are preferred as first line treatment due to their more favorable benefit-to-risk ratio. The H1-antihistamine is often continued after completion of the course of prednisone, especially in patients who are older, have a history of more severe episodes, and have comorbidities. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/60/37834?source=see_link&amp;anchor=H25107389#H25107389\">",
"       \"Pharmacotherapy of allergic rhinitis\", section on 'Adverse effects and safety'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Glucocorticoid-dependent idiopathic anaphylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Twenty percent of patients with frequent idiopathic anaphylaxis will have a recurrence of symptoms as the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    dose is tapered and are considered to have glucocorticoid-dependent idiopathic anaphylaxis. The term \"malignant\" is used to identify those patients with the most severe form of idiopathic anaphylaxis that is resistant to standard therapy. One investigator has classified patients as having malignant idiopathic anaphylaxis if the prednisone dose required to control symptoms is &ge;20 mg daily or 60 mg on alternate days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/17/34071/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8249468\">",
"    <span class=\"h3\">",
"     Omalizumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/46/38629?source=see_link\">",
"     Omalizumab",
"    </a>",
"    , a monoclonal antibody directed against IgE, was demonstrated to be effective in a patient who was reported to have episodes of both food-induced and idiopathic anaphylaxis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/17/34071/abstract/33\">",
"     33",
"    </a>",
"    ]. Another case report described successful use in a patient with both idiopathic anaphylaxis and severe allergic asthma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/17/34071/abstract/34\">",
"     34",
"    </a>",
"    ]. Omalizumab is only approved in the United States for the treatment of asthma. Reimbursement for this costly therapy by third-party payers for use in CU must be arranged on a patient-by-patient basis. The dosing and adverse effects of omalizumab are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/46/17130?source=see_link\">",
"     \"Anti-IgE therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8249672\">",
"    <span class=\"h3\">",
"     Other treatments",
"    </span>",
"    &nbsp;&mdash;&nbsp;Case reports and small series provide some information about other potential therapies.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/16/33024?source=see_link\">",
"       Ketotifen",
"      </a>",
"      is an",
"      <span class=\"nowrap\">",
"       H1-antihistamine/mast",
"      </span>",
"      cell stabilizer that can cause significant sedation. The oral formulation of ketotifen is not approved for use in the United States or many other countries. The usual initial dose is 2 mg orally two or three times per day [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/17/34071/abstract/2,35\">",
"       2,35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Oral cromolyn and leukotriene antagonists such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/49/37654?source=see_link\">",
"       montelukast",
"      </a>",
"      have been reported to be helpful in some patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/17/34071/abstract/2,4\">",
"       2,4",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8249755\">",
"    <span class=\"h2\">",
"     Medications to be avoided",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beta blockers should be avoided, if possible, in patients with idiopathic anaphylaxis, since they may interfere with the response to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/17/34071/abstract/4\">",
"     4",
"    </a>",
"    ]. Other general measures in the long term management of patients with anaphylaxis are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/44/5833?source=see_link\">",
"     \"Long-term management of patients with anaphylaxis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The natural history of idiopathic anaphylaxis is favorable, even without long term therapy. Patients who initially present with infrequent episodes rarely progress to frequent episodes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/17/34071/abstract/2\">",
"     2",
"    </a>",
"    ]. With long term follow-up, over 90 percent of patients with frequent idiopathic anaphylaxis and 65 percent with infrequent idiopathic anaphylaxis are considered to be in remission (ie, no episodes and no",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    therapy in the past year) after a few years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/17/34071/abstract/4\">",
"     4",
"    </a>",
"    ]. Recurrence after remission is rare [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/17/34071/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Idiopathic anaphylaxis is a diagnosis that can only be established after all possible triggers of anaphylaxis have been ruled out and after other disorders, including mastocytosis, clonal mast cell disorders, and C1-esterase inhibitor",
"      <span class=\"nowrap\">",
"       deficiency/dysfunction,",
"      </span>",
"      have been considered. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Definition'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Diagnosis and referral'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Idiopathic anaphylaxis is more common in women than men. It is uncommon in children. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The signs and symptoms of idiopathic anaphylaxis are the same as those in anaphylaxis resulting from known triggers. Fatal and near fatal cases of idiopathic anaphylaxis have been reported. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Idiopathic anaphylaxis is categorized as frequent (at least two episodes in the past two months or six or more episodes in the past year) or infrequent (one to no episodes in the past two months or less than six episodes in the past year). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Classification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acute treatment of idiopathic anaphylaxis is identical to acute treatment of anaphylaxis of any etiology. All patients with idiopathic anaphylaxis, including those with infrequent episodes, should be equipped with an",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"       epinephrine",
"      </a>",
"      autoinjector and an anaphylaxis emergency action plan to manage initial treatment of acute anaphylaxis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/29/35290?source=see_link&amp;anchor=H18#H18\">",
"       \"Anaphylaxis: Rapid recognition and treatment\", section on 'Immediate management'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We suggest that patients with frequent idiopathic anaphylaxis be treated with the combination of an oral glucocorticoid, such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      , and a low-sedating H1-antihistamine, such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/34/36390?source=see_link\">",
"       cetirizine",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most patients with idiopathic anaphylaxis go into remission (ie, no episodes and no",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      therapy in the preceding year) after a few years. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/17/34071/abstract/1\">",
"      Sampson HA, Mu&ntilde;oz-Furlong A, Campbell RL, et al. Second symposium on the definition and management of anaphylaxis: summary report--Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol 2006; 117:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/17/34071/abstract/2\">",
"      Ditto AM, Harris KE, Krasnick J, et al. Idiopathic anaphylaxis: a series of 335 cases. Ann Allergy Asthma Immunol 1996; 77:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/17/34071/abstract/3\">",
"      Ditto AM, Krasnick J, Greenberger PA, et al. Pediatric idiopathic anaphylaxis: experience with 22 patients. J Allergy Clin Immunol 1997; 100:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/17/34071/abstract/4\">",
"      Greenberger PA. Idiopathic anaphylaxis. Immunol Allergy Clin North Am 2007; 27:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/17/34071/abstract/5\">",
"      Tejedor Alonso MA, Sastre DJ, Sanchez-Hernandez JJ, et al. Idiopathic anaphylaxis: a descriptive study of 81 patients in Spain. Ann Allergy Asthma Immunol 2002; 88:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/17/34071/abstract/6\">",
"      Webb LM, Lieberman P. Anaphylaxis: a review of 601 cases. Ann Allergy Asthma Immunol 2006; 97:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/17/34071/abstract/7\">",
"      Patterson R, Hogan MB, Yarnold PR, Harris KE. Idiopathic anaphylaxis. An attempt to estimate the incidence in the United States. Arch Intern Med 1995; 155:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/17/34071/abstract/8\">",
"      Shanmugam G, Schwartz LB, Khan DA. Prolonged elevation of serum tryptase in idiopathic anaphylaxis. J Allergy Clin Immunol 2006; 117:950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/17/34071/abstract/9\">",
"      M&uuml;ller UR. Elevated baseline serum tryptase, mastocytosis and anaphylaxis. Clin Exp Allergy 2009; 39:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/17/34071/abstract/10\">",
"      Brockow K, Jofer C, Behrendt H, Ring J. Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients. Allergy 2008; 63:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/17/34071/abstract/11\">",
"      Akin C, Scott LM, Kocabas CN, et al. Demonstration of an aberrant mast-cell population with clonal markers in a subset of patients with \"idiopathic\" anaphylaxis. Blood 2007; 110:2331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/17/34071/abstract/12\">",
"      Grammer LC, Shaughnessy MA, Harris KE, Goolsby CL. Lymphocyte subsets and activation markers in patients with acute episodes of idiopathic anaphylaxis. Ann Allergy Asthma Immunol 2000; 85:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/17/34071/abstract/13\">",
"      Howell DL, Jacobs C, Metz G, et al. Molecular profiling distinguishes patients with active idiopathic anaphylaxis from normal volunteers and reveals novel aspects of disease biology. J Allergy Clin Immunol 2009; 123:S150 (Abstract).",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/17/34071/abstract/14\">",
"      Moneret-Vautrin DA, Morisset M, Lemerdy P, et al. Food allergy and IgE sensitization caused by spices: CICBAA data (based on 589 cases of food allergy). Allerg Immunol (Paris) 2002; 34:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/17/34071/abstract/15\">",
"      Greenberger PA, Flais MJ. Bee pollen-induced anaphylactic reaction in an unknowingly sensitized subject. Ann Allergy Asthma Immunol 2001; 86:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/17/34071/abstract/16\">",
"      S&aacute;nchez-Borges M, Su&aacute;rez-Chac&oacute;n R, Capriles-Hulett A, Caballero-Fonseca F. An update on oral anaphylaxis from mite ingestion. Ann Allergy Asthma Immunol 2005; 94:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/17/34071/abstract/17\">",
"      Furlong TJ, DeSimone J, Sicherer SH. Peanut and tree nut allergic reactions in restaurants and other food establishments. J Allergy Clin Immunol 2001; 108:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/17/34071/abstract/18\">",
"      Commins SP, Platts-Mills TA. Anaphylaxis syndromes related to a new mammalian cross-reactive carbohydrate determinant. J Allergy Clin Immunol 2009; 124:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/17/34071/abstract/19\">",
"      DiCello MC, Myc A, Baker JR Jr, Baldwin JL. Anaphylaxis after ingestion of carmine colored foods: two case reports and a review of the literature. Allergy Asthma Proc 1999; 20:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/17/34071/abstract/20\">",
"      Khalili B, Bardana EJ Jr, Yunginger JW. Psyllium-associated anaphylaxis and death: a case report and review of the literature. Ann Allergy Asthma Immunol 2003; 91:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/17/34071/abstract/21\">",
"      Becker K, Southwick K, Reardon J, et al. Histamine poisoning associated with eating tuna burgers. JAMA 2001; 285:1327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/17/34071/abstract/22\">",
"      Sondhi D, Lippmann M, Murali G. Airway compromise due to angiotensin-converting enzyme inhibitor-induced angioedema: clinical experience at a large community teaching hospital. Chest 2004; 126:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/17/34071/abstract/23\">",
"      Castells MC, Horan RF, Sheffer AL. Exercise-induced Anaphylaxis. Curr Allergy Asthma Rep 2003; 3:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/17/34071/abstract/24\">",
"      Beaudouin E, Renaudin JM, Morisset M, et al. Food-dependent exercise-induced anaphylaxis--update and current data. Eur Ann Allergy Clin Immunol 2006; 38:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/17/34071/abstract/25\">",
"      Gelincik A, Oz��eker F, B&uuml;y&uuml;k&ouml;zt&uuml;rk S, et al. Recurrent anaphylaxis due to non-ruptured hepatic hydatid cysts. Int Arch Allergy Immunol 2007; 143:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/17/34071/abstract/26\">",
"      Moffitt JE, Venarske D, Goddard J, et al. Allergic reactions to Triatoma bites. Ann Allergy Asthma Immunol 2003; 91:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/17/34071/abstract/27\">",
"      Stoevesandt J, Grundmeier N, Trautmann A. Gastroesophageal hymenoptera stings add to causes of idiopathic anaphylaxis. Ann Allergy Asthma Immunol 2012; 108:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/17/34071/abstract/28\">",
"      Sampson HA, Mendelson L, Rosen JP. Fatal and near-fatal anaphylactic reactions to food in children and adolescents. N Engl J Med 1992; 327:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/17/34071/abstract/29\">",
"      Bock SA, Mu&ntilde;oz-Furlong A, Sampson HA. Further fatalities caused by anaphylactic reactions to food, 2001-2006. J Allergy Clin Immunol 2007; 119:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/17/34071/abstract/30\">",
"      Pumphrey RS, Gowland MH. Further fatal allergic reactions to food in the United Kingdom, 1999-2006. J Allergy Clin Immunol 2007; 119:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/17/34071/abstract/31\">",
"      Greenberger PA, Rotskoff BD, Lifschultz B. Fatal anaphylaxis: postmortem findings and associated comorbid diseases. Ann Allergy Asthma Immunol 2007; 98:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/17/34071/abstract/32\">",
"      Boxer MB, Greenberger PA, Patterson R. The impact of prednisone in life-threatening idiopathic anaphylaxis: reduction in acute episodes and medical costs. Ann Allergy 1989; 62:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/17/34071/abstract/33\">",
"      Warrier P, Casale TB. Omalizumab in idiopathic anaphylaxis. Ann Allergy Asthma Immunol 2009; 102:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/17/34071/abstract/34\">",
"      Demirt&uuml;rk M, Gelincik A, Colako��lu B, et al. Promising option in the prevention of idiopathic anaphylaxis: omalizumab. J Dermatol 2012; 39:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/17/34071/abstract/35\">",
"      Patterson R, Fitzsimons EJ, Choy AC, Harris KE. Malignant and corticosteroid-dependent idiopathic anaphylaxis: successful responses to ketotifen. Ann Allergy Asthma Immunol 1997; 79:138.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 387 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-EC2EE36D8B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_17_34071=[""].join("\n");
var outline_f33_17_34071=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Mast cell activation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Lymphocyte and basophil activation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      DIAGNOSIS AND REFERRAL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Unsuspected triggers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Other disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13912230\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Acute management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Long term management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Combination therapy with glucocorticoids and antihistamines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Glucocorticoid-dependent idiopathic anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8249468\">",
"      - Omalizumab",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8249672\">",
"      - Other treatments",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8249755\">",
"      Medications to be avoided",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/387\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/387|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?20/36/21068\" title=\"table 1\">",
"      Symptoms and signs of anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?22/43/23228\" title=\"table 2\">",
"      Anaphylaxis diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?39/31/40443\" title=\"table 3\">",
"      Classification of mast cell disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?33/15/34044\" title=\"table 4\">",
"      Comparison of mast cell disorders",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/46/40681?source=related_link\">",
"      Allergic and asthmatic reactions to food additives",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/14/36072?source=related_link\">",
"      Allergy to meats",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/17/15641?source=related_link\">",
"      An overview of angioedema: Clinical features, diagnosis, and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/11/9401?source=related_link\">",
"      Anaphylaxis: Confirming the diagnosis and determining the trigger(s)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/29/35290?source=related_link\">",
"      Anaphylaxis: Rapid recognition and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/46/17130?source=related_link\">",
"      Anti-IgE therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/35/12857?source=related_link\">",
"      Approach to flushing in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/62/38888?source=related_link\">",
"      Differential diagnosis of anaphylaxis in children and adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/13/18650?source=related_link\">",
"      Evaluation and diagnosis of mastocytosis (cutaneous and systemic)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/54/40809?source=related_link\">",
"      Laboratory tests to support the clinical diagnosis of anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/35/9785?source=related_link\">",
"      Latex allergy: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/44/5833?source=related_link\">",
"      Long-term management of patients with anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/41/19096?source=related_link\">",
"      Marine toxins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/28/20937?source=related_link\">",
"      Mast cell activation disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/60/37834?source=related_link\">",
"      Pharmacotherapy of allergic rhinitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/48/36615?source=related_link\">",
"      Reactions to bites from kissing bugs (Triatoma)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/61/16346?source=related_link\">",
"      Seafood allergies: Fish and shellfish",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_17_34072="Esomeprazole and naproxen: Drug information";
var content_f33_17_34072=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Esomeprazole and naproxen: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?6/57/7062?source=see_link\">",
"    see \"Esomeprazole and naproxen: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block spa drugH1Div\" id=\"F16572474\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Special Alerts",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Bone Fracture Risk with Proton Pump Inhibitors: Health Canada Issues Alert",
"     </span>",
"     <span class=\"collapsible-date\">",
"      April 2013",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Health Canada has informed healthcare professionals that proton pump inhibitors (PPIs) may increase the risk of bone fractures. The risk of fracture was observed to be higher in patients receiving multiple daily doses for &ge;1 year; age, gender, and concomitant health conditions may also be a factor. Patients with risk factors for osteoporosis should be closely monitored and should receive a PPI at the lowest effective dose and for the shortest duration of therapy appropriate for the condition.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       For more information, refer to file://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2013/26523a-eng.php.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F10241629\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F10241634\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Vimovo&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F12817167\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Vimovo&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F10241638\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Nonsteroidal Anti-inflammatory Drug (NSAID), Oral;",
"     </li>",
"     <li>",
"      Proton Pump Inhibitor;",
"     </li>",
"     <li>",
"      Substituted Benzimidazole",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F10241664\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Reduce NSAID-associated gastric ulcers during treatment for arthritis:",
"     </b>",
"     Oral: One tablet (375 mg naproxen/20 mg esomeprazole or 500 mg naproxen/20 mg esomeprazole) twice daily; maximum esomeprazole dose: 40 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     If a total daily dose of esomeprazole &lt;40 mg is necessary, alternate treatment should be considered.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F10241665\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Naproxen: Dosing adjustment should be considered; use lowest effective dose. Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F10241666\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Moderate-to-severe renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute): Use is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F10241667\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Severe liver disease: Use of this combination product not recommended since esomeprazole dose will exceed 20 mg daily.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F10241689\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, variable release, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vimovo&trade;: Naproxen [delayed release] 375 mg and esomeprazole [immediate release] 20 mg, Naproxen [delayed release] 500 mg and esomeprazole [immediate release] 20 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F10241636\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F10241632\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM213832.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM213832.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10241669\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer dose at least 30 minutes prior to meals. Tablets should be swallowed whole; do not chew, crush, dissolve, or split tablet.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10241640\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reduction of the risk of NSAID-associated gastric ulcers in patients at risk of developing gastric ulcers who require an NSAID for the treatment of rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F10241631\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Vimovo&trade; may be confused with Vimpat&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F10241653\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10241649\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to esomeprazole, other substituted benzimidazole proton pump inhibitors, naproxen, aspirin, other NSAIDs, or any component of the formulation; perioperative pain in the setting of coronary artery bypass graft (CABG) surgery; late stages of pregnancy",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F10241650\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylactoid reactions: Even in patients without prior exposure anaphylactoid reactions may occur; patients with \"aspirin triad\" (bronchial asthma, aspirin intolerance, rhinitis) may be at increased risk. Do not use in patients who experience bronchospasm, asthma, rhinitis, or urticaria with NSAID or aspirin therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Atrophic gastritis: Long-term omeprazole therapy has caused atrophic gastritis (by biopsy); this may also occur with esomeprazole.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Carcinoma: No occurrences of enterochromaffin-like (ECL) cell carcinoids, dysplasia, or neoplasia, such as those seen in rodent studies, have been reported in humans.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull;",
"     <i>",
"      Clostridium difficile",
"     </i>",
"     -associated diarrhea (CDAD): Use of proton pump inhibitors (PPIs) may increase risk of CDAD, especially in hospitalized patients; consider CDAD diagnosis in patients with persistent diarrhea that does not improve. Use the lowest dose and shortest duration of PPI therapy appropriate for the condition being treated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypomagnesemia: Reported rarely, usually with prolonged PPI use of &gt;3 months (most cases &gt;1 year of therapy). May be symptomatic or asymptomatic; severe cases may cause tetany, seizures, and cardiac arrhythmias. Consider obtaining serum magnesium concentrations prior to beginning long-term therapy, especially if taking concomitant digoxin, diuretics, or other drugs known to cause hypomagnesemia; and periodically thereafter. Hypomagnesemia may be corrected by magnesium supplementation, although discontinuation of esomeprazole may be necessary; magnesium levels typically return to normal within 1 week of stopping.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular events:",
"     <b>",
"      [U.S. Boxed Warning]: NSAIDs are associated with an increased risk of adverse cardiovascular thrombotic events, including MI and stroke.",
"     </b>",
"     Risk may be increased with duration of use or pre-existing cardiovascular risk factors or disease. Carefully evaluate individual cardiovascular risk profiles prior to prescribing. Use caution with fluid retention. Avoid use in heart failure. Concurrent administration of ibuprofen, and potentially other nonselective NSAIDs, may interfere with aspirin&rsquo;s cardioprotective effect. Use the lowest effective dose for the shortest duration of time, consistent with individual patient goals, to reduce risk of cardiovascular events; alternate therapies should be considered for patients at high risk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS effects: May cause drowsiness, dizziness, blurred vision, and other neurologic effects which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving). Discontinue use with blurred or diminished vision and perform ophthalmologic exam. Periodically evaluate vision in all patients receiving long term therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Fractures: Increased incidence of osteoporosis-related bone fractures of the hip, spine, or wrist may occur with proton pump inhibitor (PPI) therapy. Patients on high-dose or long-term therapy should be monitored. Use the lowest effective dose for the shortest duration of time, use vitamin D and calcium supplementation, and follow appropriate guidelines to reduce risk of fractures.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal events:",
"     <b>",
"      [U.S. Boxed Warning]: NSAIDs may increase risk of gastrointestinal irritation, inflammation, ulceration, bleeding, and perforation.",
"     </b>",
"     These events may occur at any time during therapy and without warning. Use caution with a history of GI disease (bleeding, inflammatory bowel disease, ulcers), concurrent therapy with aspirin, anticoagulants and/or corticosteroids, smoking, use of alcohol, the elderly or debilitated patients. Use the lowest effective dose for the shortest duration of time, consistent with individual patient goals, to reduce risk of GI adverse events; alternate therapies should be considered for patients at high risk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hematologic effects: Platelet adhesion and aggregation may be decreased; may prolong bleeding time; patients with coagulation disorders or who are receiving anticoagulants should be monitored closely. Anemia may occur; patients on long-term NSAID therapy should be monitored for anemia. Rarely, NSAID use has been associated with potentially severe blood dyscrasias (eg, agranulocytosis, thrombocytopenia, aplastic anemia).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperkalemia: NSAID use may increase the risk of hyperkalemia, particularly in the elderly, diabetics, renal disease, and with concomitant use of other agents capable of inducing hyperkalemia (eg, ACE-inhibitors). Monitor potassium closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Skin reactions: NSAIDs may cause serious skin adverse events including exfoliative dermatitis, Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN); discontinue use at first sign of skin rash or hypersensitivity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Aseptic meningitis: May increase the risk of aseptic meningitis, especially in patients with systemic lupus erythematosus (SLE) and mixed connective tissue disorders.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Asthma: Do not administer to patients with aspirin-sensitive asthma; severe bronchospasm may occur. Use caution in patients with other forms of asthma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Coronary artery bypass graft surgery:",
"     <b>",
"      [U.S. Boxed Warning]: Use is contraindicated for treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery.",
"     </b>",
"     Risk of MI and stroke may be increased with use following CABG surgery.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastric malignancy: Relief of symptoms does not preclude the presence of a gastric malignancy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal infection (eg,",
"     <i>",
"      Salmonella, Campylobacter",
"     </i>",
"     ): Use of proton pump inhibitors may increase risk of these infections.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with mild to moderate hepatic function. Closely monitor patients with any abnormal LFT. Severe hepatic reactions (eg, fulminant hepatitis, liver failure) have occurred with NSAID use, rarely; discontinue if signs or symptoms of liver disease develop, or if systemic manifestations occur. In severe hepatic impairment, this combination product should not be used since esomeprazole doses exceeding 20 mg are not recommended in this population.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypertension: Use with caution; may cause new-onset hypertension or worsening of existing hypertension.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: NSAID use may compromise existing renal function; dose-dependent decreases in prostaglandin synthesis may result from NSAID use, reducing renal blood flow which may cause renal decompensation. Patients with impaired renal function, dehydration, heart failure, liver dysfunction, those taking diuretics, and ACE inhibitors, and the elderly are at greater risk of renal toxicity. Rehydrate patient before starting therapy; monitor renal function closely. Naproxen is not recommended for use in patients with advanced renal disease. Long-term NSAID use may result in renal papillary necrosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Clopidogrel: Proton pump inhibitors (PPIs) may diminish the therapeutic effect of clopidogrel thought to be due to reduced formation of the active metabolite of clopidogrel. The manufacturer of clopidogrel recommends either avoidance of both omeprazole (even when scheduled 12 hours apart) and esomeprazole or use of a PPI with comparatively less effect on the active metabolite of clopidogrel (eg, pantoprazole). In contrast to these warnings, others have recommended the continued use of PPIs, regardless of the degree of inhibition, in patients with a history of GI bleeding or multiple risk factors for GI bleeding who are also receiving clopidogrel since no evidence has established clinically meaningful differences in outcome; however, a clinically-significant interaction cannot be excluded in those who are poor metabolizers of clopidogrel (Abraham, 2010; Levine, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; High potential for other interactions: Concomitant use of esomeprazole with some drugs may require cautious use, may not be recommended, or may require dosage adjustments.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Asian ethnicity: Bioavailability of esomeprazole may be increased in patients of Asian descent.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: The elderly are at increased risk for adverse effects (especially peptic ulceration, CNS effects, renal toxicity) from NSAIDs even at low doses. Patients &ge;50 years of age may be at increased risk for development of fractures with use of proton pump inhibitors. Bioavailability of esomeprazole may be increased in the elderly.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Laboratory test interference: Serum chromogranin A (CgA) levels increase secondary to drug-induced decreases in gastric acid; may cause false-positive results in diagnostic investigations for neuroendocrine tumors. Stop esomeprazole treatment temporarily before CgA test; if CgA level high, repeat to confirm. Use same commercial laboratory for testing to prevent variable results.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Surgical/dental procedures: Withhold products containing naproxen for at least 4-6 half-lives prior to surgical or dental procedures; consider alternative product if proton pump inhibitor required.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299744\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F10328018\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of other Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Agents with Antiplatelet Properties. An increased risk of bleeding may occur. Nonsteroidal Anti-Inflammatory Agents may diminish the cardioprotective effect of Agents with Antiplatelet Properties. This interaction is likely specific to aspirin, and not to other antiplatelet agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aliskiren: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Aliskiren. Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of Aliskiren.  Management: Monitor renal function periodically in patients receiving aliskiren and any nonsteroidal anti-inflammatory agent.  Patients at elevated risk of renal dysfunction include those who are elderly, are volume depleted, or have pre-existing renal dysfunction.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglycosides: Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: Proton Pump Inhibitors may increase the serum concentration of Amphetamines. Specifically, data indicate that Proton Pump Inhibitors may increase the rate at which Amphetamines are absorbed.  Total exposure to Amphetamines is not significantly changed.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Angiotensin II Receptor Blockers. The combination of these two agents may also significantly decrease glomerular filtration and renal function.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Nonsteroidal Anti-Inflammatory Agents may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidepressants (Tricyclic, Tertiary Amine): May enhance the antiplatelet effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atazanavir: Proton Pump Inhibitors may decrease the serum concentration of Atazanavir.  Management: Avoid concurrent PPI in HIV treatment-experienced patients.  For treatment-naive patients, atazanavir/ritonavir dose should be given approximately 12 hours after the PPI, and the PPI should not exceed the equivalent of 20 mg omeprazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzodiazepines (metabolized by oxidation): Proton Pump Inhibitors may increase the serum concentration of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Proton Pump Inhibitors may diminish the therapeutic effect of Bisphosphonate Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: Proton Pump Inhibitors may decrease the serum concentration of Bosutinib.  Management: Consider alternatives to proton pump inhibitors, such as antacids or H2 receptor antagonists.  Administer alternative agents more than 2 hours before or after bosutinib.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cefditoren: Proton Pump Inhibitors may decrease the serum concentration of Cefditoren.  Management: If possible, avoid use of cefditoren with proton pump inhibitors (PPIs). Consider alternative methods to minimize/control acid reflux (eg, diet modification) or alternative antimicrobial therapy if use of PPIs can not be avoided.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cilostazol: Esomeprazole may enhance the adverse/toxic effect of Cilostazol. Esomeprazole may increase the serum concentration of Cilostazol. Esomeprazole may increase the serum concentration of OPC-13015, an active metabolite of Cilostazol.  Management: Monitor for increased cilostazol effects when coadministered with esomeprazole. The manufacturer recommends considering a 50% dose reduction of cilostazol (eg, 100 mg twice daily to 50 mg twice daily) with concomitant use of these agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clopidogrel: Esomeprazole may decrease serum concentrations of the active metabolite(s) of Clopidogrel.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Collagenase (Systemic): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May enhance the adverse/toxic effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of CycloSPORINE (Systemic). Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents. Specifically, elevated diclofenac concentrations have been reported.  Management: Consider alternatives to nonsteroidal anti-inflammatory agents (NSAIDs).  Monitor for evidence of nephrotoxicity, as well as increased serum cyclosporine concentrations and systemic effects (e.g., hypertension) during concomitant therapy with NSAIDs.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Inducers (Strong): May increase the metabolism of CYP2C19 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Substrates: CYP2C19 Inhibitors (Moderate) may decrease the metabolism of CYP2C19 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: Proton Pump Inhibitors may decrease serum concentrations of the active metabolite(s) of Dabigatran Etexilate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: Proton Pump Inhibitors may decrease the serum concentration of Dasatinib.  Management: Antacids (taken 2 hours before or after dasatinib administration) can be used in place of the proton pump inhibitor if some acid-reducing therapy is needed.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Delavirdine: Proton Pump Inhibitors may decrease the serum concentration of Delavirdine.  Management: Chronic therapy with proton pump inhibitors (PPIs) should be avoided in patients treated with delavirdine.  The clinical significance of short-term PPI therapy with delavirdine is uncertain, but such therapy should be undertaken with caution.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dexmethylphenidate: Proton Pump Inhibitors may increase the absorption of Dexmethylphenidate. Specifically, proton pump inhibitors may interfere with the normal release of drug from the extended-release capsules (Focalin XR brand), which could result in both increased absorption (early) and decreased delayed absorption.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Drotrecogin Alfa (Activated): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Drotrecogin Alfa (Activated). Bleeding may occur.  Management: When possible, avoid use of drotrecogin within 7 days of use of any IIb/IIIa antagonists, higher dose aspirin (more than 650 mg/day), or use of other antiplatelet agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Eplerenone. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Eplerenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Erlotinib: Proton Pump Inhibitors may decrease the serum concentration of Erlotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Floctafenine: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May increase the serum concentration of Proton Pump Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gefitinib: Proton Pump Inhibitors may decrease the serum concentration of Gefitinib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Glucosamine: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Haloperidol: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Haloperidol. Specifically including drowsiness and confusion.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Bleeding may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Bleeding may occur. Management: Concomitant treatment with these agents should generally be avoided. If used concomitantly, increased diligence in monitoring for adverse effects (eg, bleeding, bruising, altered mental status due to CNS bleeds) must be employed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrALAZINE: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of HydrALAZINE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ibritumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Indinavir: Proton Pump Inhibitors may decrease the serum concentration of Indinavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iron Salts: Proton Pump Inhibitors may decrease the absorption of Iron Salts.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ferric Gluconate; Ferumoxytol; Iron Dextran Complex; Iron Sucrose.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: Proton Pump Inhibitors may decrease the serum concentration of Itraconazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketoconazole (Systemic): Proton Pump Inhibitors may decrease the serum concentration of Ketoconazole (Systemic). Ketoconazole (Systemic) may increase the serum concentration of Proton Pump Inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Nasal): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Systemic): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Lithium.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the diuretic effect of Loop Diuretics.  Management: Monitor for decreased therapeutic effects of loop diuretics with concurrent use of an NSAID. Consider avoiding concomitant use of these agents in CHF or cirrhosis with ascites. Concomitant use of bumetanide with indomethacin is  not recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mesalamine: Proton Pump Inhibitors may diminish the therapeutic effect of Mesalamine. Proton pump inhibitor-mediated increases in gastrointestinal pH may cause the premature release of mesalamine from specific sustained-release mesalamine products.  Management: Consider avoiding concurrent administration of high-dose proton pump inhibitors (PPIs) with sustained-release mesalamine products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: Proton Pump Inhibitors may increase the serum concentration of Methotrexate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: Proton Pump Inhibitors may increase the absorption of Methylphenidate. Specifically, proton pump inhibitors may interfere with the normal release of drug from the extended-release capsules (Ritalin LA brand), which could result in both increased absorption (early) and decreased delayed absorption.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): Proton Pump Inhibitors may decrease the serum concentration of Multivitamins/Minerals (with ADEK, Folate, Iron). Specifically, the absorption of iron may be decreased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: Proton Pump Inhibitors may decrease the serum concentration of Mycophenolate. Specifically, concentrations of the active mycophenolic acid may be reduced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nelfinavir: Proton Pump Inhibitors may decrease serum concentrations of the active metabolite(s) of Nelfinavir. Proton Pump Inhibitors may decrease the serum concentration of Nelfinavir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nilotinib: Proton Pump Inhibitors may decrease the serum concentration of Nilotinib.  Management: Avoid this combination when possible since separation of doses is not likely to be an adequate method of minimizing the interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. An increased risk of bleeding may occur. Nonsteroidal Anti-Inflammatory Agents may diminish the cardioprotective effect of Agents with Antiplatelet Properties. This interaction is likely specific to aspirin, and not to other antiplatelet agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of other Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of NSAID (COX-2 Inhibitor).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omacetaxine: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased.  Management: Avoid concurrent use of nonsteroidal antiinflammatory drugs (NSAIDs) with omacetaxine in patients with a platelet count of less than 50,000/uL.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omega-3 Fatty Acids: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PEMEtrexed: NSAID (Nonselective) may increase the serum concentration of PEMEtrexed.  Management: Patients with mild-to-moderate renal insufficiency (estimated creatinine clearance 45-79 mL/min) should avoid NSAIDs for 2-5 days prior to, the day of, and 2 days after pemetrexed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentosan Polysulfate Sodium: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ponatinib: Proton Pump Inhibitors may decrease the serum concentration of Ponatinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Posaconazole: Proton Pump Inhibitors may decrease the serum concentration of Posaconazole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Potassium-Sparing Diuretics. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PRALAtrexate: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of PRALAtrexate. More specifically, NSAIDS may decrease the renal excretion of pralatrexate.  Management: Closely monitor for increased pralatrexate serum levels and/or toxicity if used concomitantly with an NSAID. Monitor for decreased pralatrexate serum levels with NSAID discontinuation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Nonsteroidal Anti-Inflammatory Agents may enhance the neuroexcitatory and/or seizure-potentiating effect of Quinolone Antibiotics. Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Quinolone Antibiotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Raltegravir: Proton Pump Inhibitors may increase the serum concentration of Raltegravir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifampin: May decrease the serum concentration of Esomeprazole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rilpivirine: Proton Pump Inhibitors may decrease the serum concentration of Rilpivirine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Risedronate: Proton Pump Inhibitors may diminish the therapeutic effect of Risedronate. Proton Pump Inhibitors may increase the serum concentration of Risedronate. This applies specifically to use of delayed-release risedronate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Rivaroxaban.  Management: Avoid concurrent use of clopidogrel with rivaroxaban unless the anticipated benefits outweigh the risks of bleeding.  Avoid concurrent use of rivaroxaban with other antiplatelet agents whenever possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: NSAID (Nonselective) may enhance the adverse/toxic effect of Salicylates. An increased risk of bleeding may be associated with use of this combination. NSAID (Nonselective) may diminish the cardioprotective effect of Salicylates. Salicylates may decrease the serum concentration of NSAID (Nonselective).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Choline Magnesium Trisalicylate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saquinavir: Proton Pump Inhibitors may increase the serum concentration of Saquinavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the antiplatelet effect of NSAID (Nonselective). NSAID (Nonselective) may diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors. Management: Consider using alternative analgesics, when appropriate, and/or addition of an gastroprotective agent.  Monitor patients closely for signs/symptoms of bleeding, and for evidence of diminished SSRI effectiveness with concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the antiplatelet effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: May enhance the nephrotoxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk of acute phosphate nephropathy may be enhanced. Management: Consider avoiding this combination by temporarily suspending treatment with NSAIDs, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, maintain adequate hydration and monitor renal function closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May decrease the serum concentration of Esomeprazole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): Proton Pump Inhibitors may increase the serum concentration of Tacrolimus (Systemic).  Management: Tacrolimus dose adjustment may be required. Rabeprazole, pantoprazole, or selected H2-receptor antagonists (i.e., ranitidine or famotidine) may be less likely to interact. Genetic testing may predict patients at highest risk.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May decrease the serum concentration of Proton Pump Inhibitors. These data are derived from studies with Ritonavir-boosted Tipranavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tositumomab and Iodine I 131 Tositumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse events may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Treprostinil: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Bleeding may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vancomycin: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Vancomycin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vismodegib: Proton Pump Inhibitors may decrease the serum concentration of Vismodegib.  Management: Carefully consider the need for any medication that increases the pH of the upper GI tract (PPIs, H2RAs, antacids), as these could significantly reduce vismodegib systemic exposure. Vismodegib dose increases are unlikely to compensate for this effect.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin E: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): NSAID (Nonselective) may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Esomeprazole may increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F10241641\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C/D &ge;30 weeks gestation (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F10241642\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed with esomeprazole or naproxen in animal reproduction studies. Because they may cause premature closure of the ductus arteriosus, use of NSAIDs late in pregnancy should be avoided; use of this combination product is contraindicated the late stages of pregnancy. Refer to individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F10241643\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F10241648\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Naproxen is excreted in breast milk; excretion of esomeprazole is unknown. Breast-feeding is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F10241668\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Take dose at least 30 minutes prior to meals.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322852\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, EC",
"     </b>",
"     (Vimovo Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     375-20 mg (60): $137.69",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500-20 mg (60): $137.69",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F10241684\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Occult blood loss; periodic liver function test, CBC, BUN, serum creatinine",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F12707706\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Vimovo (AU, BE, CH, CO, CZ, EE, FI, GB, MY, NO, NZ, PH, SE, SG)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F10241658\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Naproxen: Reversibly inhibits cyclooxygenase-1 and 2 (COX-1 and 2) enzymes, which result in decreased formation of prostaglandin precursors; has antipyretic, analgesic, and anti-inflammatory properties",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Esomeprazole: Proton pump inhibitor which decreases acid secretion in gastric parietal cells",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F10241660\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Abraham NS, Hlatky MA, Antman EM, et al, &ldquo;ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use: A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2010, 122(24):2619-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/17/34072/abstract-text/21060077/pubmed\" id=\"21060077\" target=\"_blank\">",
"        21060077",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hochberg MC, Altman RD, April KT, et al, &ldquo;American College of Rheumatology 2012 Recommendations for the Use of Nonpharmacologic and Pharmacologic Therapies in Osteoarthritis of the Hand, Hip, and Knee,&rdquo;",
"      <i>",
"       Arthritis Care Res (Hoboken)",
"      </i>",
"      , 2012, 64(4):465-74.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/17/34072/abstract-text/22563589/pubmed\" id=\"22563589\" target=\"_blank\">",
"        22563589",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lanza FL, Chan FK, and Quigley EM, &ldquo;Guidelines for Prevention of NSAID-Related Ulcer Complications,&rdquo;",
"      <i>",
"       Am J Gastroenterol",
"      </i>",
"      , 2009, 140(3):728-38.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/17/34072/abstract-text/19240698/pubmed\" id=\"19240698\" target=\"_blank\">",
"        19240698",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Levine GN, Bates ER, Blankenship JC, et al, &ldquo;2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(23):e574-651.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/17/34072/abstract-text/22064601/pubmed\" id=\"22064601\" target=\"_blank\">",
"        22064601",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15571 Version 47.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-190.111.122.2-74CF0474CE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_17_34072=[""].join("\n");
var outline_f33_17_34072=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16572474\">",
"      Special Alerts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10241629\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10241634\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12817167\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10241638\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10241664\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10241665\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10241666\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10241667\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10241689\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10241636\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10241632\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10241669\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10241640\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10241631\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10241653\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10241649\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10241650\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299744\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10328018\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10241641\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10241642\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10241643\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10241648\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10241668\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322852\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10241684\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12707706\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10241658\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10241660\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/15571\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/15571|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?6/57/7062?source=related_link\">",
"      Esomeprazole and naproxen: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_17_34073="Nutrition support in critically ill patients: Enteral nutrition";
var content_f33_17_34073=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Nutrition support in critically ill patients: Enteral nutrition",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/17/34073/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/17/34073/contributors\">",
"     David Seres, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/17/34073/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/17/34073/contributors\">",
"     Polly E Parsons, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/17/34073/contributors\">",
"     Timothy O Lipman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/17/34073/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/17/34073/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/17/34073/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 1, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Enteral nutrition support refers to the provision of calories, protein, electrolytes, vitamins, minerals, trace elements, and fluids via an intestinal route. The available formulations, components, delivery, and complications of enteral nutrition are reviewed here. The goals, outcomes, indications, contraindications, nutritional requirements, and timing of initiation of enteral nutrition are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/32/13831?source=see_link\">",
"     \"Nutrition support in critically ill patients: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INDICATIONS AND CONTRAINDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The indications and contraindications for enteral nutrition are described elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/32/13831?source=see_link&amp;anchor=H9#H9\">",
"     \"Nutrition support in critically ill patients: An overview\", section on 'Patient selection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INITIATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;To initiate enteral nutrition, appropriate access must be obtained and the prescription needs to be determined. The prescription includes the formulation, composition, delivery strategy, and delivery rate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Access",
"    </span>",
"    &nbsp;&mdash;&nbsp;Enteral nutrition is most commonly delivered into the stomach (gastric feeding). However, it can also be administered into more distal parts of the alimentary tract (post-pyloric).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Gastric",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastric feeding is typically delivered via an orogastric or nasogastric tube. Such tubes are available in two varieties:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sump tubes are larger and stiffer. They are generally inserted for gastric decompression and then used to deliver enteral nutrition when gastric decompression is no longer necessary.",
"     </li>",
"     <li>",
"      Feeding tubes are smaller, more flexible, often have a weighted end, and often require a stylet for insertion. A feeding tube's position should be confirmed radiographically before it is used because it is frequently misplaced into an airway [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/17/34073/abstract/1\">",
"       1",
"      </a>",
"      ]. Once its position is confirmed, the stylet should be removed and never replaced. Trying to replace the stylet can lead to inadvertent bowel puncture. A feeding tube cannot be used for gastric decompression because its soft walls tend to collapse when suction is applied.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Percutaneous endoscopic gastrostomy (PEG) tubes, percutaneous radiologic gastrostomy tubes, and surgical gastrostomy tubes are alternative approaches to delivering gastric feedings. A surgical gastrostomy tube can be inserted laparoscopically or by an open surgical approach. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/63/20473?source=see_link\">",
"     \"Percutaneous endoscopic gastrostomy (PEG) tubes: Uses and efficacy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/7/34937?source=see_link\">",
"     \"Prevention and management of complications from percutaneous endoscopic gastrostomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Post-pyloric",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several techniques have been described for blind insertion of feeding tubes that terminate beyond the pylorus, usually ending in the first or second part of the duodenum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/17/34073/abstract/2\">",
"     2",
"    </a>",
"    ]. All are technically difficult and require advanced training. As an example, the Corpak 10-10-10 protocol involves administering",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/13/216?source=see_link\">",
"     metoclopramide",
"    </a>",
"    10 minutes prior to tube insertion and then gently advancing the feeding tube from the stomach in 5 cm increments [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/17/34073/abstract/3\">",
"     3",
"    </a>",
"    ]. After each increment of advancement, the wire is withdrawn slightly to check for resistance, with resistance indicating possible coiling or kinking of the feeding tube. Post-pyloric positioning is confirmed radiographically. Alternative approaches to blind insertion include endoscopic, percutaneous endoscopic, percutaneous radiological, or surgical tube insertion.",
"   </p>",
"   <p>",
"    Many of the tubes used for post-pyloric feeding have two ports, a proximal port to drain the stomach and a distal port to deliver enteral nutrition into the distal duodenum or proximal jejunum. These tubes transit through the stomach and into the small bowel. Post-pyloric feeding tubes are most useful in patients with the prolonged inability to tolerate gastric feedings, gastric outlet obstruction, duodenal obstruction, a gastric or duodenal fistula, severe gastroesophageal reflux, or the inability to have a gastric enteral access tube due to altered anatomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/17/34073/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Formulations",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are many products available for enteral nutrition. Common differences between formulas include osmolarity, caloric density, and amount of protein per calorie, as well as electrolyte, vitamin, and mineral content. In addition, there may be differences related to whether they are intact or predigested, fiber is present or absent, and disease-specific nutrients are present or absent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/17/34073/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Standard enteral nutrition provides sufficient nourishment for most critically ill patients if given with caloric adequacy, although concentrated and predigested enteral nutrition may be preferable for selected patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Standard",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following characteristics are typical of standard enteral nutrition:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Isotonic to serum",
"     </li>",
"     <li>",
"      Caloric density of approximately 1",
"      <span class=\"nowrap\">",
"       kcal/mL",
"      </span>",
"     </li>",
"     <li>",
"      Lactose-free",
"     </li>",
"     <li>",
"      Intact (nonhydrolyzed) protein content of about 40",
"      <span class=\"nowrap\">",
"       g/1000",
"      </span>",
"      mL",
"     </li>",
"     <li>",
"      Nonprotein calorie to nitrogen ratio of approximately 150",
"     </li>",
"     <li>",
"      Mixture of simple and complex carbohydrates",
"     </li>",
"     <li>",
"      Long-chain fatty acids (although some are now including medium-chain and omega-3 fatty acids)",
"     </li>",
"     <li>",
"      Essential vitamins, minerals, and micronutrients",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Administration of 18",
"    <span class=\"nowrap\">",
"     kcal/kg",
"    </span>",
"    per day is a reasonable starting point for most critically ill patients. Most patients require additional free water.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Concentrated",
"    </span>",
"    &nbsp;&mdash;&nbsp;Critically ill patients frequently require volume restriction. Concentrated enteral nutrition may be useful for such patients.",
"   </p>",
"   <p>",
"    The standard composition of concentrated enteral nutrition is similar to that of standard enteral nutrition, except that it is hyperosmolar to serum and has a caloric density 1.2, 1.5, or 2.0",
"    <span class=\"nowrap\">",
"     kcal/mL.",
"    </span>",
"    The hyperosmolality of concentrated enteral nutrition predisposes patients to diarrhea or symptoms similar to dumping syndrome if it is infused rapidly. Dumping syndrome is characterized by symptoms of nausea, shaking, diaphoresis, and diarrhea shortly after eating foods containing high amounts of refined sugars. Concentrated enteral nutrition is less likely to be tolerated if it is delivered post-pyloric [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/17/34073/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/57/33688?source=see_link&amp;anchor=H12#H12\">",
"     \"Role of surgery in the management of peptic ulcer disease\", section on 'Dumping syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Predigested",
"    </span>",
"    &nbsp;&mdash;&nbsp;Predigested enteral nutrition (previously called chemically defined, semi-elemental, or elemental) differs from standard enteral nutrition in that the protein is hydrolyzed to short-chain peptides and the carbohydrates are in a less complex form. The total amount of fat may be decreased, with an increased proportion of medium-chain triglycerides.",
"   </p>",
"   <p>",
"    Predigested enteral nutrition may be beneficial in patients with the following problems:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Thoracic duct leak, chylothorax, or chylous ascites, since the medium-chain triglycerides do not enter the lymphatic capillaries in the small intestine",
"     </li>",
"     <li>",
"      Digestive defects (eg, malabsorptive syndromes that are unresponsive to supplementation of pancreatic enzymes)",
"     </li>",
"     <li>",
"      Failure to tolerate standard enteral nutrition",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Predigested enteral nutrition usually has a caloric density of 1 or 1.5",
"    <span class=\"nowrap\">",
"     kcal/mL.",
"    </span>",
"    It may be used as an initial tube feed in patients with marginal gut function or a short gut because it is generally well tolerated. Patients who tolerate the predigested enteral nutrition can then be transitioned to standard enteral nutrition.",
"   </p>",
"   <p>",
"    The original formulations of predigested enteral nutrition included amino acids instead of peptides or proteins. These formulations are rarely used today, since amino acid-based feedings are hypertonic and tend to be poorly tolerated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Critical illness",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of enteral feeding formulations were developed for patients with specific critical illnesses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/17/34073/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. However, no such formulation has consistently demonstrated a beneficial effect on clinical outcomes. As a result, disease-specific enteral nutrition is not recommended over the traditional types of enteral nutrition described above. The only exception is that enteral nutrition enriched with omega-3 fatty acids may be beneficial to patients with acute lung injury or acute respiratory distress syndrome, which is discussed below. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Omega-3 fatty acids'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Composition",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Carbohydrate/fat",
"    </span>",
"    &nbsp;&mdash;&nbsp;Enteral nutrition can deliver the same caloric density using different proportions of carbohydrate and fat. Low",
"    <span class=\"nowrap\">",
"     carbohydrate/high",
"    </span>",
"    fat and high",
"    <span class=\"nowrap\">",
"     carbohydrate/low",
"    </span>",
"    fat formulations exist, but neither is recommended for routine enteral nutrition.",
"   </p>",
"   <p>",
"    Standard enteral nutrition delivers 49 to 53 percent of calories as carbohydrate and 29 to 30 percent of calories as fat. In contrast, low",
"    <span class=\"nowrap\">",
"     carbohydrate/high",
"    </span>",
"    fat enteral nutrition typically delivers 28 to 40 percent of calories as carbohydrate and 40 to 55 percent of calories as fat. High",
"    <span class=\"nowrap\">",
"     carbohydrate/low",
"    </span>",
"    fat enteral nutrition delivers only 15 percent of calories as fat.",
"   </p>",
"   <p>",
"    Low",
"    <span class=\"nowrap\">",
"     carbohydrate/high",
"    </span>",
"    fat enteral nutrition was developed with the intention of reducing the work of breathing and facilitating weaning from the ventilator. The rationale was that low carbohydrate enteral nutrition would lead to the production of less carbon dioxide; thus, a smaller minute ventilation would be necessary to maintain a normal arterial carbon dioxide tension (PaCO",
"    <sub>",
"     2",
"    </sub>",
"    ). Clinical studies have failed to uphold this theory. Excess total calories delay weaning, but enteral nutrition that is low in carbohydrate and high in fat does not seem to improve PaCO",
"    <sub>",
"     2",
"    </sub>",
"    or weaning time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/17/34073/abstract/8,11\">",
"     8,11",
"    </a>",
"    ]. In addition, low",
"    <span class=\"nowrap\">",
"     carbohydrate/high",
"    </span>",
"    fat enteral nutrition does not affect mortality, infectious complications, or ICU length of stay, compared to standard enteral nutrition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/17/34073/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    High",
"    <span class=\"nowrap\">",
"     carbohydrate/low",
"    </span>",
"    fat enteral nutrition has been scarcely studied. One trial randomly assigned 43 burn patients to receive either standard enteral nutrition or low",
"    <span class=\"nowrap\">",
"     fat/high",
"    </span>",
"    carbohydrate enteral nutrition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/17/34073/abstract/14\">",
"     14",
"    </a>",
"    ]. There was no difference in mortality or ICU length of stay; however, the group that received the low",
"    <span class=\"nowrap\">",
"     fat/high",
"    </span>",
"    carbohydrate enteral nutrition had a significant reduction in the incidence of pneumonia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Protein",
"    </span>",
"    &nbsp;&mdash;&nbsp;Low protein enteral nutrition was developed for patients with renal disease because there is widespread belief that protein restriction delays the progression of renal disease. However, this remains unproven, as clinical trials have shown that even patients receiving continuous renal replacement can tolerate protein intake as high as 2.5",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per day during critical illness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/17/34073/abstract/15\">",
"     15",
"    </a>",
"    ]. Low protein enteral nutrition is not recommended as routine enteral nutrition for patients with acute or chronic renal disease, although these renal formulas may be helpful in managing critically ill patients who require fluid",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    electrolyte restriction, such as patients with acute renal failure complicated by fluid overload, hyperkalemia, and hyperphosphatemia.",
"   </p>",
"   <p>",
"    Standard enteral nutrition delivers an intact (nonhydrolyzed) protein content of about 40",
"    <span class=\"nowrap\">",
"     g/1000",
"    </span>",
"    mL, with a nonprotein calorie to nitrogen ratio of approximately 150. In contrast, low protein enteral nutrition delivers a protein content of 15 to 35",
"    <span class=\"nowrap\">",
"     g/1000",
"    </span>",
"    mL, with a nonprotein calorie to nitrogen ratio of 173 to 391. Other features of low protein enteral nutrition include high caloric density (in order to reduce the volume delivered), fat content, and osmolarity, accompanied by a restricted amount of electrolytes (especially sodium, potassium, and phosphate).",
"   </p>",
"   <p>",
"    Low protein enteral nutrition has been evaluated in unselected critically ill patients (ie, with and without renal dysfunction). In a randomized trial, low protein enteral nutrition had no effect on mortality or infectious complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/17/34073/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Peptides",
"    </span>",
"    &nbsp;&mdash;&nbsp;Enteral nutrition has been developed that includes peptides instead of intact proteins. The intended purpose of such nutrition is to improve absorption by bypassing hydrolysis of the intact protein to peptides. However, pooled analyses of randomized trials demonstrated no significant difference in mortality, infectious complications, or the incidence of diarrhea when peptide-based enteral nutrition was compared to standard enteral nutrition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/17/34073/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Due to their lack of benefit and higher cost, enteral nutrition with peptides instead of intact proteins is not recommended for routine use. However, there may be circumstances in which peptides may be preferable to intact proteins. Patients in these situations generally also benefit from less complex carbohydrates and fats; thus, a predigested formulation should be considered. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Predigested'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Omega-3 fatty acids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antioxidants plus omega-3 fatty acids in a feeding product may have an antiinflammatory effect in the lung [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/17/34073/abstract/18\">",
"     18",
"    </a>",
"    ], which has led to the evaluation of whether such feeding products may improve clinical outcomes in patients with acute lung injury or acute respiratory distress syndrome",
"    <span class=\"nowrap\">",
"     (ALI/ARDS).",
"    </span>",
"    The evidence is conflicting:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a multicenter trial conducted by the ARDS Clinical Trials Network, 272 patients who were receiving mechanical ventilation due to",
"      <span class=\"nowrap\">",
"       ALI/ARDS",
"      </span>",
"      were randomly assigned to receive either enteral nutrition supplemented with omega-3 fatty acids plus antioxidants or a control enteral feed [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/17/34073/abstract/19\">",
"       19",
"      </a>",
"      ]. The study was stopped early due to potential harm; patients receiving omega-3 fatty acids plus antioxidants had fewer ventilator-free days (14 versus 17.2 days), fewer ICU-free days (14 versus 16.7 days), and fewer organ failure-free days (12.3 versus 15.5 days). In addition, there was a trend toward increased mortality in the group receiving omega-3 fatty acids plus antioxidants.",
"     </li>",
"     <li>",
"      In contrast, one of the earliest trials randomly assigned 146 patients with",
"      <span class=\"nowrap\">",
"       ALI/ARDS",
"      </span>",
"      to receive either an enteral feed supplemented with antioxidants plus omega-3 fatty acids or a control enteral feed [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/17/34073/abstract/20\">",
"       20",
"      </a>",
"      ]. Enteral nutrition supplemented with antioxidants plus omega-3 fatty acids significantly decreased the number of days on the ventilator, the number of days in the ICU, and the frequency of new organ failure. There was also a nonstatistically significant reduction in mortality (16 versus 25 percent, relative risk 0.63, 95% CI 0.32-1.22). These results should be interpreted with caution, since the enteral feed that was used as a control is a nonstandard feed that contains high amounts of omega-6 fatty acids. Two subsequent trials that used the same control enteral feed after it had been reformulated to contain less long-chain fatty acids and more medium-chain fatty acids reported similar results [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/17/34073/abstract/9,21\">",
"       9,21",
"      </a>",
"      ]. All of these trials used the same combination of antioxidants and omega-3 fatty acids (sold commercially under the brand name Oxepa",
"      <sup>",
"       &reg;",
"      </sup>",
"      ) and were partially funded by the maker of the product.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    All of the trials described above compared supplementation with omega-3 fatty acids plus antioxidants to a control enteral feed containing neither. The only trial comparing enteral feeds supplemented with omega-3 fatty acids alone (ie, no additional antioxidants) to a control enteral feed has been completed, but the results have not been published [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/17/34073/abstract/22\">",
"     22",
"    </a>",
"    ]. The trial is expected to report no benefit.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Glutamine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glutamine is a precursor for nucleotide synthesis and an important fuel source for rapidly dividing cells that is rapidly depleted in hypercatabolic patients. Glutamine-enriched enteral nutrition is not recommended for routine use in most critically ill patients because clinical trials have not found consistent improvement in clinical outcomes.",
"   </p>",
"   <p>",
"    Glutamine supplementation of enteral nutrition has been evaluated in more than 30 controlled trials with critically ill patients, most of which had significant methodologic problems or were too small to make definitive conclusions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/17/34073/abstract/23\">",
"     23",
"    </a>",
"    ]. In meta-analyses of randomized trials that compared enteral nutrition with and without glutamine, there was no difference in mortality or infectious complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/17/34073/abstract/24\">",
"     24",
"    </a>",
"    ]. When the meta-analyses were updated to include additional randomized trials, the absence of a mortality benefit persisted among patients who received glutamine-enriched enteral nutrition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/17/34073/abstract/25\">",
"     25",
"    </a>",
"    ]. However, a trend toward a reduction of infectious complications emerged (26 versus 31 percent, relative risk 0.83, 95% CI 0.64-1.08).",
"   </p>",
"   <p>",
"    Glutamine is metabolized by the liver, kidneys, and splanchnic tissue into glutamate and ammonia. Accumulation of glutamine and its byproducts may lead to adverse effects, such as encephalopathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Ornithine ketoglutarate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ornithine ketoglutarate (OKG) is a glutamine precursor that efficiently restores pools of glutamine in hypercatabolic patients. It is not recommended as an enteral nutrition supplement because clinical trials in burn patients failed to show any clinical benefit. A meta-analysis of three such randomized trials (163 burn patients) found no difference in mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/17/34073/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Arginine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arginine is considered conditionally essential during critical illness because it is utilized more quickly. It is required for normal immune function and healing, and it has important roles in nitrogen metabolism, ammonia metabolism, and the generation of nitric oxide. Despite this, arginine-enriched enteral nutrition is not recommended for routine use in critically ill patients because clinical outcomes have been inconsistent.",
"   </p>",
"   <p>",
"    Arginine-enriched enteral nutrition has been extensively compared to standard enteral nutrition, with inconsistent results. Whereas one randomized trial found that arginine-enriched enteral nutrition reduced infections and length of stay in burn patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/17/34073/abstract/9\">",
"     9",
"    </a>",
"    ], other studies suggested that arginine-enriched enteral nutrition was not beneficial and potentially harmful [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/17/34073/abstract/27\">",
"     27",
"    </a>",
"    ]. In a meta-analysis of 14 randomized trials (1624 patients) that compared arginine-enriched enteral nutrition to standard enteral nutrition in critically ill patients, there was no effect on mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/17/34073/abstract/24\">",
"     24",
"    </a>",
"    ]. Similarly, a meta-analysis of 10 randomized trials (1154 patients) found no effect on infectious complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/17/34073/abstract/24\">",
"     24",
"    </a>",
"    ]. These results persisted when the meta-analyses were updated to include additional randomized trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/17/34073/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Prebiotics/probiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prebiotics (eg, oligofructose) are nondigestible products that are used as enteral nutrition supplements to promote the growth of beneficial bacteria in the bowel with the hope of hindering the growth of harmful bacteria. Probiotics (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/16/32004?source=see_link\">",
"     Lactobacillus",
"    </a>",
"    species) are living microorganisms that are purported to provide a health benefit to the host when ingested. Routine supplementation of enteral nutrition with prebiotics or probiotics is not recommended because the pooled results from randomized trials demonstrate no effect on mortality or infectious complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/17/34073/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. At least one trial has found potential harm from probiotics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/17/34073/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Fiber",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fiber is frequently added to correct diarrhea or constipation in patients who are already receiving enteral nutrition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/17/34073/abstract/32\">",
"     32",
"    </a>",
"    ]. However, there is no evidence that routine supplementation of enteral nutrition with fiber can prevent diarrhea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/17/34073/abstract/33-39\">",
"     33-39",
"    </a>",
"    ], although it may help prevent constipation. Fiber-containing formulas should be avoided in patients on pressors because bezoars have been reported in this setting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/17/34073/abstract/40\">",
"     40",
"    </a>",
"    ]. Most fiber-containing formulas contain soluble fiber because",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/26/8614?source=see_link\">",
"     psyllium",
"    </a>",
"    fiber has been associated with clogging of the feeding tube. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Vitamins and trace elements",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous clinical trials have examined the effect of antioxidants given as single nutrients (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/37/13907?source=see_link\">",
"     selenium",
"    </a>",
"    ) or as a combination of nutrients (selenium, copper, zinc, vitamin A, vitamin C, vitamin E, and N-acetylcysteine) on critically ill patients. The trials used a variety of methods to administer the nutrients, including supplementation of parenteral nutrition, a separate intravenous infusion, supplementation of enteral nutrition, and oral intake.",
"   </p>",
"   <p>",
"    A meta-analysis of 15 such randomized trials (1647 patients) found that critically ill patients who received vitamins or trace elements, either alone or in combination, had a lower mortality rate than patients who did not receive vitamins or trace elements (20 versus 27 percent, relative risk 0.76, 95% CI 0.65-0.88) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/17/34073/abstract/41\">",
"     41",
"    </a>",
"    ]. Similar meta-analyses showed no differences in infectious complications, hospital length of stay, or ICU length of stay, but there was improvement in the duration of mechanical ventilation.",
"   </p>",
"   <p>",
"    Few of the trials looked specifically at patients receiving enteral nutrition. Rather, most enrolled a heterogeneous sample of patients receiving either enteral or parenteral nutrition and did not look for differences in the effects of the vitamins and trace elements in these subgroups. As a result, it seems reasonable to provide vitamins and trace elements to critically ill patients, regardless of the type of nutrition support that they are receiving [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/17/34073/abstract/32\">",
"     32",
"    </a>",
"    ]. The optimal mixture of vitamins and trace elements is yet to be determined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Continuous versus bolus",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no evidence that either continuous or bolus (ie, intermittent) enteral nutrition is superior to the other. Three randomized trials compared the two approaches and found no differences in mortality, infections, or ICU length of stay [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/17/34073/abstract/42-45\">",
"     42-45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Amount and rate",
"    </span>",
"    &nbsp;&mdash;&nbsp;The daily amount of enteral nutrition is tailored to the nutritional and fluid needs of each patient. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/32/13831?source=see_link&amp;anchor=H12#H12\">",
"     \"Nutrition support in critically ill patients: An overview\", section on 'Nutritional requirements'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Two strategies have been used to initiate enteral nutrition. They include incrementally increasing the infusion rate until the target maintenance rate is achieved, or initiating the infusion at the target maintenance rate. There is conflicting evidence regarding which approach is superior, with some trials suggesting that slowly increasing the infusion rate to the target is superior [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/17/34073/abstract/46,47\">",
"     46,47",
"    </a>",
"    ] and other trials finding that beginning at the target rate is more beneficial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/17/34073/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The best evidence suggests that initial low-volume enteral feeding has fewer undesirable effects than initial feeding at the target rate. The EDEN trial was a multicenter open-labelled trial that randomly assigned 1000 mechanically ventilated patients with acute lung injury to receive either full enteral feeding or low-volume enteral feeding for six days, after which both groups received full enteral feeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/17/34073/abstract/49\">",
"     49",
"    </a>",
"    ]. Full enteral feeding consisted of initiating enteral feeding at 25 mL per hour and then increasing the rate by 25 mL per hour every six hours until the target rate was achieved, as long as the gastric residual volume did not exceed 400 mL when checked prior to each rate increase. In contrast, low-volume enteral feeding consisted of initiating enteral feeding at approximately 10 to 20 mL per hour (approximately 30 percent of the maintenance target), continuing that rate for six days, and then advancing the infusion rate using the same protocol that was used in the full enteral feeding group. The trial found no differences in the number of ventilator-free days, 60-day mortality, or the frequency of infectious complications. However, the low-volume feeding group had less vomiting, smaller gastric residual volumes, lower mean plasma glucose levels, and less constipation. The low-volume feeding group also required fewer prokinetic agents and less insulin.",
"   </p>",
"   <p>",
"    We generally initiate enteral feeding in critically ill patients at a rate of 10 to 20",
"    <span class=\"nowrap\">",
"     mL/hr",
"    </span>",
"    for six days and then incrementally increase it to the target rate. We believe that the enteral nutrition is paused less often for issues such as high gastric residuals, diarrhea, or vomiting with this approach, resulting in the patient ultimately reaching a stable target rate within a reasonable period of time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     MONITORING",
"    </span>",
"    &nbsp;&mdash;&nbsp;It has long been standard clinical practice to check the patient's gastric residual volume at regular intervals",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    prior to increasing the infusion rate of gastric tube feeding, with the hope of minimizing the risk of unrecognized gastric fluid accumulation and vomiting resulting in pneumonia. However, this practice has now been shown to lack benefit. Studies have shown that measurement of gastric residuals correlates poorly with aspiration risk and is associated with a decrease in calorie delivery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/17/34073/abstract/50-52\">",
"     50-52",
"    </a>",
"    ]. Further evidence against routine measurement of gastric residuals comes from an unblinded trial in which 222 ICU patients were randomly assigned to monitoring of gastric residual volume every six hours, with adjustment of feeding rate for residuals over 250 mL, and 227 patients received enteral feeding without monitoring of residuals (enteral feeds were only adjusted when patients experienced vomiting or regurgitation) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/17/34073/abstract/53\">",
"     53",
"    </a>",
"    ]. The rate of ventilator associated pneumonia was not higher in the group without monitoring of gastric residuals. While there were almost twice as many vomiting episodes in the group without monitoring, the overall incidence of vomiting was relatively low. Other ICU outcomes such as duration of ICU-acquired infection, mechanical ventilation, hospital length of stay, and short-and long-term mortality were not different between the groups. Based on these findings, there is increasing consensus that the routine checking of gastric residual volumes is unnecessary in asymptomatic patients receiving tube feedings, and may inappropriately hamper calorie delivery. Gastric residuals should be measured if the patient exhibits a clinical change, such as abdominal pain, abdominal distension, or deterioration in hemodynamics or overall status.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a relative paucity of evidence regarding the frequency of adverse effects due to enteral nutrition. The limited evidence that exists suggests that the most common complications are aspiration, diarrhea, metabolic abnormalities, and mechanical complications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Aspiration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Enteral nutrition is associated with an increased incidence of aspiration. There are two likely explanations for this. First, until recently, critically ill patients were usually placed in a recumbent position. Second, critically ill patients tend to be unable to protect their airways. Despite the increased incidence of aspiration, it appears that enteral nutrition early in the course of surgical critical illness decreases the rate of nosocomial pneumonia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/17/34073/abstract/54\">",
"     54",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/32/13831?source=see_link&amp;anchor=H3#H3\">",
"     \"Nutrition support in critically ill patients: An overview\", section on 'Outcomes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Various strategies to reduce aspiration have been studied. These include backrest elevation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/17/34073/abstract/55\">",
"     55",
"    </a>",
"    ], post-pyloric feeding, enteral feeding via a percutaneous gastrostomy (PEG) tube, and administration of motility agents to promote gastric emptying. The rationale for most of these strategies was the belief that reflux and aspiration of gastric contents increases the risk for nosocomial pneumonia. Numerous studies have failed to confirm this hypothesis and it now seems likely that aspiration of oropharyngeal secretions is the likely cause of nosocomial pneumonia.",
"   </p>",
"   <p>",
"    We recommend that all patients receiving enteral nutrition have their backrest elevated 45 degrees, since the intervention is beneficial and easy to perform. When an elevation of 45 degrees is not possible, the backrest should be elevated as much as possible. We do not suggest routine post-pyloric feeding or insertion of a percutaneous or surgical feeding device, since related trials and meta-analyses show only trends toward benefit. We believe that more conclusive evidence is necessary because these interventions are inconvenient, difficult to initiate, and costly. Finally, we do not suggest routine administration of motility agents solely for the purpose of decreasing aspiration, since this approach does not appear to be beneficial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Backrest elevation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A randomized crossover trial of critically ill patients receiving enteral nutrition found that aspiration was less common among patients in the semirecumbent position than the supine position [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/17/34073/abstract/51\">",
"     51",
"    </a>",
"    ]. This was supported by another clinical trial and several observational studies that found a lower incidence of aspiration among patients whose backrest was elevated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/17/34073/abstract/56,57\">",
"     56,57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Reduction of aspiration is not the only benefit of backrest elevation. It also reduces the incidence of nosocomial pneumonia, as illustrated by a trial that randomly assigned 86 critically ill patients to receive care in the semirecumbent or supine position [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/17/34073/abstract/55\">",
"     55",
"    </a>",
"    ]. The semirecumbent position decreased nosocomial pneumonia among patients receiving enteral nutrition (9 versus 50 percent).",
"   </p>",
"   <p>",
"    Despite the evidence that backrest elevation is beneficial, it has proven difficult to consistently maintain the desired 45 degrees of backrest elevation. In one multicenter study, the average amount of backrest elevation was approximately 20 degrees, which did not confer any clinical benefits [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/17/34073/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Post-pyloric feeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three meta-analyses of randomized trials that compared post-pyloric feeding to gastric feeding have been published. Two of the meta-analyses found no benefit from post-pyloric feeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/17/34073/abstract/59,60\">",
"     59,60",
"    </a>",
"    ], while the other found a reduction in the incidence of pneumonia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/17/34073/abstract/61\">",
"     61",
"    </a>",
"    ]. When the latter meta-analysis was repeated after removing one controversial study, there was no benefit from post-pyloric feeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/17/34073/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Surgical or percutaneous feeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;No randomized trials have compared outcomes after insertion of a percutaneous or surgical feeding device to outcomes during nasogastric or nasoenteric feeding in the critically ill.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Motility agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;A trial that randomly assigned 305 critically ill patients to receive",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/13/216?source=see_link\">",
"     metoclopramide",
"    </a>",
"    or placebo with their enteral nutrition found that metoclopramide did not alter mortality or the incidence of nosocomial pneumonia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/17/34073/abstract/62\">",
"     62",
"    </a>",
"    ]. A subsequent meta-analysis that included the randomized trial and three others (494 patients) similarly found that metoclopramide and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    did not change mortality or the incidence of nosocomial pneumonia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/17/34073/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Motility agents may help achieve the desired rate of feeding in a subgroup of patients with poor gastric emptying. However, given the uncertainty of what constitutes an optimal feeding rate and the lack of evidence that motility agents improve clinical outcomes, we believe that use of motility agents should be individualized. For each patient, the potential benefits should be weighed against the risks, costs, and inconveniences.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Diarrhea",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diarrhea is estimated to occur in approximately 15 to 18 percent of critically ill patients who receive enteral nutrition, compared to only 6 percent of such patients who do not receive enteral nutrition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/17/34073/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. The precise mechanism is unknown, but alteration of intestinal transit or the intestinal microflora has been proposed. We have observed that feeding-related diarrhea is commonly associated with concomitant administration of medications that can cause diarrhea (eg, antibiotics, proton pump inhibitors) or medications in suspension. The latter are generally administered using",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/0/29699?source=see_link\">",
"     sorbitol",
"    </a>",
"    , a non-absorbable sugar that induces diarrhea at high doses. Concentrated feedings are hypertonic, which can induce diarrhea.",
"   </p>",
"   <p>",
"    Fiber is the best studied and most widely accepted therapeutic intervention for enteral nutrition-associated diarrhea if removal of potential culprit agents has been unsuccessful [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/17/34073/abstract/39\">",
"     39",
"    </a>",
"    ]. Fiber should be avoided in patients with impaired peristalsis, such as those receiving pressors. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Fiber'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Metabolic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adverse metabolic consequences of enteral nutrition include hyperglycemia, micronutrient deficiencies, and refeeding syndrome.",
"   </p>",
"   <p>",
"    Refeeding syndrome is a potentially fatal condition resulting from rapid changes in fluids and electrolytes when malnourished patients are given oral, enteral, or parenteral feedings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/17/34073/abstract/66\">",
"     66",
"    </a>",
"    ]. It is defined primarily by manifestations of severe hypophosphatemia (including cardiovascular collapse, respiratory failure, rhabdomyolysis, seizures, and delirium), but hypokalemia and hypomagnesemia also occur. Refeeding syndrome is described in greater detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/16/30982?source=see_link\">",
"     \"Anorexia nervosa in adults and adolescents: The refeeding syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Fluid/water",
"    </span>",
"    &nbsp;&mdash;&nbsp;Feeding products consist of only 70 to 80 percent water. As a result, they are unable to meet patients' normal water requirements alone (enteral nutrition of 25",
"    <span class=\"nowrap\">",
"     kcal/kg",
"    </span>",
"    provides an average of only 20",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    of water). This may be beneficial for patients who require fluid restriction, but most patients require another source of water.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Mechanical",
"    </span>",
"    &nbsp;&mdash;&nbsp;Constipation is a well known consequence of enteral nutrition support. Development of a fiber bezoar is a less common complication that can occur among patients receiving enteral feedings with fiber. Fiber bezoars may be more prevalent when peristalsis is impaired, such as in patients on pressors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/17/34073/abstract/32,40,67\">",
"     32,40,67",
"    </a>",
"    ]. Fiber should be avoided in such patients. Either constipation or a fiber bezoar can cause impaction, bowel distention, perforation, and death if not treated early, although these sequelae are rare. Patients who receive enteral feedings through a PEG tube are at risk for complications related to the PEG tube. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/7/34937?source=see_link\">",
"     \"Prevention and management of complications from percutaneous endoscopic gastrostomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Insertion of a nasogastric or nasoenteric tube can also cause mechanical complications, such as insertion into the lung. Feeding through such tubes should not begin until its proper position has been confirmed radiographically.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h1\">",
"     PROTOCOLS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several trials have evaluated clinical and nutritional outcomes following implementation of an enteral nutrition support protocol. They have been generally flawed and have not demonstrated any clinical benefits. As a result, nutrition support should be based on the available evidence and related clinical practice guidelines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/17/34073/abstract/32\">",
"     32",
"    </a>",
"    ], rather than unproven protocols.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Enteral nutrition support refers to the provision of calories, protein, electrolytes, vitamins, minerals, and fluids via an enteral route. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For most critically ill patients, we suggest a standard formulation of enteral nutrition (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Exceptions include the following: patients who require volume restriction may benefit from concentrated enteral nutrition, patients who do not tolerate a standard formulation may benefit from predigested enteral nutrition, and patients with renal failure complicated by severe fluid and electrolyte abnormalities may benefit from concentrated, electrolyte-restricted (ie, renal) enteral nutrition. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Formulations'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Protein'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Routine supplementation of enteral nutrition with glutamine, ornithine ketoglutarate (OKG), arginine, prebiotics, probiotics, or fiber is not indicated. Fiber is avoided in patients on pressor agents due to the potential to develop a bezoar. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Composition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For all critically ill patients receiving enteral nutrition, we recommend 45 degrees of backrest elevation (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). When this degree of elevation is not possible, we elevate the backrest as much as possible. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Aspiration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For most critically ill patients receiving enteral nutrition, we suggest gastric feeding rather than post-pyloric feeding (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Gastric feeding can be delivered via an orogastric tube, a nasogastric tube, or a percutaneous gastric tube. Post-pyloric feeding should be used if gastric feeding is not tolerated or contraindicated. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Aspiration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When initiating enteral feeding in critically-ill patients, we typically start with a rate of 10 to 20",
"      <span class=\"nowrap\">",
"       mL/hr",
"      </span>",
"      and increase only to one fourth to one third of the full goal rate for the first six days, rather than increasing the rate to the full target more quickly. After the first six days, tube feedings are gradually increased to the target rate. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Amount and rate'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is increasing consensus that the routine checking of gastric residual volumes is unnecessary in asymptomatic patients receiving tube feedings. Gastric residuals are measured if the patient exhibits a clinical change, such as abdominal pain, abdominal distension, or deterioration in hemodynamics or overall status. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Monitoring'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/17/34073/abstract/1\">",
"      Sorokin R, Gottlieb JE. Enhancing patient safety during feeding-tube insertion: a review of more than 2,000 insertions. JPEN J Parenter Enteral Nutr 2006; 30:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/17/34073/abstract/2\">",
"      Lee AJ, Eve R, Bennett MJ. Evaluation of a technique for blind placement of post-pyloric feeding tubes in intensive care: application in patients with gastric ileus. Intensive Care Med 2006; 32:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/17/34073/abstract/3\">",
"      Lord LM, Weiser-Maimone A, Pulhamus M, Sax HC. Comparison of weighted vs unweighted enteral feeding tubes for efficacy of transpyloric intubation. JPEN J Parenter Enteral Nutr 1993; 17:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/17/34073/abstract/4\">",
"      Itkin M, DeLegge MH, Fang JC, et al. Multidisciplinary practical guidelines for gastrointestinal access for enteral nutrition and decompression from the Society of Interventional Radiology and American Gastroenterological Association (AGA) Institute, with endorsement by Canadian Interventional Radiological Association (CIRA) and Cardiovascular and Interventional Radiological Society of Europe (CIRSE). Gastroenterology 2011; 141:742.",
"     </a>",
"    </li>",
"    <li>",
"     Abbott Nutrition products file://abbottnutrition.com/products/index.aspx (Accessed on July 07, 2008).",
"    </li>",
"    <li>",
"     Nestle Nutrition products file://www.nestle-nutrition.com/Products/Default.aspx (Accessed on July 07, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/17/34073/abstract/7\">",
"      Fick TE, van Rooyen W, Eeftinck Schattenkerk M, et al. A nonelemental versus an elemental diet for early postoperative enteral feeding by needle catheter jejunostomy. Clin Nutr 1986; 5:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/17/34073/abstract/8\">",
"      van den Berg B, Stam H. Metabolic and respiratory effects of enteral nutrition in patients during mechanical ventilation. Intensive Care Med 1988; 14:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/17/34073/abstract/9\">",
"      Singer P, Theilla M, Fisher H, et al. Benefit of an enteral diet enriched with eicosapentaenoic acid and gamma-linolenic acid in ventilated patients with acute lung injury. Crit Care Med 2006; 34:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/17/34073/abstract/10\">",
"      Gottschlich MM, Jenkins M, Warden GD, et al. Differential effects of three enteral dietary regimens on selected outcome variables in burn patients. JPEN J Parenter Enteral Nutr 1990; 14:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/17/34073/abstract/11\">",
"      van den Berg B, Bogaard JM, Hop WC. High fat, low carbohydrate, enteral feeding in patients weaning from the ventilator. Intensive Care Med 1994; 20:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/17/34073/abstract/12\">",
"      al-Saady NM, Blackmore CM, Bennett ED. High fat, low carbohydrate, enteral feeding lowers PaCO2 and reduces the period of ventilation in artificially ventilated patients. Intensive Care Med 1989; 15:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/17/34073/abstract/13\">",
"      Mesejo A, Acosta JA, Ortega C, et al. Comparison of a high-protein disease-specific enteral formula with a high-protein enteral formula in hyperglycemic critically ill patients. Clin Nutr 2003; 22:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/17/34073/abstract/14\">",
"      Garrel DR, Razi M, Larivi&egrave;re F, et al. Improved clinical status and length of care with low-fat nutrition support in burn patients. JPEN J Parenter Enteral Nutr 1995; 19:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/17/34073/abstract/15\">",
"      Scheinkestel CD, Kar L, Marshall K, et al. Prospective randomized trial to assess caloric and protein needs of critically Ill, anuric, ventilated patients requiring continuous renal replacement therapy. Nutrition 2003; 19:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/17/34073/abstract/16\">",
"      Clifton GL, Robertson CS, Contant CF. Enteral hyperalimentation in head injury. J Neurosurg 1985; 62:186.",
"     </a>",
"    </li>",
"    <li>",
"     Protein/peptides file://www.criticalcarenutrition.com/index.php?option=com_content&amp;task=view&amp;id=17&amp;Itemid=40 (Accessed on January 30, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/17/34073/abstract/18\">",
"      Alexander JW. Immunonutrition: the role of omega-3 fatty acids. Nutrition 1998; 14:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/17/34073/abstract/19\">",
"      Rice TW, Wheeler AP, Thompson BT, et al. Enteral omega-3 fatty acid, gamma-linolenic acid, and antioxidant supplementation in acute lung injury. JAMA 2011; 306:1574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/17/34073/abstract/20\">",
"      Gadek JE, DeMichele SJ, Karlstad MD, et al. Effect of enteral feeding with eicosapentaenoic acid, gamma-linolenic acid, and antioxidants in patients with acute respiratory distress syndrome. Enteral Nutrition in ARDS Study Group. Crit Care Med 1999; 27:1409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/17/34073/abstract/21\">",
"      Pontes-Arruda A, Arag&atilde;o AM, Albuquerque JD. Effects of enteral feeding with eicosapentaenoic acid, gamma-linolenic acid, and antioxidants in mechanically ventilated patients with severe sepsis and septic shock. Crit Care Med 2006; 34:2325.",
"     </a>",
"    </li>",
"    <li>",
"     A phase II randomized trial of fish oil in patients with acute lung injury (ALI). NCT00351533 www.clinicaltrials.gov (Accessed on June 11, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/17/34073/abstract/23\">",
"      Buchman AL. Glutamine: commercially essential or conditionally essential? A critical appraisal of the human data. Am J Clin Nutr 2001; 74:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/17/34073/abstract/24\">",
"      Heyland DK, Dhaliwal R, Drover JW, et al. Canadian clinical practice guidelines for nutrition support in mechanically ventilated, critically ill adult patients. JPEN J Parenter Enteral Nutr 2003; 27:355.",
"     </a>",
"    </li>",
"    <li>",
"     Glutamine file://www.criticalcarenutrition.com/index.php?option=com_content&amp;task=view&amp;id=17&amp;Itemid=40 (Accessed on March 03, 2009).",
"    </li>",
"    <li>",
"     Ornithine ketoglutarate (OKG) file://www.criticalcarenutrition.com/index.php?option=com_content&amp;task=view&amp;id=17&amp;Itemid=40 (Accessed on March 03, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/17/34073/abstract/27\">",
"      Heyland DK, Novak F. Immunonutrition in the critically ill patient: more harm than good? JPEN J Parenter Enteral Nutr 2001; 25:S51.",
"     </a>",
"    </li>",
"    <li>",
"     Arginine containing file://www.criticalcarenutrition.com/index.php?option=com_content&amp;task=view&amp;id=17&amp;Itemid=40 (Accessed on March 03, 2009).",
"    </li>",
"    <li>",
"     Prebiotics/Probiotics/Synbiotics file://www.criticalcarenutrition.com/index.php?option=com_content&amp;task=view&amp;id=17&amp;Itemid=40 (Accessed on March 03, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/17/34073/abstract/30\">",
"      Barraud D, Bollaert PE, Gibot S. Impact of the Administration of Probiotics on Mortality in Critically Ill Adult Patients: A Meta-analysis of Randomized Controlled Trials. Chest 2013; 143:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/17/34073/abstract/31\">",
"      Besselink MG, van Santvoort HC, Buskens E, et al. [Probiotic prophylaxis in patients with predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial]. Ned Tijdschr Geneeskd 2008; 152:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/17/34073/abstract/32\">",
"      McClave SA, Martindale RG, Vanek VW, et al. Guidelines for the Provision and Assessment of Nutrition Support Therapy in the Adult Critically Ill Patient: Society of Critical Care Medicine (SCCM) and American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.). JPEN J Parenter Enteral Nutr 2009; 33:277.",
"     </a>",
"    </li>",
"    <li>",
"     Fiber file://www.criticalcarenutrition.com/index.php?option=com_content&amp;task=view&amp;id=17&amp;Itemid=40 (Accessed on March 03, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/17/34073/abstract/34\">",
"      Hart GK, Dobb GJ. Effect of a fecal bulking agent on diarrhea during enteral feeding in the critically ill. JPEN J Parenter Enteral Nutr 1988; 12:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/17/34073/abstract/35\">",
"      Dobb GJ, Towler SC. Diarrhoea during enteral feeding in the critically ill: a comparison of feeds with and without fibre. Intensive Care Med 1990; 16:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/17/34073/abstract/36\">",
"      Heather DJ, Howell L, Montana M, et al. Effect of a bulk-forming cathartic on diarrhea in tube-fed patients. Heart Lung 1991; 20:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/17/34073/abstract/37\">",
"      Schultz AA, Ashby-Hughes B, Taylor R, et al. Effects of pectin on diarrhea in critically ill tube-fed patients receiving antibiotics. Am J Crit Care 2000; 9:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/17/34073/abstract/38\">",
"      Spapen H, Diltoer M, Van Malderen C, et al. Soluble fiber reduces the incidence of diarrhea in septic patients receiving total enteral nutrition: a prospective, double-blind, randomized, and controlled trial. Clin Nutr 2001; 20:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/17/34073/abstract/39\">",
"      Rushdi TA, Pichard C, Khater YH. Control of diarrhea by fiber-enriched diet in ICU patients on enteral nutrition: a prospective randomized controlled trial. Clin Nutr 2004; 23:1344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/17/34073/abstract/40\">",
"      McIvor AC, Meguid MM, Curtas S, et al. Intestinal obstruction from cecal bezoar; a complication of fiber-containing tube feedings. Nutrition 1990; 6:115.",
"     </a>",
"    </li>",
"    <li>",
"     Combined vitamins and trace elements file://www.criticalcarenutrition.com/index.php?option=com_content&amp;task=view&amp;id=17&amp;Itemid=40 (Accessed on March 11, 2009).",
"    </li>",
"    <li>",
"     Continuous vs other methods of administration file://www.criticalcarenutrition.com/index.php?option=com_content&amp;task=view&amp;id=17&amp;Itemid=40 (Accessed on March 03, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/17/34073/abstract/43\">",
"      Bonten MJ, Gaillard CA, van der Hulst R, et al. Intermittent enteral feeding: the influence on respiratory and digestive tract colonization in mechanically ventilated intensive-care-unit patients. Am J Respir Crit Care Med 1996; 154:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/17/34073/abstract/44\">",
"      Steevens EC, Lipscomb AF, Poole GV, Sacks GS. Comparison of continuous vs intermittent nasogastric enteral feeding in trauma patients: perceptions and practice. Nutr Clin Pract 2002; 17:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/17/34073/abstract/45\">",
"      MacLeod JB, Lefton J, Houghton D, et al. Prospective randomized control trial of intermittent versus continuous gastric feeds for critically ill trauma patients. J Trauma 2007; 63:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/17/34073/abstract/46\">",
"      Ibrahim EH, Mehringer L, Prentice D, et al. Early versus late enteral feeding of mechanically ventilated patients: results of a clinical trial. JPEN J Parenter Enteral Nutr 2002; 26:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/17/34073/abstract/47\">",
"      Rice TW, Mogan S, Hays MA, et al. Randomized trial of initial trophic versus full-energy enteral nutrition in mechanically ventilated patients with acute respiratory failure. Crit Care Med 2011; 39:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/17/34073/abstract/48\">",
"      Taylor SJ, Fettes SB, Jewkes C, Nelson RJ. Prospective, randomized, controlled trial to determine the effect of early enhanced enteral nutrition on clinical outcome in mechanically ventilated patients suffering head injury. Crit Care Med 1999; 27:2525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/17/34073/abstract/49\">",
"      National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network, Rice TW, Wheeler AP, et al. Initial trophic vs full enteral feeding in patients with acute lung injury: the EDEN randomized trial. JAMA 2012; 307:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/17/34073/abstract/50\">",
"      Mentec H, Dupont H, Bocchetti M, et al. Upper digestive intolerance during enteral nutrition in critically ill patients: frequency, risk factors, and complications. Crit Care Med 2001; 29:1955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/17/34073/abstract/51\">",
"      McClave SA, Lukan JK, Stefater JA, et al. Poor validity of residual volumes as a marker for risk of aspiration in critically ill patients. Crit Care Med 2005; 33:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/17/34073/abstract/52\">",
"      Montejo JC, Mi&ntilde;ambres E, Bordej&eacute; L, et al. Gastric residual volume during enteral nutrition in ICU patients: the REGANE study. Intensive Care Med 2010; 36:1386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/17/34073/abstract/53\">",
"      Reignier J, Mercier E, Le Gouge A, et al. Effect of not monitoring residual gastric volume on risk of ventilator-associated pneumonia in adults receiving mechanical ventilation and early enteral feeding: a randomized controlled trial. JAMA 2013; 309:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/17/34073/abstract/54\">",
"      Lewis SJ, Egger M, Sylvester PA, Thomas S. Early enteral feeding versus \"nil by mouth\" after gastrointestinal surgery: systematic review and meta-analysis of controlled trials. BMJ 2001; 323:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/17/34073/abstract/55\">",
"      Drakulovic MB, Torres A, Bauer TT, et al. Supine body position as a risk factor for nosocomial pneumonia in mechanically ventilated patients: a randomised trial. Lancet 1999; 354:1851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/17/34073/abstract/56\">",
"      Orozco-Levi M, Torres A, Ferrer M, et al. Semirecumbent position protects from pulmonary aspiration but not completely from gastroesophageal reflux in mechanically ventilated patients. Am J Respir Crit Care Med 1995; 152:1387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/17/34073/abstract/57\">",
"      Metheny NA, Clouse RE, Chang YH, et al. Tracheobronchial aspiration of gastric contents in critically ill tube-fed patients: frequency, outcomes, and risk factors. Crit Care Med 2006; 34:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/17/34073/abstract/58\">",
"      van Nieuwenhoven CA, Vandenbroucke-Grauls C, van Tiel FH, et al. Feasibility and effects of the semirecumbent position to prevent ventilator-associated pneumonia: a randomized study. Crit Care Med 2006; 34:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/17/34073/abstract/59\">",
"      Ho KM, Dobb GJ, Webb SA. A comparison of early gastric and post-pyloric feeding in critically ill patients: a meta-analysis. Intensive Care Med 2006; 32:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/17/34073/abstract/60\">",
"      Marik PE, Zaloga GP. Gastric versus post-pyloric feeding: a systematic review. Crit Care 2003; 7:R46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/17/34073/abstract/61\">",
"      Heyland DK, Drover JW, Dhaliwal R, Greenwood J. Optimizing the benefits and minimizing the risks of enteral nutrition in the critically ill: role of small bowel feeding. JPEN J Parenter Enteral Nutr 2002; 26:S51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/17/34073/abstract/62\">",
"      Yavagal DR, Karnad DR, Oak JL. Metoclopramide for preventing pneumonia in critically ill patients receiving enteral tube feeding: a randomized controlled trial. Crit Care Med 2000; 28:1408.",
"     </a>",
"    </li>",
"    <li>",
"     Motility agents file://www.criticalcarenutrition.com/index.php?option=com_content&amp;task=view&amp;id=17&amp;Itemid=40 (Accessed on March 03, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/17/34073/abstract/64\">",
"      Montejo JC. Enteral nutrition-related gastrointestinal complications in critically ill patients: a multicenter study. The Nutritional and Metabolic Working Group of the Spanish Society of Intensive Care Medicine and Coronary Units. Crit Care Med 1999; 27:1447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/17/34073/abstract/65\">",
"      Luft VC, Beghetto MG, de Mello ED, Polanczyk CA. Role of enteral nutrition in the incidence of diarrhea among hospitalized adult patients. Nutrition 2008; 24:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/17/34073/abstract/66\">",
"      Mehanna HM, Moledina J, Travis J. Refeeding syndrome: what it is, and how to prevent and treat it. BMJ 2008; 336:1495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/17/34073/abstract/67\">",
"      Scaife CL, Saffle JR, Morris SE. Intestinal obstruction secondary to enteral feedings in burn trauma patients. J Trauma 1999; 47:859.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1605 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-58.240.98.179-5450C57513-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_17_34073=[""].join("\n");
var outline_f33_17_34073=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H37\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INDICATIONS AND CONTRAINDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INITIATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Access",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Gastric",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Post-pyloric",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Formulations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Standard",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Concentrated",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Predigested",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Critical illness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Composition",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Carbohydrate/fat",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Protein",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Peptides",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Omega-3 fatty acids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Glutamine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Ornithine ketoglutarate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Arginine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Prebiotics/probiotics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Fiber",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Vitamins and trace elements",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Continuous versus bolus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Amount and rate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      MONITORING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Aspiration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Backrest elevation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Post-pyloric feeding",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Surgical or percutaneous feeding",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Motility agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Diarrhea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Metabolic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Fluid/water",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Mechanical",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      PROTOCOLS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/16/30982?source=related_link\">",
"      Anorexia nervosa in adults and adolescents: The refeeding syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/32/13831?source=related_link\">",
"      Nutrition support in critically ill patients: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/63/20473?source=related_link\">",
"      Percutaneous endoscopic gastrostomy (PEG) tubes: Uses and efficacy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/7/34937?source=related_link\">",
"      Prevention and management of complications from percutaneous endoscopic gastrostomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/57/33688?source=related_link\">",
"      Role of surgery in the management of peptic ulcer disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_17_34074="Lichenoid drug eruption";
var content_f33_17_34074=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F80165%7EDERM%2F59258%7EPC%2F59807&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F80165%7EDERM%2F59258%7EPC%2F59807&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lichenoid drug eruption",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFEAbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwCCwSOCXNxG3T7o70/z4hIQWUN1xjpQJi8m3qTzk9ars9sHkkIKnPBPJNO9jX4hxRjIQ0hMfsKfsjYAbhn+EgUrTwSQjy1YvjO08Cks8ybyqYPc+lSVZk4jZBvdsZPU1U3v9rYuzLt4VezVfeAuoLMBjjJOaYSokVW2s57DtSYkMiBQbZGJyc4UZ4705YHA4zjPy5p4YxuN6RlF/gzyTUs12fmVUCqRj1xSukOzexUHzKApIOSC2KkmjG3Y2SMfnUkUu9GcDjOPpUshxCCY8jPXPaquha3M5HTP32Hy9MU9J4ywHzF89OlTTRIx3lGG0cntVWLEcrF8BmHI67vQ5ovZlqKYjrIrl4hwTgmnQm4c4lkxGpyB0p7ToxIbKNnoegp5l/djaBIMfjUt2KUGRyHa7LhRjBP+1mq82GG8EZzgjH6VJcHzHATGAB07VFIhCkE4XH5U79hqJXMqiZd3B5+fuopsqeQwDEsA3UHt6U0yCUmdkIU/KBjO7/CpNiSXXlRq0iNjgDv3xmtE7bmijYrxXmJ9kK+YyNgBV6+9XoY7hvNWbKEg5Vz/AJ5rV8HXFpaXrtLawC9A/dvMMD8O2cetRGN9XvrmSN0AjDSH0PPQepNVJK1yU25NNaFdBGDGiEyxlC2GGMEdQPStjTY8W5IwATyinFVPszRTxvIg8kj52z19AR61pWzE7ggAG0g5GMZrCT1LktBZCzjgY7baqzQMz4bCluueK1UjeNMlELr1BqtdbSqsi7mBJbP+NQ2ZLcxbyPyriJAocEHIxVG3u54rrb5YCYOMjIPbt+ddDBZxSOzzFUQgnJ5IFWJrKAgRxDEGflb1B96LM2jJLRjrJ1a1CsCBjg+9ULqd9oWNwGAye9XJmaGOYuCoQqigHk1TESPIZncAnsB1PpRJvZCUVe5b0xfPQSyDjJypHT6e1SyZL7QBtHcDgVHaSFQMnaGJGcZIHfFW43jPmqew575prUwmrO5Gu0P/AKobe/NEfls5X5m2jIPcmpVgZVlAc7Nu4k9xQSkMCZcBx8uQOT3pk6FS9ilEW2FdvzbmAPJFVfNeMOoG4k4BA7VaEUkh3Alcnoeaq3fmMgByuON2ME+lKw0Si63lDIi5zjkZzxVbc7qQUHX1/CpIt0CAyOWPTjg087M5DjY3I3CmFivdxHajBvlZcdOnPB9qqpbtZybgSUzwM5C5q/iFnLYZhjGOmfSrnlq5TaQ0jgZzyAfSpW5vexUsopXDkszSAZOewq9YyR7WWRj5jEDd2A7iliszGHJTfGGAbByVz6GmTIZIfKhl2gncEbjOOnNGxLd9CYGOWQL5XyntjJqMwwblMRIOeFLUqs6wyKnyyDgEfrzRapj/AFgVs9MjjP1pXuyNStcBw6hXKqo3etCFzIFUL83DEelWJ5ke2KeUd7NuUqew65pturb2Bj2kADjkD3pXsyraEyh1hCgbZDxxzwe1SbDk8/KvzMW/pSI7xSN5XzSqMgjg5ouLfy5BsbfkAqRxz6VTehSQ9yJQQgGTj5iMAVetiiQhGce6gZzVFvMRsDc2Fwd3QEdsUkZaJwz7TuOQoPBqb6g43RYu5dmSqKir/d57VUQiRwCclhk5PT0qwS8snzMdmcY4xTxaGAFlfliPu45Hb6c0SLjohIcFG8xCQBjGe9NhAaeLAaMnuOT6Yq1NC42sZEVwQpKkfhxT0hDEIg3kA8j1/rUsdxi7oQQm1wpKDcMDJ7/hR9mmjTzIRn1fHGe9WI7IKqrPIWYHlE5H51MjLGQoHlKpxkg9fejXqK+uh5iJMgFSF3DDt3qrclidsaBkHrzx61ElwgAypCng5q0tsdymFiykc57/AErobuc8Y21YRLmEkpwDjHpVy3icIpJAVRnHpQEGQqjPH3qsFfJyy9Dxj+VITIX3RN83APP41VOZJHAfYDxuAxk1c3IxbLEjPfk0WsDMzjjb1Ge1DGiOC3kQpHGCWJzzzmrMUIJG4gEHoe9TxxsVJclGB+UjqKSIBXOfvA4HPNTsTuMCxK7fKzLnoDjFErALsk+UHHzN6euKRJtskodSFzjIPOfXFUL+4lcAGQk4I+Y9Fp8xSg2Mu5z5jqp3xg7RgkAj1qsXhdFG5kcf3uh/GmfaUEBkVtxJ2KM4Puf6VsadpqSWtzcTos1nEP3yh+Y89Ce5wcVcY82iNGlBXZkDZNFsLjzc5DZ5I9MVa0mDdNsDkuePbFJPEtiYT5AKSSkgkcED0PpVqyUxSiRCCWOQB2zUS912ZvvEdLpyKQQShJIyec1DeRtCCVG/AzWnLL5ilQoIOMD0PrUUaNkgr833cmlfXQyV+pgrGJY4FjJIiQiRewJP3hS3u5ipicjJ5A61vLbQhZScIXXDAc5Gc8VRks1UrtZmRuqFece3qKbkXGxSgV0nOx9uAAQhzn3rUtkSNzPnJVTlR0z2pqRlgBgjHIAGOnSnln2jeEX5iS6rzj0NPnKs3oOtmSOB7kMDI3yMhXGeOcCrFpNiMso3KrbSeeM9Kw76RnK8nnPtUaXUkTGAtIVbGApwGPbNS31LVK6OvinBUAPgcfKOc+xp10AQGYhVH3l96zbBQt6IE3yvtGCozk+grTu7WUo3AAUhfp7UtzGUFFooxq7LJHCokDHPIyRgfyrLWWVZCiMS5cAqe/0rbZiuGgDHaMZBx9fwptlC0rsvlEvn72B+NTZvQuDSTbAlwkLStGBtIywJz9aiG15PNwP6D8Kvm2Gzy43JD4J3enpVWS2eInKfLuHIHNU0JNakli0R3q7fOW2jnge/rWk9mBGBCU3MeWx3xzVMW+GZfKy2AWOOQKslHRUjIY7gSAD1+tCTW5lNJu6I7iH7NEcyZHB5OSfpVZ5WlSMgEHGQp7etXpxGsBYgBQMr3JOelZ88++YGBcpnAyOaL2EopjX1FllVM/OAcYHXHpVhpkCHHUkMwJ6cUwaZAjLMilnwOSc4z/KpVgRC0W9ti5Kgjkmmm1uDUfslS4bznXylXYBn/wDXUhFtNDEGQrMG+Y44I7URxv5o81MRkZzntUsqCB9sDP5v3m9BSuDghjxRkoSSi4yARwP/AK9RSSsNyw7Y1b7+3nnsBUwmTYQ6hiTyMZzUYEIGIjuYtgoq428dT/Kk5MqNMsLNJDBs3kHIPOBz9abBCJZVEjNkctjnj0pVkZyGKAKR97b39amS3lZciQKjdSOMU7qQNNDJkhiuFjYuu77wI6H61HFIx84PsSJfmbfxge1I0EkbvGgLordaS+khkjVAZN+ec85GKW1xWuQwyxSsxaUBGGME4GPTNXUdFc5bczfMNrZAH+NZ9tCjSNJJny8DPYVqRm22BY0wy8E+3rUp9y5QtsRJGsRYbgzDLAsfyqQzOfIaRg5ByCRwPwp7QQsA+9UOQdpyS2fp0pzoDal4AGIbvx2POO9ALsVjJLO7SOETaeq8Zz7VOVKHMiZDDO7HJGOKzraa5jQxoQ8RO1vlA3H3PetSa2ndEG0Hy8BigOR7H06ULXY0lCw+ARrtYxRzR4OQR0NXI0jiiKsQTgEDPAyP51SjSMmOKRXXPJIBwKfKI2Zgn7wgYBPyke/H5U1oZSQSyiGfyGUbwAWA5IHarSKI3VwVZcBm/hxx0qksccW9pVdMkDgA5H9ab5jCRkjfMbHaBIcMPepKtcvTzRROhQNHubbuJznPNXRNbiLbHIGkxgA85/Htis6SBZY1QESfN8pP3QaLW32BXXDDGMZwF/H2oTuDireZ5xFpvzYc5QnIGavi5igKJEuOeuMAn0q/I0bHYo6j77dT9aaYoSo2DzCOSoHT8a25exz+05tyvOckO3lgng7P5VWvJ5rmYeXiJe6j+dWBEAr4x8vTJz+FU7x/JwODuGcik2EFdluxhKrh2BA65PWrts6GQqR0PGKxtPuX+0KjqcHuORW2yfvlcACM9/ei+mg5xadmMldnLqSFHuOcUsAjJ3IpBIxz1J9qsPa4VZXUgHhSehqrNGok4ZgpOBilrcStYZdIsZ3ORuYchecf41nTKLmMxbeD8wPvWlcxeSUJDEuMLuPamrIsErSKoYMMDAwM0PRmkNNUc/LbGJNzA5HAXHb1q3arcxytLbymGRxh2B+8Pf2rWb9+pVIsBhgk8496oyTES+UFDY4GRijmtsdCbZIsUs8/mXEvmyMNqg9vQAdqluBLE4RtoPcjg/SnWMxunfEbDYBjAwKs3NupUMc88gHsae6uQ5WdmVRKMMI1Ck4OGGRTZXZU3oxLA8qeM1MscZUv7Y+YVUkZ96yFgMnGO5A74qQjG7LlmTIQQyhhjIx09KZPDsuf3jZVeSVPOPQVLpzmSQfKVVu/vUuoynaU8td6KDx2/wAaTemo+VxlZFBQRmQBlUnAOf0qRnYxEooZScMAPaqEt1O7E56jqPQVa02ZnfBC4IzgjaDSVjVQdiCaBJ1aMrIZn+4F6dO9LaaeTJvc7ZEwNmOPrXRw6UqIbjcMNwI+jIODu+lTbVRAsKs5zjLelUtUDqW2I9FhNtI1zBA5mgUsWVvue5qSCWa6uI43URxE43tyFpt1M6II4ZnVgCHAOB9OOtUYkQz5Z2EankDOPrinzdDJrm3LSrGZiqggKODjj0/Wp3nhjR4ow6RoB2yT6/hVS3ygwAMHONw5Bq1EksoUMmevzDqam7RDQ9CihW3DK9FbjJ71b86KO3PlRb2YEl2OF/AVnzWzSMr7ed3zc4xT3haSKLyw2B09veqjK2jIlFMeVl+WQHlsdDjA6U9mVnCFiByu/wDvY7j1pINwB8wfKOvfH/1/aohMrzBFjIQDgkc0AkVpVDSJEysFc7VU9qt2lttLHevlLnHHXinIJZZECoCo5w69Peobjzt7OmNgx35+uKLjtcmD+XbMjqSSpwQMEmqYhLIkkp6N8nvUziUTKsgYqcNtIwBx3NStbzrmN0CnG5ixBOOo6dOKbsxRujOuZXSQ+ShMp43N/KrGn3puGxLtCjkuV44H61K8KtkK2Sw7fSqsdj5JZoN84A/i4A/Cp6mqSa1INTumiUQgYT72/uTVWzvQxUEn5jjhSSR3pNUheaJkiQuWAbcOo9qh0+C6maGCPbheSQOgz3qUtTeMI8p0SQNK5RZQCoyOeo69KuMUjtWWNy7EgELxj86rO7NuNuRH5n3sDAIx0Hp0qtK08cWBCQmME+/GacmZON9Bf3jSghSXH3sHnI9KsWyxujGWMqecZbnNQOzLACFYueGOeg/zxUcPm+WWQ5jYnIA+79PwqFuNQuh93dxwjKhEIO1s5Oat28SzwxSFSm/oQc5HWsWc3EdwCY92/gFuRWra3RhtggXqvY/4dDRe71NJU0o6CXMcsEw8xdiH0Xt+NTNGhgUsW3M2ACcYHrTzeCW2YMAzH59zHkev51SluWeKNVUAnpt+9ilsQoORfgt1xsPyoVyrgZ2+h45xU9tYS+Y8u4zIeSwJ/maq2AljEYZ4EWQMV3OO3/66slMg84G3OVPH44p3CUWhfOlMZMyM3fHUYHrVGEu10TtYMTgY5J9Kt3EoSAKsyKSCCvXK/hSW+6ZDtYjaM7N20kdeKG7ohKwTT3EiGKUEBQQu5QQfU/hSQ20mR9oVScDvu+lOYGNhGsmTu3NuGMVK3mmR3MPlscbcDgDHBJoSuP0RYFiphVkKMrd1POB7emamntEt5ljKlmwDgn5WyM8VUj+U4iuFkkXOVZPb0qeC3lQMshCq4GV28kVNxWOHEUa5zcpI+BtVATnP+FNdZQG8pgAfvU2Q+Ug2hCc54Oae9yWiYhFRem3Oc+5ro5lY4+V3IJdqiMEYI/UVWuo2WVZEAbdhSMdKtsUaMMcbs4298U5mVCuAMMOO+PbPrS3NY6O5Wh2x3EZc4JGFb0rbiZIU3Sj5AT1PJrORI2kXGY5AT1Py/TH9avLFayH96zKFGd78kn0xQOTuSvc7ym1Nw7d8e1MkLyMjqAHB5GOooZ/KjVomwg5HHJNMTehZ2DDPJ5zmi5KiNMakYYZx1yfyqCeNVjEYdWJGSMcg+lW9kodQVORyFHpjINRwwoUYSsyqwO3I54oZaVjOXehbB+Tp9KbPA7zi5427s4A4J9DVi3EU8juVMMQPKkZP4+9S3cjIY8KoXbtQDt7n3qIu61N+az0CzLwvuR15B4x7d6m8zgbvmwcHHdvSiNg5KiLuPujkj2rMv4X+0oXjYqeAo/nTehK996mz5TSoHeOLYF3ZHB5P681G0bLvZEVsnbg8lap6VDchQE+4TnaemPWrxu3RnCooYHcGHTnrxTHblGCNUy8TYBPTofyqC5BEvHG3pn+tXJ5fNQlEbttwM9O340JGrITJ8p4JB6ipavoK/Uy5Yo9smFUZGMdMUltZSeZDGPlV2xubOK0xaoEkMrKMDaN3f8at2UUMMTlgHlAyDu5K+gpRjrqae0si1DbSu21XLsFKruPUChhJHblYo1LA7mYNnA9P51FbzMX2xsFBXBAGSPaqdwsouFYs23NO66GdrvUuzwGWKNWIiwDgHjPvSSwwRboEkG9VBDK3Q45z6mqksoRU+VTIM8EHLZNWSxZAvlImBg8c4ql5EvQhto2wxJVpM8Fudx+lW4b5oAsYROOScYYmmxBIi3ykgjB2nknsKrzAudsw5BwD1xQ7hpLctxXDebvdzgjGW9P8asQo0rqBITz/AA+nvTIFhd44HbG//Z6H/CoDNJC8sUMhUt8pweh6YxSv3It2LnmyodilBH1ZtvU1FbyolwypDFM46A8YPYH1qBF8u2/el2LnqDyQKrwwFMSkptY8ZJ/z7U7sLLqWJmkmuCsjLFx2bgDqSf8ACpYYlkEhAIUjLtj34HsKp2+yRmGSzA5YseCPTNDTS+YVLIoU5XacDA6fj9aNEFrl8mJlkxIJGxs54wKlEXyAE5QAsFPTA71QlRpU87a4BGcEdD/hV1o50CrkKSBuB6nPaqJcRrTRllG0licdKrzyOlsyoESPnK++e/vTbiGaKbZLtQg8B2zx+FQJsMzK0jOAeSFzn86zcjaMF0IGh3ckMF7kcVYs7XFwgSP5xz1Hr3qVCuyPr5RYLvKjHvT47n7XCFdwph+UIgC7l5/MgmlzJM21sSzTC3b5wSxB53DkjjIqjPK0hDKckj+AcA/So9SQLDG0fPmHDbuxp9meF3ECIjYCw6/Spbuy407LmCyupbWcA5bdgfrWvPY27XDhCApxzyNvvTbGziR/MLgPsLZYZ4HUVcTdIh2urjbhCR6nsKtaIib10KF3apCy7CxUYCAncfb9e1U76KSBirJsK5JVa2AGgXyww3v82Qc9O/4Vl3czgbH3sUG1OM4Gc4NQ3ccG2QWsLOAJCUU/xFasJpW2ZDPhBIAQ/wDDtp1nPvG8El+2eRVtp3lKDGDGDhSOPoKpITk1oZ9zKqy/PHH85wRGoOP84rRS1t/s8PkyRuCm+QBidpzjn0z6CovsnnRG5nUhVyBID0I9u/5VBp0DKpV0AQctgjOT/OiwSd1oTTRoCqooyTng9fapZYo0AyCxOWHHH44q/HbOVI8vzQiEhHOCAB3x7nNUjbODuDhOfmw2SR6Ad6LWM077jZxFkMqSo/l7lDnfk9MD/wCvUdpKIijMBuUHIc5z6ce3NaHngSqsXzqAoOV4Cj2P1oSzWSWR+jlshduBjPP4elNtdBX6MeRbyuDFG0agZZ2GQOPQU+KC5lVJUlVXlG7LN2/HtxTg32eVV27oxuGJBjgd8jvVa9nuYpZowWRMbCGOQF64/wD1VDegRXRHBJnzVUg4JAJA6UyZUd2USRqobG4dOO9aE0cMMSGW4UruIwvJOOuP5ZrMuroJIq7FRGGFGOSPetmkc8U2J9pihYhiH+g/Wm2ZMsjvLEfLzjk8AjvVK7uEWILEBgNy2cn6f40/S52UuJ3VmLAIc5wO9Jm6p+6bsMYZR5m0qTgsBk49qqlFVsHLKMtjOCVH1qFJmVmIOUxnPYmpYSLmP95H8xyy5qOYah3LgcXKHk7QOp4wKsWhIgZvMBTIVc8ls+nt71Whcwwskg3qf4OmfcVft1SVCZARt4AHHHYVVyZIYyyRRpLBJksPLIzgj/61Zt1vyYVfPOSw5zWlK4EpiQAgADK9j1/OqykIgkcgMSVAU/Mfr7UnqKKe7KlurxM6FuCfmwO3pVoeWIFPLA5APp+FPt/s++Tzm2oxySf89T0pjXQjUKluoUqeoyR701ZIrVk8ErqCoYosmD6Y+tWVZHhKbFDkjbxyQPSsqC5kW28wQF4zz5hIwAp5/Wn2+o5bJBLZ4bsP89KakDpt6ovwxnGwcK2FJxj8femARRZRxnI67eSew+lMlleWSYOiLEnzAentUdx8oJjchl4bK9j3zTb0Eo3JTOERVUFUwcHOOc9arW07uJkIO4nAO3qPrSfN93v0+brzVy2haOHy5CMnjkd6m7bNElFEMomEZMRyUXdgnNXNOldYg8wUFiAABnoMkirSRhWZbjYc8OB0+tPSGJN0Z3kgZQqPahrUnnVrEqLG7DyxtZj2H50XpVIVR9sjId3yjpnt9OlNtrd94KABQMnJwOlPuYyImjT5HHXb0J9KRnfUq+ZEyuoTtxkfe9fp7UyOFJ5GIb5gvfnP+RQwhjIDRkvtwWP+FULqXzYW4GMgOw4A9qvbcpLm2LrBIiqLKWBJZB2A6Zx2qSNJLhQ6opU8kL1zXL3F1LG4SMsy9WI71uaZcyybCWk2gYxuxwfSp5i3SaVzVaaMKVdGLY5OeWHpn0rPijl+07UTerH744APvU7TRzsoJbI+VQWzkVBI7fcQjcTz7gUMmMGWmvQkEirlWK/I684PqKqx3cSshl8wLwduOWH9KkkjIbA55yoHTH0pCiq/mQEqTx6lc0myowS3HssUcziEqyjOGNPZ0S0EflKkzHIbHP41ULeRJHsOA/O4Yxx2FasJdIxLOAAxDMWGSPw/Gpi22DjbVkQZwgcmRlUf3entVp/Kx5s1xuZx0K/MT9Kju7meWMRZ+XcSPl2hvwqOQPK2+UYYEE554/pVJvYnlTI2ltVLBoM8ZDdMe+PrVSOa1j3mTc6HBwoxz3H0qpquoYiWGJFCpkKwHPHb6VWWVsoJU3B8AkA5Gff36VL3N4U9NTQ857uQbAhjfgqE2px7VN9mjWXCDDY3bef0p9jGrO6eVhwdi7GO4nHOfatS0tmdUbzI0MbBQH7n0+n1qWr+Y27GNdxmVUUpKeOWxkL/APWqWONpY40tY0fYN7BugwP6VeltpIGZmZSxbccHoM9h9abdiFYllhLMq8SAjBHv7ijbcuM+iK673tWCkB3Tg+vtjtVq1tjHp0MqylSxLfMeeB0A+pqujq6OUXKvjJAqytuOHG0nbuIU59hSb6hK5YZHdAJ/n/iDgYJ9ef8AGqKnF0A0MjIGBwCAT6+1a1mgYqHlRUUYYucEDqcfT096opIJoTHav8zHG0jOPcelNMzTaZW1aNIYm8r5CQHCtwRn6VFZ4kikyrZ6jGSTmtZNOaeJ4pIdxX7zLxj2NOs7R7aCJlI8p+TsfLcHGCD0PIpictDLggjDyLGJjgEn5s8ehrX0q2e2ijdYPvMAAVDZNTM6Et9nRAxYjBH5/wAqhvp5bqYLNvhRyAAowfl6H3NO9kSve0NeFIE3MZcy7Sdp42jvmkkEWArKA7HI5AAPb2qjb3bWULGOZG3kny2j3AHoAc/n1ovZ5VtnjlhLPtwq59epqeZsjkSYwXFussnmKm0t/CCW9sY7022nT7S5USeUDwrdB3HNVyihfMRfJAPfqT6GrFw0RxKFcuqDDKvBx/eH+FO5Vh7usssiZAwc8jr7frT5kW4+V8nB+70JPrj9Kp2+8HctuMnPysM/jUsJeTISEq7Hr296jVDaVzzcP5xZVB24I7cAdKz7oSJKwchto+Xb3/wNXrcBYpGBPmHgE9B+FZmosPlGTuPDP1Az0rZq5FOOthHCwGJ2QzygEtG4wintn147U2QlryOOyUzPIOVjXBzVP7S8UpZWORyT6/UVt6dNGsgnPA3DLD5eo4HH61SfQ6OVRLSRQrbqSQjFtuCMjjnHrUkU6JcAqABv+6B2/rVe5KwRysJw8jcBkzg5POM+lORPLiEkh2bh1xzg8A56VLWpNrk6yxiRvOZgitgMTyM/0zWrA6mNWxjb8sgH/oXtWL9kN1B5LRtIhYbip5O05IrbszCFMY2mSR/lQn7idT0qeYiokkEiogd3j6j5SW6A9PqapXC+enmqNrAgFT0I961zbeYUT+HaCuOOKge1aNSECLIOMnkj0OKGmzOLSZz0+7zXUHdtPIztBpJnmS0JC7ml43OcD6Y9sVqXVkwKhwCc446j3qlqUbbrdZFMbbTIc+h6EU15msZJlnR7e2eJYr2dUlbcytGvzZPO3H9elLdQE3sytvECEFCRt4IH9c1TtWjACsR2IY9Tzz9RWpK+5fklMqbsEEcsBz+nNaN3RTXK7lOQiSaTywIzyFDn0x+tU5r10laCSQMwOH2NwSKZeXMUMWWj8yPeXzk8+gA6fnWdLGz2e+DeZS2CNvcnpUPUuMUdBDO8rR7Rt4J3NzuA71o29w7oyzsvnHAVgMgqOvP6VyOntM1xGIgfNHy4Unn2+ldfFtEkayRsh2glWHT3z6YppDnCxJCxMq7Spzyo6ba3micKzyuFnXDFc5479OlZsBgUlUZWyCOE4q3DIED7AwduinkN70/U5JsrSiQAqgLMyjknK46/n2pLZmim5YlwflAHHP8ASie525iBbPXOegqm8wRmAL4ILccdu9KyFZjbidWjkgwySICAy+vp9Kx0tNxWSaUkZ/WrM9ypBdEXYxwSM8//AF6qxXcUkhjdWKg5cxH7ox1FB0wg0tCCa2jWaRnkcZA2rjqevWp7O92SiJYlk/vFuwHTP5mmM6SzJ9ndXdsBlcZz/nilTzxeboHLAdEPHyj2qb6myjobcMhLKwiRXTlu3B9qsMolDSNHnJPI4FZlpJK0jSHdPcHJLZ/AmujghaUrGxQRqMDj5V+vvnNU7GM1y6kFmEhhUyqX28bs5yO49DUc05JC26ujjOZAcdT2/CrflzW8BeEBUY7WLH7x/wDr9qeke6DIZdw5T1PqMVDuZabmcqkShZWJXblgvGT2ya0HKSQIuNrLyTnrk+n6U03DlW8mPcFwMheADx+ZqmDcAsYUXaeNnTI78UoO2w5JsvShtxkcqS3yqG5JHTjFJdSSyWodsBFAGP7wHQH8qhtZWiJEkYdsnjJGR2x7VM8ykfOFIdDhfeqQkjz9LOWbUnaeR0UsR5YXJxn+XpXRQCO3QeWSyr0UjO0gcECp761KyJtZhHj+7yPx+tS2VnFKQjSAsoJaOP77Y7nt+J6VCOpzTRLZ5JVj5oCABZAOMntx61s6SYoI7iT5hIAFZiATknr+NUVgLuEgUiBfmC7+h65I71J5v+lB3TyZCAQQMZ7dKpGb94o38ridi3zIo6DgcdqqF5VtvPg3Bhzn0GORirWo3BhldIAxVsfMw68cj/61NsoVMfmKreSGEbLnAJPQf1/Cs9LmkbRRbsbSWRY8IuJCOBwo+tb+m2DxYceU4YHG4fcHI57HIrOtpRbQosjENgB1I+U5PtWnFPFFAWTcoQcjOTz61aSRjUcnsU7q3kSSNXijKY3Yxyc9MmqzW9vauxSQyKBgFQOCevP9K07y5e9UR253OAZDs67ePlz39aoSBQWj8vOGPKjBapdk9CVe2pctLlwg8scshB4+8PQiochcmWFlEADg8jaAepxyeasW9vanJkmkVguAC2Dn39vpVG5it5DIjy87kBc9fcfzqr6Ercp2m6eZnjB8sE/N0IHrk+9X22mUMrNsKhfmOSMdzmobKVIh80mE5ADLxjPG7/Pepbq5UvLPMizdm4K844xipZdrsb5SzOdsiogH8XGSasyQxmQNANkkSEkScg47g1RSJ/KRgJizrhkHBJ9AfSrlpp4ntPLNzJ5i8mMDkt6c0o3CSSWo+O9mYFW8ty3UyRjPqefWo5SJsHZJEehOQV2j0x+tQvG053SFt4GMKvb1OOlTQxMsoMBcZGWU8g9uP/r07sSSWpJaRSCRBCxLyDB3Ng8VJO80E6OJS/lYUscdfQ47CkYPCVdUXBGfnXgepp9rALfMckbMpGcLzweRn2pp2DzPMJ41U7lA3ADBzjIrK3W4kljk5LlmVzyFI5wPrWsrho2PlbkOcqcZHpj8aybkCXMvAAGGWIYCgen49a0T6jpxIba2VpUkcqLYguxJHB69D39qswO1zGzCMEDcyktjCjmsd5QC0YQ5chgM8KO/410WmWFk8E8st385iHlxLyS394e3Yjrmmlc1lotSCG5R/llCtnAVjwNvda0oBJAksF1AzTOQY90mCAAdo29CPpVPT7Nv7QSCNdzqdyZGeeuKty3EdsQiSYkGVD/exnrz+NEW1uS1fRFuKFSB5STFpG+dycKR1wBV2CEojNKcZbqFwADVeNk+ysqyHcMBF5Ib/DFXdJia4RklTcc9zwo96lbmM7loyj7CSxyVI27OPz/CmoBPAzjgjAO89P8APpVtbWOOBWTy23gtsBydoOMfXvVNn4k27kUZVR6CqMrX2KOoSrGdsYYBiM4HJ9aytQlEl8JDkRAMiKTxgY/lWncsksBKlmuFG4IvYe59fauYl8+7lV0uEWGFMEEcY74HfrzUyd9EbU4Fu2vY45cRxm5IO1nK4U88fnxW1dWsYi2NIolQZfyj1/2c9M81SsbJZLcNAxzKoD7jwccg/XitCBAto0bYzk/OQMEAfqc9qqN0VN3ZkzQ/6IU2AWyxkkbc5Y4wf/r1mx2VwIxsOLQv85DA/n3BrdiRkkEcanEy52t0C5/XFNiCiT7oMb5G4gct2xSUrFqXRFfSbPyGMkSYYBiXxyq46An1qV/PjWMKF242JGWwQM55qW7uGDRRqzGderE8E+mOg4prEKyRMvnyMwLAnoByB9DmjmWxTb3ZeRQLeMIczByGJOMDHFXoIZbKCN5pYpN43eXnJXnofQ1LaotxGEL8b9wAGNoA5/TvUV4scsvl+YI1BCqqj1H3j/Wr0OZyu7Mp3CCd3kiOFPKg9hUN24WAkpIzuSM8AYx0q9lYpjDlCR8gLHII/CqOqvlzIw8tCy5x2PsO2RSsXDVmTM8rExxxojPjBce3T9azJvMiikz8qlhj5s9Ov1FXZ7iZ7pHtEb7Q7ZQ9zzyMfTrTLjULafUHhuI2g+b94QMsXHQkDp70+h0w30IbINPeLHgor84P59a2NPSKS3HnRKCAeR/EM+vpVey0ae6tHuFaNEQ43O+09fT+tb+kWSw2x3yiTholCLuUqT1DduR9ahlTasXbK2gUN5Z3xtjYehPbBH15rSWzMczM52FTnk5H1NUVjELBssQRwRwcj0rXs7ggAtH5oBwXHcdelTHU5Kl9yG9iMeEuGznrtIP0qrFb5SQYZQvRDz164rRu1Z2idshghZjwc8//AKqheOdBnlfL+Q9Cqk9ge5/lTkSloRx2zw2xf7QyhsCRAOnfDCkQHaqkIu47s45PYCn7pHjk8yViz/eIPr2PvTI98HlvMxz6gZwN2B+PGalaA07E8jQEhEYhlPz5AyV71mqwA+6MY+6eD+dSy5AkZFLITjpycn+dYd55j3Mi24cbcuCSMBffPuQKfMaU6dzYvEEdufMeMtGMqEIOfr2P1rLiXfdllL+X91pUIGQeSMd81Hpt0xs/Mm2uB8uQQCM8Aj2zTLSSSK7CN88nI8thgbehJ9qztc6I02ro3dOuYJp/IuVMYz8zkcv9fSpJNPW9hcvM0UiY4HG8eo96i0uIyNKJUQlWB2kgEqcc464/OnQTEXTyWyCNRJtHJxnt+NU21uQ42egS26wWUTKwuHOMAp90jOQT9P50yy1G3mdba3EULt8rKy7Q2fc/nmrLxSCJtsjMQrYG3PXgge9ZlxZJvDqwcHA+YdMdMiobe4JXWrNG8t1IIMgVxxuRskn1HtUc+YrSOM3Uc28bhGDuKfU/jmmrBJNIwGIxyFxjaD/skdsVK8fnNbm5BGMjzCo6H1x6f0qk7ol6biWFrJHcLEBtk6gbTk+1acyPY3IERRkBDEnuw44PX1rFnubm3unELlXQ4IbnPPatCB2lt4/OjQlBjchxznrz35pJJEyXUtCXJzuUSk53OOgzzUF5BG0js0cZdlLAq2cdscficVPAU8xjJGyuoAUP95fXHuT2pL+7Z4E/cAbWLdQAwAwPxyaq2hn10Mu7lht4ySXIXgkJnJx6U3TWa5dg3mqwUEDO0gVaaPzEOzeB6MMgD1PrTTFcWszJI+2MgdfnyRg8dzmi1ze65bLc0bue4WRkcBpODkg7gcdTj8KpbZXlBjczZG8rk5U4z9ar3l200zmQiJtg6k9R0FQW15cLco8PyiM5ILf54pSfchQbNyyfEqsqLgkZ3Dt3p80m2VFcFgehHYdufzqvHcx3UxCgbzyMNgMc84HfPNOgcSB0RSJiWUO/QjpjHY0eSBxtqy0IAzOjSu+zA2yHk98frRaxPbRyyISSchlPYdz7en41WUXMXll1YlBxvXcFxyatzSyXC4hywIJdMbc89vahvQTX3HkdyrKCyDMboG5/gJ4xUK4QNAwAbBAY9Fzz071p3M3mw7W2tHjAjzj8M1nZKqhkRdhO7h9xK47VdmTGTtcpNaecqyJF+9XnAHUe/wCNWI0ltJjFcpIkysAy7Qrg/WtWyeOGRCok8vfj5hkH/IqG7UPJ+9B+0FiCxbO70qrpal893YtRqfINzC7LKpxc4PByeMd+DUVvYQvAzbSjcbTkcnvn0q9aMNogAAG3aTjAI9KmFpDHKqFt0Y5BIw2Pb6UWEqltCC2jki8yKRSZTgqwPA56e9bccaROwd18t4xJndknpwPfNVp2URosSsZA+0sxz8uOv1/lTdHst8xaWUxpjKsRyAPX1HbNOKtoZyfMrs1pINxdnjLOq+XhiBhyM4/Cse4JR97kAOm1yOinr/IdKlmnMLSIWcHONinduz2/+vUL25MYMhLTZ4Vfur/npSbu9DON1uV5FedRGyIquuNoXHzZ+8fVv0qkNMYXZZx5YiG0g8Hrjp+Oa2LeQW8LiTc7BOMcbSf6VPC20jASSYHDbhuOPX3ApK0i1KUFpsMs7KKWwmYLJGsbgdcLj1P4UlmVmfyZcqiDdn1HfH6mrLGRLKZDiRHwSf7v07VRjQsZVwu7G1st0HtVaohvmILyJz5klu4dbeI4JPIGeAPXOa5whmuFRJJGkbPCrkk+wra1RZobuGRV3IyEHI6qvr+dRyWQa8E6eXFGMMVJ6dyKlo6qbstSazsgI0dwokUjhvvdeuDRdWL2l6zM+VH3iByp9M+vNK8chjaWIeUgUNtI++e4H4c069u3k8qMqAAgGFJYyern164pSshXdyVDKLXeZE8stsWMN88nHYDsPemMWM7xgOhJVgx681Tw7ytEF3bOceh6HNJqVw4jlnt3VWULkgY2j7uPf/69CkHJdmj9o2SKjhH2MCEJ549aryqJTM0r4RAeB3J9fbtVC0RhGsksUjtcYEbnjB4rZubUyQCSBRv3DcpH3vxq/MbST0IfD8VrYyO99Gs8JkjkRH4KkjovIORj6Eda6vWodB1nVoIohDHdbElluLeJedxACnP3cc5HJrmY9KW6ktrqaZDIsnlOHJJ28Y/IZ/lWpNYwwXLx2sExRgCWdwWf5uuAPlGK1U0kZygpT5ru42x0+K5mupJoPsoScxE44Ukn16e+KmuLP7PcSRbUjfGTtOQx7EH0OatQyv8AZEiaBZIYWLBCuM5/w9aZZ253LIrELnAJ6Ae1Yydy+bXUhRSVAYLiNsDjJ5H+fxrUSCKK3eQAwlivlxtnJ+pH86jeMwxE20pXcxV2GM568DsO1IizC2JZ2DIcAA4O70P86klu60JpIm8w7Rko3Y53fT1phAe3ePOQpBAHp1NMtzKfLjzs2nGT7defWpzi3Fu0LlGJJZ1J3EAdMdh296RPkZ11IEmYKwKcnd14/wAKj3F5FyiN5fBYAqSOvI7+31oCRsZFckeeozk45z1qzG2+d3RZC7OoRn5IHv60jRWS0Jpod8FubaFlXDKSw/H8xnrWVd2KXv72USCXaFTavcdciujurZ7ePBkDRvgAqCACeRkduBmkMf7p3CIuQpVweQeSDj3p2JjNx2OUstJjhk8u4Uxoud2MDLdsVJ5TQKXmUSTFwTIGydo6hR35I6+ldHsWWIynZlCFkU85BHX86rxRJKFaPymZSM7sHH0HcUtUzZVb7mE01w0UYRVUMRhvvvn0Lf4YrQsZJAyxxIA7Oc9fnJHOfp6ipFiy8s4hVMHDCMY9xx6Vei1BwzKY1ZwCNzdORUydwnLsivfyiaKGONsSgFnc9T7fQCqlyqw28KK6K5JBYfNwP557Vdt5YmlkiICpIQrK3Reeuf8ACqP2NJ53Cb2KrtLDj2JP+NK7JiJZ2dx/Z6XqpsJLAgHPy/3gO2KQXLxMGjkH3QRleP8AdwetaH/HrA8ck0x2r+7Ctuxzyp9PWs/7PLHdMtwNrkBl4yrqelaR2C99WEqNdWxaFYkncZXYcFcdyD6ioba/cuVuMq4x+6xkDAq5PasHdHZVJTqpyCPQe9PRyqiORo2KH76dx9KT0YXVrFoXKM1udy7QwKpgr+JP6UXRgiYGKSOXPVQ3AI7fSqsEiZRVLMik9unc4/IVU1bMsxYqASoGAMHgdT9aTkTGF3Y07yfcrTgEK0ezgAr0xxjv9azYRN9okQySSSEBRlc4J6/0qrZXU8ZVXC+VLztzz171rLFstmmtCJVUbyC2HHBPX0o82Xy8uhXlmie6fzQLeYH7rAkKQMYJ/wAaS4hhS3M0K+X8+wbDncO5PtnNVbCKSVjcJcBnKZMYBdm9jjpj1NaSxIkBV03zfeAyQcYyRxxiizaK0izJ+xu943lShSijYo4JI7A1u6Y7GCOS6HkFl5jJ+Y9qrWUMjOSY16YAc9fp/jWnEqpatHOh+UZj+XcoPXhv50LYdSV1YuJdBGRYW3zeWWCqwVsZ6kdwPWq2ny3NyBM32ZYTIRDJFJw6Y6k9M5z0rmJZLjTtWur6GxuLpbhERJbbBeMAYMbAnhT1yKteG3nW3vFe1+yx3E5lW1GD5YIGOnGTjPHrUqRhZ7HAzXBtMI7YTaeSA20H0+tZ0UyywSRyLIm0l12e/YD+lVb9AJHRm3svA+fPP/1qdpdnLdExQfeB5X19TXRtoNR0Ny3bzHVYwST0VOQp+tavlx7F88blGDlepHfn1qC0s4rMr9oG7CsqjqMjt+ZBqzDM0iIE2HP+zxmsmrMiWpbWOKWJmgYhWPAJ52465/z0pNQnQvF5caeYAMZHDkcEn61FDA8d0EiRg5DNJG54Cj0+tVtRALIFICbSRn36Z9/8KrmdiVFXJRePNuMcahiCPlX7mOvHtzzWpaXlssFuoMrlmJnU4AX0A9fU1jxymG4S4jLFlQpt/vZHt2NTwiTzYvLRVDYlQ4x1PT8+gqed3CSVjSeOUGW8cj92cKQOFJ5x7nrUGySbLQyHYCGzjqR2FSyXKyicyxkoqlcAcBz/ABfzqnYyuFn8zOUBSIA8D3qtLkJaXGTp/pjyRbmQYU+h9Me9T2/lW4YlnRA23LDv3FV0l2ZiVQYgQTk4ywPB9fWs97keau9PlIJ2qB17Zz+tLRao2jFvRnTQXqtauqbRET87OuSCPT2P9KzryZzcx3Qc4TuOMAnmqlkXW0fcodirJvySCfQilkaSBYQGD+ZuUlMMCR2zVX5kR7PldkTtKJ42STO5eVY9Md+KLaaN5HRQQQeQV9qoxz3Jcb1QxAhCQSxUkf8A1ua0kcvaASRwrNwwl/jY9hnsMUupTutCTNtA0EatJJHg7lY4wPY1HqFuIxD5Uyy+ZGrjy8/KCcYPuKrmXau5mAkhYltwyD/dOe1amkhLy3V2nYSSnDIy8bc5OD6ZxTVmyZXirmZb27PKu4HYFLbmb+7yc+uKhyJIDA8akHk5PbsF+hOa0r+AW6B1DeTJIQuDwSMbhj6VEsqlTOYwVR9wOOV5/Tk/pUvc0jK+pct2srrTrS2S3AmhYyyysW5HQKoz0/xrT/dC2KEFJVO4KDzjJ/IAYqvpzwyrHtiZWyodmAwO3H4cHNaf2VJVmnUui5EbiXbuJ7YP0FavYiTS0Zn9A0Bi/wBcVfKrycdD+OatQhjc/aT5fmlwChXgADHSnQW9vKXDGZ5EITeP4178dsfzqaee3glkSV22hhsIA3Y9PrUWG5dEI940ErB40VDglFPp/T2qaHUI/KlRR5aPjdkD5vw/XiqAZbxcoCnl4YyseR9faqxSImQkiQsWO3unpj1pbAknuXjcRKsq7cuZMREnOBnlvc1WaOUyPPbmVizEgMcEAcZI6fjUd7Dm3JiR2ZTyg647kf4VT0yd8PE0kkyFAqlgQRz0H6UuupaWmhpxSNJEC2GY/eB65z1471JHcIA++NMKOuTlj6fXmsyO4ZJvKaT5WPGCBk+/pVlZSt8I3CJLLkgKMjPp+PrTuuhLgy3LM001v5kaR4UswABXGMAVYs0WEu4QKSFbGe309/6Um4CwQbUTa5wGHt0PqKigm+WQRy7G2sNrYPmA/wAOPWk3ZiTbHX0izyBLUyqF++sg2qD9aDfIgZZMGXI3N6ADpgdeeajlGxt13nK/Iu3nB4J4/rVe6MCLZ4MaRyMQ+T93B4Prk0rtO5cYJ2FMn2iYRyNMsQAKtjb9QPx/WtiyjtbZjGciNRwXByVH9a54nZK0rM0oU7VIbI454Har0F+Z9uXUMh5bBIIPqKLoqUdNNi5cvaOUdV+dMMUbPcdB2p8rQyRxL5LeYQSxA7+/oKht7iO3ljjmQrHsIb/aJzhsfjV7SoEIdFdjMSFOPusMdaUfMh6blUwR+S8kQV2G3aMgsPcUTxmNka3JBdRkkdT9PSn6tItvMI5IwgjGdhH4Zz3Hp9aytR1VPLEDKUDZZHB2nd249DRdIpRbQvmvF5sj7WiJxIHz19/erNpBE1u0skp3qcqpwFx7Gqk8pu7G0ilQuFkMmQOp7Zz1q7a30iWmGtpSq/eKIGTHXkdRyatBJJIiurfYrPauhjU/MAMNj19+vaq6x/vFKRyq0mQMdPcVXeVHuZCMMp3MpkOGQ9+Ki1GSRnh3MXWOMBT6g/zNZydhxjc1CBbXJ+zy74/u4UYPI7CotWtPJuVEiyhgq8H6f4mqtveG9RPNYExg8tH6cdunHerkl1J9pxIBJ+7ARh/EepJ9/wDCle4kmiJtNmuIGkhZgIiVVwvLVOlsY7Wbzo2CmNSpYnI5GefcZ4p1tdrFEoMjo5yCc4C85/nVySWOUzRB32nJAduD9fpVK3QJSfUxTGls+6IMgc4KgkAjtmnTs84DtNErsAMbsDA4q5dGK2EhiG4MoKru3Y9z+FZh/d7vK+YFuhHt2NEdTaN3qXY7rTpDEl20gnUFPMMhO4D09vpW1YyLJEbeGUeQGCnd8wGejZ6j6Vj2sVpLFAY1w/AY7eR6nHf0rVtbCN5JFjuPLWQbFkDYZDjGQSO1U0yKjjbsc9q9lpQ1vURqVtezgLGIDEkjovB3L8vcnBzV7w/bWsdlMmmRyxwBtzearI+/gZw3UfSp59HurUEL4i1d1U7FkDKRx+HWpLNXtYZVmu5b0s2Va4b94vtwOnGamUTmi5HneoaPbXGiDXplW1DzNGkT/KZj1YqR6enesrSJYlcRxiUSseq8M3PA/Pk/hTtZiuRcee10pELO0dsH3CFN33TjjJ46U+ygeS3f7MgZgR04wp5Hv7fhXTVWoQ0jqzor9Zbu2EUkBV0c+ZJwRz7jvmmaDAftEcDs7KMlgMbsDuueop+kmYWDkN+5Yj5ioyCOMZ9OarCUCfcyEJnbnuuOtZPe5Klo0aeqXcVzqHnxM62zMI2z0OB8tQ37xgDgOV+eVgPujPIz096r3R88s8UnmK3AKjhiPQegHes5tTlkkFrZSsqlSuzI+Y4+bNVK1ginLYnLi3nRvLGzJBGMgHGa0ILtbR45496eUQUUcjPUZ9cHmsm3WSC2+0TA+QzkBc/MQOuP61NcOXtEihcEOoTaQAVGcjn+tZpdy7XLKyrNbAiQAq54HUd/51PKkkNq053I7gHaRywJ6+1VdMRIMRHetxIzq29ARkAcAdR1P6VdhQTxKZEIUPsdmPzE+30HX3qmtBOPKyo0YYmRurDB2tkAnuRSxWivcB1jGwL/AKtmyfzHrWp9lxE0qxuFzuYg43L6/XOaWCEPayXangBQAy8MScYBHcdamK7i9pbVCNElsRGkRj/eBmdmyCuOnpx69eazbgPbzhV+aMSCRRyM5XBA/Ste7WR7PzHlJRHGF74HGazbsvA6tCDgNlNw5B9atrqEHfUTckGlDchEwYjA4I3DGT749az4LiCK6UXcgiTywyLtLhucbT+hzVqbajNDI7EyOrSGRjlmPvUl5Ztd2aM0P75SXLAD7uOnHXtQ9zSPmQWjrNNKItjxMhVQQMHnk+pNaIuWt0W2tyDhSOnA+bPX6mszBa7uGV44I0UOEB+Z3wAR/npV+cpHIHJPmbgrN12/4mpS6lzsTB/tsYhlJIAyUZdvPQ+9OMUCWflwYL7CqocgYB5Oe9MRnn2ogRZWOFYc5PrzUFykVw0cyAqUKiUdcrn73sfajfUzirMt2aT25Zt4WNo/M3KMhgDg4/XmtOCQ/aN+R5DHJZRuGPpVAeW+mqUkkaWFNrBjwPm9fypltKJnXc8VtHEQCwOMnPX/ABov0Ha5ttcG7T92cMATljjP19vaqU6xn5t+x03cY5X0/PmmMY/JM0Q3yKRujTPTn5h6j/Gs/ULxkjkZgSXULvD8ewP0pN2JS1NO0u0tWZIclWwC7LjceDgA1k3d1NLdSPnYd+cDAHJ56VQXV+FKBvMB+bcAyg4PzAdqs74JYxcReSXDYEfIwcdR+Jo5lJWOiKs7yNjS71hKk4MrnJ2yMAcgDHIqzLsd55I1SNdnA7ZzkY9Kp6Fbq5+0SbI1jGWjY4P+f8a2r1FigTyt+wnlWTB5549Rmqa0MqllKyKcdoFc/a4QwlXAG3JGf4sfSqFzZypL5kTGa3jDEL3jx7nvWo0zRSKX3vliZcHb0Gcg/wCeKryyNIPNRAcnc3QZHoBS0tYE3e5Bb3sU0q/6YFAAG3GSMdsU/UUKbwqEsrqocnB2nkHH071n3tkkcywIFXzJSQxH8PHPH17USRSRljDdeYsQ3fvOQT6Vnq7pmvIlZo03DPawyGQlidg3HkYz1PpxWXMIJlMhzOEbPAPB7H3qhqN9dW0uxtkoYKWdG3ow6cYwfbijTrVrgvKl5FBK0g2wMSh2k5zk8YFPlb0RpGKS1Zuo1tJb/uUC3BJYlpMAj0HvVrSZYkWUxxR3G88jkMOcYB75zUSJEsb25uFKnZuGNrA+vP49K1orFoYVSOTzGYF1BYH5fQHuf8KfJYzk0lYjt4y98YkjYq7YRJOWjwemT/KpSZSz/dBUkbuhY5/nUksw3rI+RMrAk9W24HPvTfOQM6uSsZY4dF5Lf57UloZt3K9+r30ZLT7geNxGMfl1rAsLaGK8fz/NYqDhiuee3WugitYpLa8Ebt8uGjVuMnOD9MiqUyJawiSS3zIQBhn5Azk5/DFRJdSovSxbabBX7OC6tGEBP8JPOP504C5mVPKjx82GYS4Cjpn/APXVC1iklcsxERAyy7eR/tH9KnghhnLhpGJ+9yeCMcZq9WhNJFR7fzWICMyzSGPdgEkr2H14pP7OfzdkiMsSkDOORknnHetVtOimAS1vVkRcSCNeChJx+Boe5ktyIZm2ocIGVcHA6fh7d6nbcObTQqOIRKI4RhVGA6jkgd8UirEyx7UbzAy7XUdV78etaMj71FuQpB67V5J9c1UUPuCszlUHlpkDI/PnFHoSnfcc9vD5aSGN5CSWWVsBc9wwFUr26Bjbyo9rqOeo2j61q+bFdIsMhVM8ByfmB9feseaNY4S0is2WZQ6nDH0yPSm30Kh3YQTQPYl1mKzKwAQk/XI9Ko3UzyTYjE3lqBvjzxn6mta0DMIUKL9mJAwuBljyBmqweKGSZQu4bu/Vc+vrTfmbQaTbJNNZlJdk2ueQyjHy9sj610AljOSzxuAnIY8fQd+KjgtSqbIQzYVSwBDBvc+lWZreFZYbd2EjSDABUAj8QeadjGpNSZBcToltGzSRRDBlO5+Qo/iwe3PWshZZ5GeW0vbS5tmBMQgX7wx/Ec8nqDisfWtFeTXZYj5aWt28KPLK4VwiH5olU8nJx0ro/DlhZRxytdwQQtd3DSrDFLkRKAABxxnIzx60W0MlKz2PGgGuCslx+8t3lWBBnbHuB3Y9/X8a2rqxurGFLmXcjynbsAGxl644rNt4lvLA26kA53g7dpJHQjJwcVf06GSeCGK4LPM2dhY4VVHOfQEnvW7dwl+Bet5ZDD50abgp/wBWDgFvUf1qsZAdzxykyt98DqT3/CmTXazt5S5hWBADH0LHoT9Sf0qrbxvLCHcokaMBIVxgEnArJq4Rit2a8Cyy2b3FtGzrEm5goxtHAJJ+pxRoCWlus93eSK0KuAkBG5i/JAx6Z75qGxvYbS6dYXfydvlSENuQkD5eO4z/ADrGuXEbvImFdn2kEcHHXNPmUQSbbR0crlJhPIqySbVZgwwAD2xVjUlhh12RAgxMd21eiDGSB/npVFJZGRDd7sxoCisBuIPb369KlTbDcRNI2XRGQEnHJU4b8+MUNgoj7yExbJEjARmDquS23cOP05q1psMVzp4DXEz3Ucg2oeAAc5IP5cCn+VA0dvsQr5kW8o7EDOOCv09Ku2FtDbTIruVcHKs5wpXHT86Fv5ClO0dTQiV4LaVRNK0bquSuCMjoOnoSaxgXh0yG0E8pRpiSAAVP0x1P+NbEcyMwWFNqOpKoDlhxyfy/SsAP9h80xQlxbsqMD1IOSMUSdjKGpoxTCRfJnnI2K2BgAPn/AAHFUkmmRZEmBc4yCwySR0B9OPSpZHM0oeFI5m/2V+6Sf4v6VpXFmYJCYf34WIONy7WXAyx+gxgevShIHaOhyshEzkHJbzDJuOT2/wA/Sr9gPLZ7a4lNuxA+U9GB5/lTpLZGvDHJxL5m1tmOV/lTTZbFia5i3QuDgA4Ps2P6VLuma8yasXJI9pRrYk7Y3ViB0UHJBPc81BEUCyB42bzU2rtPSTPB98envTrmdX0jBmjlNmgiUjh1jwQWI/i5Iqtpl0iqkLKJFdgySbcsWwQAtO93qNJtXJNFXzpfKdcMhAJznPPHXjPNTMI/LbYP3JJUkDnbnriq1rFMk926IHiQFhhjgHGcjPc+9Vhd7LEY3C52mPJ52rjnj1P8qEyrXZbTy8LEkwDbvlRxjbnqS3pgCnSSjKuREvlvtZ4s85HH171nyWw/s2zkhuMzyllkjVT8qds+oq/Dfiz0wC0jJmuUBMmMhVA/hHPOeM/lVpLY0S7GlFHutZpwWjf5VGcYbOOPfisvUWjBlWKNduGIyT8/OPz9qsafLcvYXIVIpI4nRmfbjazHAGetUr6AmwmJyrpyGJxgHrx2+vtS9BWSZz0u8kToqqXUKgRslm7jA9B1rQt743phhFsqOBg7Sck+uKteF4TJr6vKgij7eauUHydTj16+9b+mxDTol1BXViRvchQQSTjBHVQfz4rSNKLRcp8rsR6PJDJYvDg4Y/KGGGVvp1rSnmn+yL5rmREK5/vD29cVnAhboKI1XYzIGc54A+9+H9a0XaOZGjj+eQ4YHPXn9RWbXQznq7jbu6E9mkIgMTxnqrZB65Bz3qrFPJaxo8kW1T/FjIIz09qknwghU/fPMocYOc4/HgVYtbS4vEkkiBeOPBK7sYX1qLMSkktdiee3hkngubcO4Ukpu4YeormtWEkMkTeUQijrjdk56nPrXSSuDLdC18wxo21c988Z+tYl8jSGXfJiZdwVACAP9nFOTLpNrcyLuCM3UUjEiONduW+V2Y8npkjn09KlvntpZZLCMGWaJVcyuu125yWTsMn9Kr6kn2Oa3uSoMQLE7vvEKP8AHNa1vFHqsRvriKWwNtbq/nK5nXBUnlTjGBzjtWkEmdEpKNmzft78ySwW6TxzlcbsMCjfKNygkYJBP51LLEsl1NJbExFDtZQM5HT5e1YsVlC9+YxEVihXdG24bWLdSMfyretYVmhRI4lG6MkSeaFBI65HsaiabMGopXQtxZvJpxkEzkRjapIH5E4rH2XMOVaRirLnJGfyrcjmhFqYpWQYBCShSQce/ftXOahqE7ysGVJFUYVlXnPtisXtcVJN3RswXD2wkBVYywyGwccc/wA6tiSWdXtpYI3mKE7Qx3MxIbOe5/wrKhg82CDbIBMzEFMZDL1A+vHWnwf6RJsG+NV5J6/X3oWi1JlHUgnvfNkZJHROdo3HlfUZ9OKsQRFQ6qjYO3dx79vQVFpywvNcB0TcvzKrNjIB6g+tb2pzW9zHbCI7JgNz4YHJ789/anHa7Y5Ss1FIpxJHcbdx8sZ+VI0wBnPfr6VPcRwRMBO4Z8DgdT2wT24oLttCgtDKUySBwe/HpniqkrEhCzEpJkMzdjnn8PrSa7Gdm2aSpGlvPEsYQ7cg9z7fn6VmXMyRxqxZXkJO0INxwOualkv4/syROXdhhfmTnABwM98etVwUeEykGJ15G04Ix7U2uw4ruK7xSwqxDhguWOMAe3NV0V1kEvJjGM/NnINUXvUuJrqR4nEZXI6kK3ABz9atxsNkQt5QZGQ71xxnPT34xSRo4tDZ2e4dktlyAcmNQQxx6fSqFoZDKUVd4cliV5I59ulbCQSvsmjR4jEcbk5YHHp2qvp0QtJpzISSy9UyCST1YdCKOVt3KT92xqwIYi8bF4nK/L8/NWb1oLUgPCCCuFkAx83HOO9PudVhlkQNGpdeCXXhj/nsaoXpMx2+fHsiwDhQN5P3hWjVtjnV5M5bxQ0MOtSyyQzXLNNbvbz4MhjRD86EDlWzz71c0dXhkuJRG9tHc3LSwQ42mNCoycHoScnHbNZ3iC3tP7VZpNRlsyqR7I/O8tH+U7jnuQeMfjWdpEk/9qW8Vrqd3Ik07QoLhiRNEFyWHptbjPeh3sVCK3KFtIdPInVIXLD5g67/ACMngj69M9qhur9obcQsqyMSdrJ90D+6PXvVW33TSvCQyFzyM45zggHp9alu7eBY4RKCISSiuDgZHc1Tb6EWV9SVHWJVupFWRAoZ1I3YU9Tj1FU4YrY3OfKCW7SsUMnzFVznkelWDsikaK6CyxwMTKA3ylMdVx19fekun2XTS2sIiWJ12qG3qFI4z169fShalpGgIbZNQkR4Fa0uiQWQAHdjg7SccZ6flWMsKpNLFIGZN3BAOMjvj25re06IX9vJGXaMxKXB25OB0Oe4zx7cUv2ZnkVrhPnXDs2Dh8jp7Gk431RKkk7Mq3Myr9kdt4V0CygFj8wHAJPb6VuXKxmNWs5kntCmT5mCFYgA8dRg1mxwie08h9xnUjHHYZH581csLZIJZIbuJo7iNSis3Gc/wuPbtSV72HdJFnSvKLxTSMrdYyrZATAG05HYnNa+rTC4to7RYfKliwAeCCoyQc++cVgTGO0uEVd32cuGkMbYbGMMo/HFWbKVGeBDGZpHY716EkD7v+7VJ6WZnKN3zEkGpRxQSCSI/ak5WYMQcY5U/n1oklSaSPGGWbYNzccjII+nINU9UhLF2JczxttwqjbsHQ5/SmW159ouEsokCTRoz7nwANoz17+lTd3syuVWujZ02KXTNThjjJEqyZKEZ+cDaTj17ityWaSW9it0TLRxAHkjLFixOO49a5qzSVdVhuL4ywsciQkYYMOT1rbsVY3a3wcMFlBwTncM88/Stl5HNU7sybiJU1aYqm1C5cA9h2FaGP8AQLnBRmz5KsTyCeePy6/So7zy28+bzPnZ2dNvIxuPH5VUhuCoVpW2wFl3MDnYc5z64NDdthxV3c5/UIETw5KxJMscgkJ4wMnbj2rZstPsG0OKZ7mWKcOo2RjcHYrkD29iPxqnqWl+da6ikUpaRLhECKDiVSSwIHqMVV069FrGLd2WSLcSA43ZPT8BWSsnqdl3Nbm9cQ/ZEJmTc08Ksw3Y5yARz97FZRiS6VdgYomEfb8u1c/ez9a2NRmW50q1OxnWIg7G5JbHQHrj2NULHcVkZG/0jggEdR3yPQDtVSjqYxlbUcGaD93AfO835WJ4LHBwufp19cVC7RWsCJG0TXTgjIPJUjOF+nT61ZsLWMNdyxzurxxiXeTnZuXGCPXr0rEt9zalamXaRb5KtgncCMAgD86o3guZl2O8X+zhZq6QbpNxZxgkdgc9s/zrR0WdJtRtYLh5ZEI5DIHU54Cfjk8/SsfUbCRNE0q8kYXBdnQMo4cA889QfQdqvaaktosV3ZMJbaOX/VF8Pn275FFrF2TXuk9nFPpKajBFEWzO0D7zvdEA+UEdM9we3TNalg1lBI8U1w6ajJk+Y8a7Q3QBxnjrxWLcu94t2QjZm/eE5KnAPQVHpMctjZh1nBMqkhWQPhgwIGD6YPWrVW2hHs+bVs19VDy3rzRszRxhUBbPLnqSOuMjFSz3nm+avlxQvFtUQruDZHXB71d0ywW3lUT+a6TqGkWQY3HnDn6etUdRaT7LPbLsQwkFkYDJOeue/FZSlbUV03Yqw3kl2yTv5H38bpMEbvTHb8eta8KXS3Ru1VWZJAWVVyuT2x0HFYlpBLZyDEbyRv8AO+RkdQeR7Gt9Q8xzbqJI3VEKg4GfYevWouOdr2RS1Jw2HSHFvuCFicbiDkg+lVr2BreczKSVbG5c4Y98CpZlkhuDZ3CuFU78Yzn0OPyp7yxR20T7JJljBUC45Uegx9T7ULUOayRmNE8ssEcsHmboXllZWGFL8q3TtxxWhc3l8dMutL1SUpCsOA8cPEh65zjjjisu5FxDdzboTA8UYDru+6DzgelW7OaOeFUmuHh2xEld5KyEkdPbBz9apSa0NbJ2bNXTZkkSBbODaIYd+5gNxfAyxxxjmtCSAtpxVYswqdxYgBiM98VniwS2ltybl3tpSDFJH3Xoc+/StU3bxLcJLJFPFnBkTP3fX8KTu9zKTXQhjAZ4E2LH8h4eQ8n6/hWHvEXmPASCq5GTglvx6CrlzP8AZ5JkO6WCRfkyMY44I9u+K5nUzK8iGZPlEYYqWAHTr+dTsaU48zN/TbqKU27EpnzDnYwL9D68VeWOHYxWbeYz9/YQMHse+RXLWltMGSRlSNEQMpKlg2e3HQdvat+O6i+wAJE/mSMAzpISrDpjH1pWCcLPQFUZZ/k8xODhc49/p0rTsRcJGqGKJpWIxg7g2fX04z0rOgXypEVScsMKGIYMoP8Ae+var88r2bxTKrRqvD7WGR7qe1KKsRO+yJftSENujSROmWbkEDAB9u9QXPC/Kq4b5sK2do/2vT/69RB5ZrMvbxq7rJ8o9QR0/SqEl4IwPLeYbyfmzj2Ip3JjC70NHxD+5tbW58oCZkwfUDqG/wD11Vmuhc6f50qoJU+8IyOvYn04rJ1q/Z541sVeFmQB0kkJUHPYnqCPypUSR7dlPBZN/wAvcAZ5NHNqWqeiuQ6nG8cZkgkKiYbD6jml02zdUBuVGYxvdgxbdnofQYp8UourRHiLNJ5ihc4IVe+79Kt2kc2nmUrOJEPDrGx24bkg8cD6UKy1N+ZxjY1dLR/s29ZHl+UBg4G459cdMdqdexm0k/0hZJEIGGTqMdBnp1xU1ncMqMjKkLKvC9dwPP3u/wCNNmuWdbaJlZlDEgdQc/Tqad9DkbvIbZ3UqrMWjScOS0iA888Zwe9Y4mKSkhhgybl4+6B3B/pWtA0ULbJtrzo2FI6Hj1/L8qr6rpcZneNxsOAcZ6Njr6fhSuxxaTszkdVvJ7x75XvFgS2liU+ZEJRIHPMg3DjHGK2fDqySvqC6jIt5fW0rR78BFCbRgLj2wcVnyJc3N7e2sdtp85hhSGS5nU7pA3O3A7ds+tavhzSV09FEzxwkOWMVmpIH1DHr7076AtGzihtg1C4AQIjr5yFiQOmNv5mklMtxprRvhEdgwAwcEcZ9snrVW5kF1HGtjulaEFyxy3ykdGJ6YxxV+wlOoZt0iZrhRlWQ4yCOPbt0rRu+hz7amK4eZ1huGRCuAxB/1gH8P1GBW3osSz2koa3UK7Rw4ydzDJPAHtnGfSs4okZaVgizB+dw+4ynHPr16VHpVzqGj6giTNDiJwwEh3DJ4Vhjnj9KqNlubu8loXrOZ7e4ljnJhdOcH+6emffFdFqts+izxK00FwPLUyFGJGGGVOO/XFc7qanUVkuopCWRlSRn6nOcHjtnNWXvgI7WHU4FZYwxd4X+Zwem73HFQ3qJwvqXVt5Ib8ouIbiMCQLMwCyRkZBz6Yq3cTo/lo7MHAO/dxuyMrn6frUWsXYuNOt75JHma1Xy3UEfuk/hHPLDjkmq8l3Lq1iIbpD58XzGQL68kk9fSk10Fyt2bL2qWs0SqhfzIgeBtw+zGQx9vcdKbZwQiANdmViAwUxEBy54HXt60yymc20U167ywqwg5bBXgkD2HWq+uwOZhcWAlhjbAy/cf4Zzil0uLX4WS6tO6SOrFN5Ty90WdqkD7uP6+tRsq6iEntMLcY3McgAYHPHcVD9tK232RwI54gS0w6nd2+mKW0Y20KSRth1chkAGCcdj9OaS1Y7WNqfVG1Sx2XaETBt7TM2TI+Bg+3Axim2GoG2cRseDwpYZ57/jVS7Kx2ZSRlVXG4BTn5gQcH0BHpSXe15tixupU8qTghGHBBPU55BpuTTuRyp6Fm71FY7gmMIXbjJ+6c8dO1VtOSIOUkkx1bPOMjoPx4rEjMv2iCK5XDhQrMwxuwepz3x3roZZIrmSWGG2W3aFvMG5z5m0DPTufpRF8zuW4JKyLV5CbRoZwMTyKHBfvg4zWfq9pb3bwGMmEOo5Cbdh5zn69an1S5a70tGnmPmW7EKSPvIx65+v5VRl1COF1jaMFjHg49Tz+BxxVPexMVJG+L+VxI86ozHbM7ouAFAA6dBgUkqfZgLm0XAIO7cdxwehPtS6FPAY7s8QJJbPGiO2Crccd8qelVYp4khWCRfMwNhLddp6frVNmetyrHKtzOgSSO2cMo3ucDJOTkj6dKh+xvNNJHEjOufLMqKACCOoP5n0qTU7O3WEM9uzxcMTGWDLx7fnVdvOtIsCTz4HQEKecj0yOg9qz5mtzqi9LxN/SL9LZ7CxnVDa28hMcxT5lLLjDD1B71mWlkTfysHihDSFZJFJ2A54YgdvekS8N5ZxOm9biM/c29Rn178V0GnLFb3NvcLDFPaTRESMGxtdRyAT2xjI9elW5c2gP3UypGkzXhjkj3RhdxMHOOOPwJqtdWtssSTW0rfaMfvcNgEkc4HbHfPWr2oSpA5VAAykHYox8pHY+9UZRumkktpYy1wQ+w/Lx35/SpcrCTuX7K6lYwwCRo38pkEwJYHnJPt3qzFY295pU1xG4a8T76q3Veo/QVQLNZWpnERikUFdpGd6vjj6Y70qX8t/ExaSP/VsNojABxj5fb05pSfcmUb6oYXmkijEk+Si5jA4LYPOfU/X0qyJY1jjS4SVZA2c/dJHoM1WvIUtblRcRktyrlT/ABAdRjrnjioI0NxZzOJpTGqghXJOB0P0oS6DRqK6TSEgfPJ909Nw9P0p6yx3rFbrMYdwvynAYkHn3wcVjWciSqEifDpxhhkf/q4q2vn2ty0hwyqDuVBwCRwfYUluU4FCG+t7O8lkntJLt2YHaz8BQMEe546Vqre2mqiRLO1jsJJIhO205XKnlQp6kkjgdK56ws1n1KYsweOJ/OG59m0Dk89s8VbWWc+b9ot7d59wkSRUAaMngksOMAfnWifum06abutzqcSTwRQTDarN/wAsyDu7/KB909KcboI0KQouxC5dXGVB+n0rO0ud4LGI4JhEi4ZcjA6kD3qyJ49v2uUSZY/MOSX56HPr7VN+hjKLvsVNXWKK22QBiHUMrB8oQTnA9vTHrXNzyFYnjvso8yhVIORtzjHqPpXWXVrI8JvPJ8qF5tqllBUE9gOwrB121ee5idIvmBKFtw2lwTkqfrUta3NaLWxv6JFI9qYDNERGsYilVizjcSp9hwD9CaS3sFhlc58xgpUBGI2n3Hr/AIVz2lyhDhWltCQFlZJeMg8E/j6Vp/anM5eWSC4fzFbJPyksp+XHUgfzqpTTQODbepclkAtIRGruY2ITywMgdyfSo5pvPQkRsAse3cp/iPQkda1NFa3nljtbhI2iYIqbhzn0JHP4+1UdRtBGJJxKglZmjDDnIBwMj6is33MrpSsNhkhhDq8ZjU4PPJX3471Su7eVJEZZYSso3L3A9znjj+tM0yZ0umhukjmEoAY8k+30+tdFBpazW65ZdwBZgxGDjuoPX6VShzLQuT9nucyPJtrhJtrtGzfLGxyAe+M9jV37BGi3BbcUBDR+gQ9j+eKglWdLkLAyA7icSYwPcZ6cU67WWVYprt5VPAYt/dzgfX1qLWHfzK/9nwQTwny1CsuSz52g565HXPWtg2MlrBJGsiyREDqeCOwGe1XBBIxUyYdUxHvKdsdAPaqzNEL1xGnmW8SBQVHDFjwR+ANU+yIc2yK1v5ZN9tbAwkr5ZGN2R/QVHaXCSLMLp2ZIiCyIdu4g4PPp2xW5BYW11bXV1EhjlhjLARtgYrmjEsshjgQYchgS2CT9c8c9qNYk3Um+nclt9pmkaNERXbKp1CHsP/r0ur6gxkeNtjMWHDDZyBjr6DmtLTpFt3ECbUldgjswzgdD/wDrFVde0xtRtpJQR5khfBi58oD09++KOg4tc2pxmoalpY1vdrNhdTNsSOJ7fOEPcDaQG55/Guj0tbX7KVttPuYIi5OJ1ZZGOByCT06Vk2PhS5M6fZNeueR8wMakfQgjg10NrZzWRSHVLue5IbKtIoJHH3ccccU9HEdkpXR5y8MdrPZX+mSgrPGPtMCtgKd2MNnswwee9R292UujHayHIy6qow6+w9waoaVLHbtbzXLtewgBJcqEDDp930Pr+NMu4ZdPuI5rfcPn3wyAk4UHB59uhzW0lZ6GCSe5q3ESXUclwS7RyR/Nhf484bPoQcH3rP0pYppNjlkugcCUH5T9R6njirtlqCl5ZbbaZCn71CNwbJIbHYHHSsu5kiS6E0Mm1ZVb5enlt7nvSkuxpC+xt2Lx2b4mMkal9rsuTHIw/hIPfkj2pslnc/2iI7ZoWsXywYsOF75HqOKx5Fuora21FWbyg+WJGQSO+PbNamuQJeaWusWIjt7d38treN2xvCjcwB5weD7E0RXcb8iyyRDVGtra7iuFf5POClVY9NrA9M+tWh59pJMkkrRx52x+uB1BI6isEWUtnbQ6hbznzH/1kW3lMj5T7g+vatSC7MkrRXMkipwVVRxnHIJ71LepUtdtTTkuYWiebaNzAKy7hzjvj3pwv3uVjh2Pcx7QsexfmXB6EGrFnDHczyWtsN7xjYisuHU45DHuPQ1iy6hLLKtvGghnilO9IxgjHp+VFrEpXLoeJfMSVY0SRjJEz/eBP8Jx2+tGuwJAIZ7aTf5MaqVI2+cueG69BkjPXFPhkgvrG4aQFWGwTL/EMn75z2B9Kijka5try3uiqyqqornkMg7D09alroJprU1LG8ttR0o2pgjKMwMZPLQgdV+lY7vIQYnZ1aMMBJjO8DoPbHarenq9lKzwsoKkqxjwdyEdcfz9Km1WON2jOz93KoDOv8Jz1z2yPWktUTezKyQrdwwuyhGQhEwe/wBe+adZNPp90F1GGZrQMYlmKlljP8Sn9Pp2qK3jWCZrQsGkDgBy2Bz2z6elO1C8u9PvpIbmCWS3d8zwSyEhXGMnjoSOM033K12LU9n5rzWMbpPCEdrb0AHOR37HGaw4J2eSO3mh8xlkAGDjLHuD68it6F4Z7m2uQ2EVWQHdnJPqfbOKw7ctt3AF1UmNw3y7R/CQeuR0z9KUmxRZradcNaXc0U+2VE+Qhxu8sHofr7+1QSP5X9ptGhfy88rwFXPDA+h5rJv2+yC3uP3kiqR8oblV6hWPfvz+FdBYIhvFiiuYZ7aeV0yr8qv/AMSQenfBoinLQH7vvE+i3EqeU7AzgBWLBcqoJOVYdx0zUbJ9nWW1Tm183zIA3QKc569v6im21xHp1wXtyqhW53/dGTwOeo781fnvUuEkSeNN6NzgYJ9we9VpsClrewulJY7WW6gZkK5QRvgb8feB69e1TwicSSQQbpR/GjbRIMdfr7GqDo1svmpGygoVU5znt+FOvAXksLiMgbwUYqQGjKnBJI7VIWvK5ZeYC53zeZKhIIlAGcD37en4VLdtHcoZGkhWKXo+0Kq+mcdKrPa3V1NFMDKj7vLKqufNGOc+3TpV22lPnSD7JtRgQ4hXcNuORg9uCeaA2IdQLxWPkq3nBEQlxlVcEj738s1kOWDSyIq228EhFJGB7etW768igeSG0dpbWaMjZkZ/xB+lV4JYZ0f7aksqom/zIWHyjGOR/WhpPQuN7aliCfy3BuoRE8pUBlbsR1/HirNpqLWc72xhhVQAnmsOACO/YZ9aybaMXUCeS7CM9CcFRj078CrOp3Uis4khAl2eWZiQFbnvxjHpn1oT5VqWoq9jdSC2isp94VVODE6MDs9T79aqeZt3SrNvgAYLJ0Ljnr3qBLJZohPC0i26gBtxypPfb7VOFYWjeWisgV2QK2cAg5ANN7iStuVI7Z75i0UQD7dzFRxg/wAqt2+m3EDYjlQO6DKgYyvcNxyabpd6kCExr5sOw552sM9mHer9rLJJAZolgniddgPJ2Env3B7URszSUpbEWpX1vaxqzJi4JG5FHT5jkbfpV+21qK63S7ZQFRlSMJlUHbcTnlielc3q8Mu0yDG3zMiPk7fQg9xUOk6jLaSBFCvAzATPjbhTxz+n40lKzsw9kpR8ztr+JP7JgP2oJOs26WMfdBPIbnnGcdODXOwzy3VpNblVMMaKVy3IbPJHrz1+tW2uGm0fZOIZJARsYD5gf7p/ziorHULe1k8qYJHGZF5kB3YXnbntnpTTVzKMXFPqyraGCWWNCiRS4xF6OenJ6cZ61cgsrC4jdGVjMhHm4biQ57Y6Y4wap3HlT3qvbYDliASeCpPQnoDjjNVrCO4hnuZ47hgvmEeX/CEPQepqG3c15W+tjWuRLaSPHaxqke4n99gkN6ZqGKa6uplto9scxziKTC7uMnHY1qQ7J7G5ivdguy3mRI3Rhtxweme9ZkcM72sIkkVkLZC4+ZfQ+v40NakKSM2HdFqJjvG8racrK3Yf4V0NndsZYytzDcSyrgKwKAL2xn61na5ZyXhtw0izG4YBWzt2sD93PY9/yptraXenyLHcTGMwk5JdW+btyB6+1EG0xytJGjKEnnkysZ3ZQgDv3IIqU6bcRxlHQSkfdAIO0dsH3IqC2nEsiPJGkMgUfNn5S4PX61qtqMk08slyuI34Vol+83fA+mauye5zycloigb0gmN96NnEm48Z+vf61UmEZnlNnJhT1DYAwOn49fzqxqWDrSvbyK6oc5z8rKcYDeg681iWUkr38pjAa3dmICfKVOeOe4rNvozSCuro1oJ2jEkbNlJ1O7YTwB0J7Y9qrTYhmjVoXMZOUbuw961Irc/YyjxJIZEYo5OGjYdcj09jVaC5ad0URRbhghJBgMO2f/rUn2Q073YiAKMIDjbleAe3TP1pmoyPHpha1uJImkcoMqDtBH3s9/pUZhna4EdqAj4KKpOVBJ6Z9Kkhh8pVguw04Uncv3lXPXmq3KsrXMaRryxuljuvEccLEBgDZZZgemdv6CtXR2+2W73U14NQ2SMqSiAxbiMYUL365qG4065SbUILO6hVJY0vIUkbEqNERgEHqpHftmrWkTSXMM92WhSW7nMyJbPvRPlAxu/DJ9zV6JGMXLmPJI4Vtb64tpgzGSJQXUjYoI53D29RS6fcSWly9pfgyI2VV1bkg/xA+h9O9MvpQ+oxvaz7y4VxKnyrnAyvPbP4VFdzrejdIxWVMhgp4U5PT0GfSt56MmLbVixb2PzTiENDdwN8wYEZ5AGF71cvtNtm86SyC+QEBlRRu2uOrKOvJ4I9DVe+vpwkNw05kuo+s24HeuMZ3Dk46YNUi92t7aXNpcA+dGzny8jyl7oexJAzx2ofoFne9zTlvfttmLSCBBbW6txIcMTjIGR2yfzFY8F15duFdpPsrnayDOBkYJI9enNXdMSaC7uJ7Xyy+SQrNtGBggbT1zmmXywLJIHAjiuSzoFBCIyngj1BIIpuLerLg0tEWXM6YeRv3KRquG6kcDOO/rzWr9neO6uVuI3cxqqMhGGYkcEDrxwa55Le4u0WV2DRj92sjZ+XHK5Hp2rotTkvrW/S5v5TPMqp+8J2NIoX+nQHviolHqUnfQ3Lyab7LZ6hZRvCqKIWlU8TEJnZn6fzrnr2JrW50683lmngBkYrj58nIx9MHNWdL8yfKQlBGzBVSWTAy3AYA/qewFR6mrW88lrcruhwojk3cpzwffAz+FQ7lQVtBl5dyXU4ubpwTAhCzRpjK55z6jkVpPqvnW/l3EEaJIpmViQMN3xj+E8cVi30c0a3duWL/ujt7AjPLDtWj4ZgumsjfFYrq304KHcfMURuNn600uZim4pak9rIlvcmUbHRiJFCNkH1XHY1s6k4Eji0HmQyxl2RedwHOSPb+lY2nmK4tpLdITC0Py/MTuY7uD6jj+VKl3JZXHmSBWEfyNubGzPBGe4OevvSty6GLjdjLiUXlivlPjy/lwehB/hz7HpWjaXTTbbW+hDqhMzLnaZCQPmzjnis8Yiju4bZBiThUB5RgecdiPpTHeSO4Fza7kZVACOcZOMHH40X11HylWCGZtUaCyw3zMI0Y4Ukc4HpmooJWilufMheKST9xLnkIM88d8+vtU012scha4UxjeGyBtbJHcdRVtmjvr77ORvZ0ADIMbcjPTvg1KSZpruUrRonhksrxUkDfcfcdyc5OP7w/rUsdqltFFNZSlXbdnDEFcdAe1U0khFyLW+DbAxUNHwyH1Htnn3o1G4fSvJSZ1njnRzGyMME5xk+1KMe4creiNkawInaaQxicCP51AZSRwQ2RwSOtPGoW9xemUKscUjk5TDAAjlcdh6VStLewvbCdWui1+VHl5wA2P4CPf1pLC2gGHkiIQEkqzlSD7eoqpJoSSWx0iyNFCsySnnkqDwRjqKkaCB4VE8ZSUuAVf5VbcMZ+nT0qJLyOGJGj3gxgBwQCGB68dCO2KdOt2sKyhfOtZcOoZtwQKR07jGcYoZCvuQ2EsqzvDFJIJLfd+6eTcoB6gZ5rWs7mBroJKBHHjdkcmMHr9cdqzL+KO2voXkhKl/3zyFjnaR/jU1nbx3MazRMrhlBCnIEhyRjd2/xqUnsOTT1LesWtndWJuIlYHzSWmwB5ZI4XPVuB9K429cyR7uYlA2y9t3oP5V0F3br9meW0uWI8ss0Ug+6y/w8fU4+lY7ypPN+9CpExwoyXVWxwDnnnnn3p8t2a0VYht9kmmStD8t1GyooC8HGRkYP51qW5uIi0VzbqqyDc+9yVkXtj6H9apDTLk5bS2hlMqb2hjbLrjqCD07cVqwrcTXdr5wWTdGQuDjYf6YOeOlXNaGrtbQqwm4t490FwcI+BE0gbCkZ+76Ur39xNpq+XLFEAyptViSxOTn/ABFXdSspNMD3lqizGSPym3nlWzuDL/dz6VyWj3MpvLSK2ka3cyqXLYIIyOR+tYpa2YQXPqaFjdCa5IBZNsv7x1IA288g/X9K6fWNLu9KFrK8hSGYgBlUKHyCeQOh6YqjcaZpht9TkjuVhvoy8qpInySKG4KEfnitJ5ml8PWEd7Pc8tuCSLuEpA/hHYDPfvyK25FZpg58zTjt1Kt+13C4XzIf3aB1VR19jnvTrSSyu3S5KW8VyrHeFOAfbHI55p9yGayt5yGMaytHuZhkHHIPf86hREsWOIYo1lPzNs6H1Ye1ZPcd1a5I8SJeRxAvHCyFtqcmMHOFYjisu6WdY1e4QzIUEhc8bVJwOfr+Nbtqn2G5k81dyywsHUnKlT0cEen86wbqC7Aw0cRE24orOArrwd3Hfpz70aFQ1Zb09i4B8mQnH3AMpz3561aRd1vIxRfJicr5wHQ+me9akUks1hbRLbEeWgU78buwwD37VSEUUFxMgiXypGBlh+h6g9iKppIi9x17Yy2rRwxKQ+Ad68qc9PwpLObiZL4zpMPlTb90d+n17VJLL5ETmJpFMgOVIyFXpx+PcUsU0TAi4WT5lLLg8A+pB696lmetiWWCCaNYTCwjjbIZc8lucnuDSTSoJUWfekYTErvkk89M+uKlW9iu4fIWEK6jLEMVLjtj/wCt0qtdZI2KWVAMuFOeR3wfqKUWSt9SwtyDIECRSQrgRrIuOMcfjzU0KS2k2LZAZAwyc4wDyR16VX0+4a1hHmoiRq5yJcFTwOx6Z9aS3mhmE0rFoySVyi4UfT1HbHvVb7C5RbrMt0x8sFSmMpzng5z29azrCZ4GRULBMb1Y+vqf5ZrXn8qOBvPYJI2MMmCDj2Hfmq8kW+2SVIiFhQjIfIxg8MO3PNSkiltqSmadkVUJRnPzuFJDD0NVnnzAEliHygqHIq5ZXRSSFmkhy8YwoOBzyS2fTrUN3IVkFqhEzJvkwoG3JY8gjqABSt1Et7C2aGXJW4RNgCorr94+me31qzplyLbct1D5e/5Qx6e/8qy/PbGZuXJYqh4zkdfeoYlkvpLmOZJZYZRsRU5Rgeox1/Kqv2K5LpmjdyPpPiC5vY7VrwToq7kdfMjKrgrtbqmDnNU7S3dLW6uJ7c2k15M0qxJ/qwuAABjjPc9uao3VoL/VZIk8P2V6LaKPzJJpjGwBHyr+AHT0o0lpkljt4rCK0he4aAqkxkEcmN3IxwCO4ptcyMY2jO7PM/E8kaAizjjittqIqpznuT64zxms60vEt5U/tNJJbfhWMbAMAR0+verkCm5FxYuWHnRbtoOcsoyp/D0rEhixDJFKuWkwN2fu89a3qNt3JppRjynYaHJaxbBAylWLRbJsZkBHLkevTp6UvhK702wgv4tRimS4L/u2AyVjxjgevNc5pM0lheQtcqrRRPkHGQSO4z1qfU5Uvr/7TagxM21GDMOoHX3q1PZ9jOVNydjo5NPim1UzR3UbxrbqUdWG4s2QCwzweOSK5F5po7+KJy0rW7lcSHIJJ7DsKntZXjaZwp3Q4IUjgHPpU6o19slNqFdZEzdMp3Dc2PmPTFD95aGsIqm/eZOhP2i7iiuPKRMs+xvkPPAU/XjHep0gmuZoZHNy/nRFo2fjOw4OOvA5q5FaRwx6pFMFlNrh1UrtMmDzv75HUe9TT3gk1GGziBt/NVUMQO4ICMlfx/XvVOC3FGq9kh5aSKQLKnlT8vE4OFkGM7c9jirMMtveWCztDM7n+ItnAA4HI7VmWsE0kvmRNJFp0TAKxAJdhyCQeP8A61X8Y85xIxhlJ3sMJg4yTjt9awlF9Da6Za+xiTTmR5ozNB88Sbcb0PUH1Ht2rL07VbjQnnksHWO1vEMUkR5TB6gr6jtWhaSRXF2LVnLBSTERwemcDPbGaxb90juZo4S2VG7a/Bz246Zqb8uqErWcWb+mXiy6civEvyFmWVeHB24K9fu98etSz2zXha5hZHt2RbWZuxJ6Z9M4HNULBEuIcKHL7CZCPuhsZGPTmrukSSyQSXCb4jbIqyrjJZSSOnfGT9KTld2M3pqi1b232iKKNXbPMYR8AhgDjmqN5KTBHHdOr3MMmcqchgeeMcdqrX9wY55PLf8AcPjcvRWOKi3IV3xokPl7fvcFifb0oViox0uP1mUSzRy2jNI6orYdehB4+vHen2WoQW2q2d5J+/iC5dJEzsY9RgYyM9qzJPKXUR9+OJgCpR8BMjp+FaCv59wsRaJZgFUknG8+vseOtC3uadLMXxNB5OqLeWBDQSxZR02nBHpjgdc+1QXv2W509Bt+aPGHXBKsMdR6HvWuJopZrlY0hE0cZlERUKkjAjIx7jrjmsq7igknSKIRwxTuXXYTsB+p6gUXJUiO1tbm3ZLnylKRuG3oCuzHPIPqORV+7vgl99pWIncNrKRt2n6e9MX/AEXfFco0cuwnzPMbdx078j0FVjL5hUSklGyVdeUJPO1u49PxpXshp3Z0NnKJoo4CgQFHCMBtEm45BJ/u5HFWtDuzbyPHPH5kRwAvVomzyQPzrnLW4cQLHb71wMGItxkdefarUV1OHysbiUYIZWzketPsDhc6DU41uoluYUWRw4jwWJKls4UD0qnZpdWdpcRxCSWF3CuHzhW3ZwCOM5GMU2edG06a489lJzHuTIdXHILe1VYNXuPsn2e5x8rKI2wflYnLEds/Wh2TuKMXaxqX18sVnOY0CrOphk2rkjI6HPpn61gIEW1tzAGeVX2EleHXpz6NXR6X9mudOhlZJkZIGSWRIw4k543L+eG6isARLHOiXQkMW44kh+8QO4/Q4puT0NIPldkaNpLdTXCJAkUV3aAlZjhHdSQFDN/Ee2K24pXNwsUqNHchckBdp355+ueRXNQ/aEjyJYr2yY5zkhlPYY6g/pXSWt9FeX8jPI8c7Y/1oAw3fJzyB6ZpvYU+xZkuFlikiEiecxO1s4V1VSQuP72Qa4m4042l3vb5FRkYEDcoUjK7v5V2lzZn7Zbq7IH83/XD7sikfe2nv/jVC7MZMAhkxd22Y2mUbo1j5G0nHOM9+lJpPUKU1HRFaObfHbpq0AfzEJ2yRjgHpsYdRjnJ6VJNMqLYxyohggRo1OSCecgn0PSq4uYhZiKSUKyrxG5O1Pp9euBVZZ3vo4VVW2sSkZ3ZAxyee1TKbasaxXU347SG50tZpGIQyjcFXPrnnqffFNvbPZHE1hcPNLwpAUttJBO3P0/Gs2ylutJT5hujbIQvhgDjBI/AmtGyvbN9MuY4WlacypKjhR1B6bu3GaV1sZu6d1sVpbiT7MmISUxsLJIGVWwN3v36VQjglLM8ciSLkqF3YZeehqzDdw2t/wDaIJYFeVmSWCRSRsJ5yPy/KrFx9m89SImjiY5VlOBg9Dn9eaza6mkW4uxe+231wsMrxE7FQkYwFIGB9eTyahF95d3PIYylyhV1Q8AY+9weufSprCCciQlQsedyPPgljjI57g49qo+I4JmnSVPKVmbhlAO1sA8jqKq+lzPlV7DJJrSW4tp7mW5gCwkFVX7rbicH1BGKf9paUPHcETuY/MjKkYwDyuPoTx61Uvre6W4ZbkB0jH30JcEgDnNWNLudP8mVg7+bGSTg857YH+elJu7LaSVybTrhGkSOdtluNxEeeVHPTNNF4DLcLbvtCqceYclwOnP+FFlatd3d43nRw28aFjuG7OOw9CayrwOjsyxs0bZVivBx9PzprbQcYRbLzyQS2ryrE4uWkKt8xIC+gzzjGetX7LzpYxlovs8+6NQOxXGQT+H0rAc29xE6Rma3jbDoOT0GcfTqa17G9jewihtSzApnzIxlw2ejDpj+eKcUipQtsbEOns0okhVTldwHbj+tUJ5JbaRoxEZHZPmAySM4wP1rTsGyfNilkKDgj7vOMYwe1RawG8hmgfzDv3dPmPrmh7aGG0rMydFtZ471Ulf95j5PMHX2IPYVqJBdjVJBaFFfIAZVGAe5BPY+lVrS8jmnSOdWZgoTOcAn2P49fapYGniuXKosvlHDq7f5596mOiHK97lV7caeyz3VvKRK5VpM5HIx1HT2q74duIhHLJOrQsWzFKo+6MYx+lUru9NwzI0BXIxIjPgYGduPzqKwtGnsTaAkENztbJOOgx2ABq4lpc0dSG8lY+IJTpq3737IDO9nIiqRj5c7+N2PyFWNAsYLm0TAu47ixllkkWd/mMxxlpCPvHB+UjjBp1vo98t1cyabeW6+bGDKt3BuyVGAylSCDitLw1BFHZXkalrm5NwftM/3A77QQFHTaFxQc8rJnhFpeQDab9HfcMRSIcFXB/i9Ripb6xNxfLJaGNnkBYCNsqSBkiq9k9tLGLe5zFG42FlGSpzwx9gf0qS/0+XTY4ojIjMfnV4W3KeeOfcV0WucylZi2iST2nnMynLbAjNjB/p6U22tmeRrdlzLLGSFfAweSCD+FF0qva/bYyCGwkygjAPZvxqa9u1uYori1QrLABhGw2FH6mp66miY2xu5LBHeNGF4R5LCXBC/4/8A1q0vDHi2fSY7pZpGkNyGjDsoPl7vvN9c4P8AKqEKJrDtBaJBDckExrI2FZh/Ap9+cZ71niGIRRRtFMlwJGErEZUHsB/XNWpNbCcYyVpLc6KS+uLqzuhBOLl5AY5JB/GM5zuPJJIGKxLuZ3kYlt1zxgleWGO59f8ACr2jXscd1BC0SyszAIhOEDZyG9zW5No1vFaXN3dSuLuBSxifkyDueOAOcD6VTXMgjUjTfKJo4jl0m2F9cRySxqSFhcRuy5GVJPBf09hT7dhcXEjWpaWE7o1RiM477u3pzXJJcQrLg/u4ZMjY/wA230wfX3rf07TDB5c9ldGOVm2GTqijGT8wrNSbNXaGtxb20a0jRHEijCtHnoDzkZ7jHSoWaa9kiaXZcSKChZT8+0jgH171qapc3GoWUdrdFQ1pHshKDqgYnDep5OKzra4KnCn95xh84BGaicdTNz+8XSJJluTC/mFHjbAH94LwPp3zW3bCa3VJAzNuUGOReV3EDI5rOtnzqFyrqY03E4YcKQOn49KLRpJrKWGTIn3NJFgfMuDgr9P/ANdQotIOYsX0TRuHKhEuFbb3II6qaJtNf7HE+0uzdBE+flHPTqD6VNFeRXOlOxZHb0ZPmB7AN39agsLmWGaKMSlYjuYRE/Kdw2t9DQlZlxkwcw6nDbSbClyrmNmA79j+PerVtLFbSTb0hE4ZV5jyCoHIINQkxxWUflSr9olJWXsUx0BPTn/JrM1Ay4lE6Sq6YHmqcqD7t0qn+I0+Y3NUtILv7NqGnusUasBLtfd5ZP8AFg845wcdKoXhurSV7cKtxEx2qvfHUhT2+tSaPbnZ5gl82EKpki6Ahj0z/P3q3q8HlBWj2zRM4jV8gFSF5T/69K19Q5rOxhpqCRPOksMhhmX5FZslfbPfpSWdwXt0Wwg8t1YsxZs7kHZh7fyqaP7JcQJE8iRuhLK0meBjoKW3WJ1EUMQjBIbzBzu57H8/ypJMtW3JrN3nng8oxRPv2khcorHkceh6fWtGxvbqzu2DWjzMu0tEhwQD2A+uaxnjeS+kiiJcs/lcnaGOeD+HWriX0+h61d2V1vS5VxtfO4Dj5fY4ySPerSZbdzah1OwNjLaXtlILtpdweUbBsP8AAR7e9Uzak27NbOxR1yyHnGGxnPpnv71X02YXkyxTFGO8tG4fc7HuWB4JJ5wfoKuYf7UwghWWNnO1F3R5UHkbevPpWck7kpcr0Jra4ubZChgcIgwyI2MZ7j1BFT3WzUbUy2BWSNCvmiTCuzHAO0egxVSGK0urkMoCwxpkwh9rE8naC3oO/rUt5AltfrDA8U8TMMFjtU8Dn2PrTWi1Gn23KdjJ9kuIUinaKTBOPTHQAev+NacF5DeMIEMaMzHLPksGPO0qewPFUL22hF00ckXkvGWCsD6Anr37fWs+SKaJLMXccjEsYyo4f1yG9eaexokpbnSxSXdwkiTsSFBZcHn5eDt96ntry1SKOFpwu+3EDIzFAWLZ54x3zVTTY5HgVJi8moDPnLK+CB0GOMfjnNDQS3TvBJGpu1baTkKx7YIPBIqbtbE2SdiG1kgubWWwlEUUytlZ2OCvJDZHXB4PFZb28UMEF3aXDxkMUkiYYw2BypHDA1JOohvZoAEG1WPmFcNk/wB32GDS6jd25e2iEzzIYzjI4X6cUmjTroalpNeXaJPOY7mM5DB5B8hOeB6HjNT2NxFZauAcaZeBSpz80bHHcdgaxLWfyYmj8uSVPNRioU8DoMEfX0rdunh1SG3eKNrp0UCV5mDEn0JABxijUTVtOhVgWa01b7VZsgYENukT5c91zyMfX1rcS9S6k8q7hkIcFtpAYYXsMcHGMc9uazfs0CW0FxaTNbCRSroxJViP6H+lSr5dxbJ5caLcRIc5/u+4HXr1pq4pe8bCaM8UqC0k2M6h2iUk4B4/U9KzdRkNhDi4tFEiMw355xxUMN23lmSIs0LAKVkfewwOx4wf8ag1O8QFIArzLIMiO4IJJPHB9enJptaaEKDvqQ6dfxXSM1zPsfBbCJtZmz0P9BSSWgluPNguXN0MbUEe5W68ZHTr+lNgHnWbOv7wIeY2UkxNkAA9++cVbaWDTntjFJ5F9IGYMrg5HrjsOazcb7lta2Quo20+mYdUeOWVSjFclWJ96x7XVFVAzxqUU45JbrxnHfFdddW99LGJJpEllwMuDt57g9j6VzllpgaSI26BjLlxDniQA4IptPoODutSTT7D7RcpLayRI8eTLjIyD39AK0NIiSAEzwHbnaZFIOe/I61FbWUqXCm0FzbsGJJP3OO3qfTFbWUUQ+dDHEqLgOvrnuPUc1KQpVGtC3ZxvbO06TM0UajG3PQ+v8sVBqZe3liCgCYMXBxyOeM019RVplgt/LO47towu4AE9fT29qmnkjvbl45MF3TzE9GwMnmrWxjre7KzCApIs4VUYZjIPzZ9vbrVS/tJI7lkttyTTKkmCd2QASRuzzWxZyNCFEgSSNWDEEKSCecgH2qPX7dDNDd2JjVSfLZQMBR349+arpoJTtKxjW9xI0BMqrKWIG5f4R64qvfeXHCk9oCk+Sq5cgA44z7Vfdo7a9lEedhU4B4YDuPT6GquqJBDDbyzOXjk8xzHHyY8dOB1z6VmuxvF3ZRin8Rzhd508oFLdZMD6n+VaPh2bUdLFw+oxI6zTtlYnI2HYAM+vTg1hNrluhWeN7mayyMmO2f7pPQjHsfpXUaRrVrqUXlWSXvlRSkR+dGwChgeNp68mtklbUmXK7W1PATMjw+euA+QGVBkemcdqLqeS2eABihUAqd27APSsiJit055IOckdxTrhizPFHkrGNytgdDyQceldXJpc8KNbU3dIkil1BbO4mEULniQkHnt/k1JEJLeS7tJ1Rxuxk4yp7EEfXp3rm7eTzmWPaznsFGT+VdLZE3MSRMCoijCM2PujPXHcjms7HWqltSudyyvFwqxt8u3pwfX+tXraYPKWQbZCQG+bkjPBBPcVVmiGF2MQVUKSBwxz1piOka5lR3AGOeBmlaxspJoutc3IvRFHcK0sbYjVgM5PHB9ac0N7ZKYbvMV0n7va75LRt2HtVVLdby3RrFjJdIpJXGGCDknPtViw1FVlb+0ALlXXD+Zn5QDxg0r9wur3IZrZTdRpCQAeNp5Ax1GR1HvV6xe7jna0UjcBxCPucj8ulXWtGZ5JLdIo4N3moA+dnGMewwePWqo09ntYri2KspkKMxG0ew5pJa6ESq3Wo6OXZcKQ/kOBgZBwfXI7Uy8aS2n2TRIqFvMiwdyjJ6hvSpNRt5UhVZPllXDbe+COoPc1n3WsmW1jstQfctshVG2fOq/3fcc1vGm5HFWxHKLHqWdQMV0GG1iZZCSxZewOO3uK6HU5kb7LfaXnYH25JAbPTJA6e+euK4VZ0iiCQncWzhBzz/hWrp0rGyMDylQxJIK9CR69zx0ocNLGlGrzam+sitbOnnR4jYRIyYBI55I7jOaS+xKsTW4L7BtIbPIGMkn15rNSZ/sts8rqogbagA+YN159enetB7hbq2FwgVZQ+12Hyg8d/cmsHHodiZFcvcW5aVgTG58lscqzAZxx7VXGqSxniQwg/Lsh+UHPHI9KrSXrGzkhzuUv5qgg5B/wxTluEheASw5Pl7vnzyxHQjsBnNSlrc3Rv213bebGttFK0sj/MF6hcdj07ZrWlubeWzkgnLbZhl5UXIYjpx6j1HrXMaVI0RkZdoRsxurrwFIyCGP06itWyFqupQ+TKWZQsgGPlfA5Xnvnp2q32REkjEuNzRhIlwclcjkkc8U/T9XnS2FrGmfLIZAV5yBwfwBJqeURvOLmOUQv5rpIjccHkMf5YrPskLyyomHdlABX+P2+tTGNmXdWNTzLed7cwSAXLHDqTsbfnrnoV+uKsXttdWccMkdwrtDgElQxGeQR64/SsK2lkt5PLKoHOQWZAfwNb8Nv/aFjdSxSLCbQ8gDCk9QQfU8jFaWsDaW4+PP9oyPq6RGedVd4o0CgjuxxwpPt3q7c3Li0S4tBIFgf/WE7sZ6Eg9Pr3rOkd7qzRo4ipgR9wKjqxxkNnkdKrw3F0tu9uEZVdSrL13Ac4/OsnvYtI1vtSyXGNQbF0yZWQkFXGMjBAqzCmyWaLzDcpCxZJI+NzL2XPUEVyjSNJEsbqEQAsDnkHvVy21B7e1t5LU+XLCQ6urZySccg9OR096ktxutDo7jUheR3Ec8okjZtxLKCyAAfN9RnHFJe2eoy2cN9CI7uJskOHDMMdQw6j8awb53t7qSSWz8sz5Dqy5UNwSVPb/69afh2WS3kmEc+xZAUKYOGBGcE0aPcdrbFq31ZoLorcmWKfAyk8YwxHHJ7cZrYlSO5ad0IaQsHRlXIXjlQfT9PeqYvxKJ7S9t189DkE5O78e3HNPubF9MhhkRnubRx8s0JIC5/wACcEUJtITsZmryKgSeJsEsY5V69+49fpUUOkC5uJ4fMEJiIVHb5UHrwfmyPak1+AJDbX+92ikbb5pPKsvXGOuOOaqW8V7DBNdG5jnspfmd1kDNGSf4lPIPSnHVlLbRmrdW95ZxQm0uyqnb5TqhG4lj+TDH5Gk0zVbmJ7hJopElmwpkC+WVXpnjj8Kge8uLvT57DbJKcechTgoFP3tv8Q+nPFR+Grt7S7cSspZJGO9lPLehz/nmlOOugK7WvQ6mYII02xwx+WdjCV/lLrnGR2BGenGaw4L9vMmilQkIT+9A3eUD3+mAcV0NnaadfLndDC0g3xxxrhSe6nPPGOfzrlJbcpdXCv5sYMbxyFeVLH7ualxd0Km1qaJlgljIhO2M/NGysPmwTg8/xHHI4xg0vioiPS7coGae3OycEZwuBtYkcZye1YkUS280MU+EACkk8ZPc5Heum8QWdusCnTo0ijaIugWYurnuBnJ3cZ2k9q0WsSpPlkrFTSFgudNvJ5LuSC8WJHkuiSVQ5+Xp94ngVHHDbanJJeCDI2Lk79+1lxktnkA+uKp6T5k+yGOOVlkJQCNh+9LEEg+nQdakhtJINc2yOltcsXSRZs/JkEHdj9KaXMhaJvU6aBI101rtJ/lZtilfnbnHfP5Z6Vntc3EdlHLBF+9gc7igH3fcdc571TNtcaLCIPPDMqFkz3HHX1rT07fcb4nRk86MOAXVQfTPPTNRKNnYV1bmWog1J52Rp3e3ZwCsgGQGPripppbmLT55N0NwxmAZ2f5zkfMAvp33VUhit7qYWyz+XsfzNwTO3AwfbpUtrLPaT28cM0MqTAzInBAJyBkdiQP1qOXuTdN2RTsJYp76PKQKYCFSO4GEYckgn3Pf3rfkeK3mEuQyEYiA+dF9ie1VrX7LKokmjUSRsRIioCRnuOMED86t3AjggRbO5WSCZwvzLgMcnHHr/jRy8qHKV3oOMqyxq4lQO3uMD+7nPSmvqSxQxpexqxjPyhTlW545HbPeqsbGO5jW4iXcrYlMWGLKfve2as38/wDxKbmKZY5I0kBRWTaR7g9s+lLW1zO13YmulW+EzPNC8zRjaN+WLAdMeh/TFZV1Ay6etw8axiEb2wANh9xnngdabYsq3UJPlzkDiCZSyoMnnP8AjVi4CSMGZRuky7DGAP6YpWb1NEnB7lGyvtEmV5TNYRb5DJK7TbCxx2UHocdhzXV6NNbXLtJp8kF3CjbCVYPj2/SvPob/AEfTvNW2kDR72O37MZETPVVOORnmul0DV7FnmS1tIpI8DEqqU+bvwPyx7VVzN3ktD5n8zMfAYlenv7VasLhvIkZSqTKcqTzkEYIqlLC8BaNXGXwODwB6/rSW0whgkgkVQzdW7+2PavTTs7HzMtdjVs3jtykkaskrEgdh9R710NhfwW0iGVJHKjKMj7dpPfvx7VxEbt5i5LEp3GSMVprPvDjeg7n/AGama00NqcrvU6i5+zup+y3DsoG5dxxlu4H9KzmfMfIJz1Df561U0+UKoKuAxyG3jj2INWLzfbSiNNpVhu3DlR6896522z0IaaDo1xALiCT/AFfyshODk+ntitG31GCayEM20eUpMQIzzn7ufzrIt1MlwkQRiScDafXvU91YpHOFWRXUEEunQ+xHY1MU7aGl1szZs7nyt7QTI1rcLiWEkkK309qsXV3Jb2YXCmFwPMCOSpPZvY4rEkeSJQF+769x7VMCZHWWaNiCpARDw+O4zTUbvQzkXr4zXFh5lxLE7ShlDn7wK46EVi2uqf6PJHdxQTgjADjB475xnPvVudo5wtzg537ZAqgBR6gVgaiPKmlj4RlbC88+vNddOXJseZiIKWhLFYi6eeO1ESz7fNRS2BjrhffGeK1dLeacK0rERxYD+Wo3R54BI71i2KyB2iZgk0ZyWboQe2e1dDpEouRK0xdZmJZ2QgBh24+tEtdQovlfKaF7DJLmVQXjwAfl28genrVSCcxWc0WCTNjKyD5cjoR71v6aokjkt3LCfb5kLqMq7d+PXGawNVt2tyWc4OcK2flauZ73PSozvoUzLJHO00X7qQKRz0z60+zVJpHEk481xxLLk7T6n/GorzzLm6eIblLjeQrDG4DJqJZozJHgBBs2nB+970oW6nXpo+pqxyzWrTW4lUpjDCN8xsPYmtdnW7sIytwTNbjhcAFEz1JqjpHhy7v4ZbgypaacR8s8ynaz9VQDrz61LpbRJIlkbtreRwy70TdvboEb/Gq5O4e0UtIvVEWluUuD9qjM0LH972IUnqPfNQXKfZLyMJMJFXLpIhwwParRs2itPO89mikJPlqCS4XPIJ9+tUfmaIgx4IIY89B6YqVpoWpNkn2iRCsp2vKvCswzj/OatzP5EbWjhpELq7yHO08cDHfGazljLujK+wFj8o5IHr9KuSyyoiFjIHzkRleCf7xz0ob5i+VI1Ip7MxiJVeQhlV2BwcZ7fhmpb9kNx/oiytFG5x5g5b0JPr0Brn7mVfLRXUx5IO1fu8dz6mrYu/PnVYI1DNgFiSSeOtS7vQErakUzMsjKMRyZKkZ5wec1G1ysrAEmOQfK5HIY56+1WL6IPdSGaVBIgAODkNxx9RVR4SwKn92d2Rzt6UnFrU2i01Y7FLUXelCO2HmbQcuHDbZOCOP5ioLJjnZjLhT0xke+PzqjpFt9ldGuC1tKyblkB+XBHGSPeuk0+5thLK7tA3IL7vnGe5BGPxFKauzNvlRHOxmtUlgdv9XtfC9McZz/AFqGLWbq12rHCyQDJ8pz8o+lJe6nDCJInS4QkEHy2wpGc5I9Kr6U0uqzX8EVxFhlBCySgFjuHCk8Z5zip5W9gT0uy3eW0d/JssRcfviZMEbgpAySQKxooprSWQPF5K55J6MP54rRtUNrqH7u7eyuFbGH4GQcYGOO2av3oluolkiEUkkQwzxnIYe4NC01ZXPbQzbC/tbfUbffC3loixpNC+1ouTkj1HYg9iRT9TniTWJTdRlgZdzDZ8jdg3B4NVrqD7QwaOEg8kmMYGPepJZ/3gjvpZDA8e1WjTuMYzTdS6KSXNzG1YfY4+UczruwfkZGH1+vYirE0n2e4nZo7eY3WVjWUA9wAeMAnt7Vl2yRxssUV1GY2CkvnaOD90j1/Sn6vsihSKQsxUnAbkA46gUKV0S7NkckdvJdiLVRPDKRhPLXhyMjBJ4GKpSJ/Z5WSGaV33ZT5OSO57ir1iYCitM08MjRklHw6SH1Bzle5/Ci6aOU4SAPcPys0WBvHpUPQHN3sYkLNaCRgskZYkEq+1gDxgj6VsT3Ok3VxKNVa6hv5ERBOGGQyDAzxyCAKht7N7lriCOKORXxskklwYyOSPfPSp4544mEeohJoX++8i+Y6Y6Y6GnGTiDabv1LIt2nskV1SeOH5twJyx+n5Vr6No7Sv5819GrSgbUUgO2f4cEY/OsnzIGVX01FgiJBZZZt/PoO4NajXUM1pHNdKWbaxWeP52yOAD+Pano3dmc5StZE19p5sp7hGjCy4OcLtDDAwR781hNoc8aQbyYZItzBuDuGf7vfmr+q6pPAqKz4imjAGGJAXseeex4qa3lj1K1uftLvDKEHkukYZH74J7E9KHZsUJSiriW6zWdyIjEjW8mGJDbtoHXBHT8am1NrG4sFNvmKbbkFVAXdzhuvXFLEPJkheazTcysT5fC5AwM+1NcQPaQSgIm5stvTkuOoPtjFQ10KvfUmsWWK1CQyyLIik5b5kJ/i+meMUt1NHc258+YqAoDoidQO+fX3NVW03ypUE6GNlJbaJCVI6jjofzq62RYXUhty1xKiiOXO4OOcn27dakfW5g+RIku7T3VcZyHkG8Y5ORWnMl0dLlSWOGNHjZCyN8wzkZFYWpRPFMs0MLKrco3XnoefXNad09zd6LcfaljScRmOORM8MQcZOeM9zRG7Nai90r+ZqE9hGrx2zuv7tH+0hUwo5GOq9uPWo9E024sL+Sdbm1aR5N5EMmERiB8oJ74Az9aoQWqR2Vrc6bbLYajGNnlyxcNgc7yfvAnofxra8ONFMLnz4TGr3W54JwAFBRQSCPcdR2q+W5jFyVj5+OMMjP5YUZXuKqHZI0YBXcCVx7duauyhZl3Imx8YIBzuNVDbgTDzTt3DA2evvXf1Pm7DXLIVBO2VRgqncE8/jWqbqEoy283ETbSqoAuzseeSfWsjcqlEmj2KGKlh9761BxHckq2Vzw/rT5mtAjFXR0QkR4stgEnJULgGtK2klmtFtiQ0SH5WY42Z/pWRYgMjkLu47+9XoI12khwMfwtWDTbud8ZK1i1NCUjUhg652qydA3vT7eURhUwQuTgsc9e9NE7bHC7eQA3HpzmmNcAr+9AVQCVG3jNHoVzNmnqJt0tQoQpOD83PDD2FZgujIYI5N7InCoD2z2qS21N4gY0lRlYgb5FDYH5cVFd3gDq8yoQeMqNu73xQ+6ErrRlq3t8yudsnlEFS4Xgem4ema5m8byZcsw5yQMZxXSRSG5hzZMY7gjaFVz+9GM8j1rKnubuWJxclWWNSOgBIPUHFdMYppHnVZy5mVYZvLmR2LlGOWx1/DNdPpEUFxv2xEOrGRDnO5fQ9q5KNVJQAMOcjJyAPat7T9S22whc4ZJCVI7cfyq+hCi+a6Ow0+QS280UiKZC25HDbWVqw9XEsdwsN0N6x7sHPUfWnRXPmyI0bOGwOTxhv8KtazcXEiRS3kWIiAhWMABgO4PrXFM9KleLRjspkgM6ECQyYKnvkcEVn8AFJUPmA5YDsK6Q29qUXMZEZX5XQ9T7g8iq+rwW0cpnFoyIYwMZJGfUdx9DSfc64z0sEU2LHFrLP5JA8xMlgozwwU9Dz17VZSx866jexSSRhhvu4YNjJ/lmseFN2GikdGPByxxj1q7ZCRXUfaXKE5ADYx7mrUr7j5WtUadrPFK8tjMWjjk+Ybv4ZPT296c0F2ghYQGUKuN8Xz98/MPWnTO15BG15HCxj+SOYLtLY/hZuhP15psl1FBAyqZYJCM5X/VkDoMeoNTsyk+pBcv5jyTTIiSNyMDGc+lV75JEiikkjlQ4KMCMcjkfjitaTUZJY0E6W8gwByucY6D29xR51jdSyLeSTRiZcElsgP2PsKncuM9TEYPJZ71VpEjPO5ecd/wBeKsWPktcrCh8mUfMwkOFwBnrTprK8iik8vDwAZ8yNhjHXnFNsJIjMWeGH7UMbJJGOAcdcd/xqvIq/UtahbXvnRLNayCRFDIwA+aP1AHXHrWfdTMzyyykuzHO1+ckdzWpHA0Mayxyr1ClNx4+n49hTZjdRtuniVsLtjZUBCntnHXHpUPyNFN3K+mXAjjaNiwjlIBQEHj1966SCxaC3ivLeVWP3WAU7h6ZBrKM5u0iWSNHWLcA8JKkHsNuOOnQVZMpgjHkyxzhsgJL8rDjPNJg3craheS2l3IiSPuHLI38JPYe3Wsq1gO9GjUbGb5lBx9KnufI+0PvmMLJEMJLEZAzdxwfyNdJYvp1xpYggs7Zp4UyZSWJkZsDg54x1xVU0nuKU2tkP0c+Y7W90Y2XOdkiZUdicjvirptw0jrp12YHP/LJjnKjnlu474rLhlazZYuF7BA54H0NMma1kXdbkRueJIyxG70K1M9RO+5YDC182R1V2yvmRBsEt6gfTrTLW7tC8Sl7mONpQJSSGUL7ccYPepLphetHFcXBjSZRte5jUEnHHzL2rJfTL2EjZCgQn+F87s8Dv0qb20Ljqb8LWrSP5ghaJMDchySO1a0V+MRhJUdgcIsigjHTaT/jXOWEdoJSkivHImRnAOO3ArUjs4I4HeP8AfhGJZGO1lA7MO3FO99iJblS4FxbxTbEQFG3FlcdDwOO+KgsbiS+KlYkMqHe7qfL49sdD9K1b++8mF3MUbxgc5G5SvoM/hWDBdRyy/aE2QQkhWCDnI/2R2qepUbtG5Z2cIuHa5LWUmOAFyFGMjnv1qrqKSJNF9l2StJ2xnJz05+laNo9xLbTSQX9qXVDtSdypkHP3R1Jwc1UnF1FAW1GJ5nxtikRgSh7EkdQRmm0nsRHckhne6URLZrD+7Kh4IwGVvxPP4Vp2awPHizbYjMcheN+Rz8vQdKx7FpMiWNJ3CnK8YXpyCB0zzzTvtfkM3nIrIylArcEDsKhu24ON3oa15YQXcEcbXcDRhCVLptZTk1Q03T7yBozC6qATtViRuPpVj+0IJoo1azWFhISsgyc47DP8qs3M4y0cCrJF/DkBGA+mfrVOz1JTnHQnKstruuljjmchwFbcxPTOfw71Ddxie3BDbn3bVUYGaydkst7I8DlwF3YLHKAdueauBJ1hYea+8KchlC8emam9wtymlbaWpMiyzukyrt8okfIcjj8vSpJLSKO3mkEcj+WMuyvjZ7H2NZJv5o1JjuInJwpR0yWq9JOILOR5AQkiFRtBZfXr2J96atsgfNuzIubG5kgaaFp1cZZU2ZAz1HtUMNxcCONJkWMD7zMgVc9M4x+taM13ItuCtugIxk7jjHpjoara/LJqOlXEgjl+1ykqC7DYAR2I/KpSu9DeMnazIbCWS8indNOlvbNWC+cswQrkkAoCeRn6ZrSsLEtHHLDbG7tlOxZGZo8MM5BHqPSue0+4thpl3HutwbknzC9wIxGMYCurdNpHGM+orf0tHexllt79GR2AUyEq0gCAF+exI49qqysY+0kna587gnB+lLIN9srNy3rRRXXHqeLU2Kd9n7QykkqAMA9qZbpmUR7mC9eDRRWj3MOp0OgwpPKFlG4MSDzjtV8wrEmFzyvc0UVB0w3Czwlrd3AVTJCQUyMjp6UkiBwwJPO05B7kUUUl8Jstx0EMbX3lMilGO38OKzZIVkGGzwT3oooqExbuI7MhYKxG3p7Vr3aKulw3AH7ydcOfXB/SiiujDnBit0YTqFkwmVBAzj3qW1LPMQWPfp7UUU3sVDc0YJXTaQc8jr34rrJU+0WkPmsxUHAXt0oornfU7+xk2WEjmAAPz7eeeMVpaXELtTazlmifIPPIx6GiisYbG0ilNCqXfkclEYKueoHpVyeCOJURVBEkfmHPXIYjg0UU0aLYltpWtLTzIMLk7WUjKsOnINUbxFzKVG1S33B938qKKTGi22TqEqknBUnjj7o4rMgmaKQcK+7j5xnqKKKb3HDYsKfJlKoAFMXIrQ0aGG/vYY7qFH3SpHu6EDIHaiipkavZhe20dt/aCxgkQSiNNxzgZP8AhT0maezcygGSIKFkAw3pzjr+NFFMSLFvLJLaHznMnk52bgD1HNRSNunXIU7mVTx2oopPYsz9ft44WDIDy7DBORxRoN9PBMFibaDyOOh9RRRUx3NGk6ept3uoTXEtoLlY5wQAQ69ecdqbc2scV7M0RZCuMYPTnFFFFTcnZaFq3ijkkkVo1+XDg4557fStW8hS2EXlAfNEjHPr1ooqVsR1MaG7mETEkN5ZyAQCDg8Z9avNdOWFwVjMpxklRzmiilHqVIueVHdW108iAfuWfaowAa4aMmG5dY+FLZxRRTl0NKezNCCd11OJFO3bnaR1HHau1WVxZHLFvLYbc+4ooq4mVXcmxHvvI1hjXYDtYZyMfjWTqcSR3bYXcMqcMSc5FFFRPYIdSHVoIYrSCaKMI7E5AY44/GrciLNopd1BbKJk8nBGetFFQhz6DbG5lS4MJIdJQsZ3DJA9j61tW87oPKIDxsGBVxnpRRVx2Mp7sw5beM3rZBwHKAZ4ArR1APZaWlxbyyK43rgnIxj0ooqI7s16Fa8UQaiUQfu3KgoeVwQM8VqWVlA1lbv5YG9irAdCCKKKuG5EnZIwrvS7RZ4pvJRpd7fO6hj8p46it3Ro1voV88DJViSoAzzRRQlqypfCf//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Erythematous to violaceous papules with fine scale are present in this patient with a lichenoid drug eruption.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lichenoid drug eruption",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A lichenoid drug eruption manifesting as violaceous and hyperpigmented papules is present in this patient with dark skin.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lichen planus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 387px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lichen planus is characterized by flat-topped, violaceous papules.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Andrew Samel, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_17_34074=[""].join("\n");
var outline_f33_17_34074=null;
var title_f33_17_34075="NRTI resistance summary";
var content_f33_17_34075=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F69695&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F69695&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    NRTI resistance summary",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       NRTI",
"      </td>",
"      <td class=\"subtitle1\">",
"       Mutation",
"      </td>",
"      <td class=\"subtitle1\">",
"       Cross-resistance and replication capacity",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"3\">",
"       3TC, FTC",
"      </td>",
"      <td rowspan=\"3\">",
"       M184V",
"      </td>",
"      <td>",
"       &darr; Susceptibility to ABC, ddI (both still active without TAMs)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &uarr; Susceptibility to ZDV, d4T, TDF",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &darr; Replication capacity",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       ZDV, d4T",
"      </td>",
"      <td>",
"       TAMs",
"      </td>",
"      <td>",
"       &darr; Susceptibility to all NRTIs depending on number and specific pattern of  TAMs",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       ZDV/ddI, ddI/d4T",
"      </td>",
"      <td rowspan=\"2\">",
"       Q151M, T69ins",
"      </td>",
"      <td>",
"       Q151M: Resistance to all NRTIs except TDF",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T69ins: Resistance to all NRTIs with &ge;1 TAM (41/210/215)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"3\">",
"       TDF, d4T, ABC, ddI",
"      </td>",
"      <td rowspan=\"3\">",
"       K65R",
"      </td>",
"      <td>",
"       &darr; Susceptibility to TDF, ABC, ddI (and 3TC, FTC)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &uarr; Susceptibility to ZDV",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &darr; Replication capacity",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       ABC, ddI",
"      </td>",
"      <td rowspan=\"2\">",
"       L74V",
"      </td>",
"      <td>",
"       &darr; Susceptibility to ABC, ddI",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &uarr; Susceptibility to ZDV, TDF",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_17_34075=[""].join("\n");
var outline_f33_17_34075=null;
var title_f33_17_34076="Prim resect met br ca";
var content_f33_17_34076=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F59007&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F59007&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Large retrospective series of resection of the primary tumor in women with metastatic breast cancer",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\" rowspan=\"2\">",
"       Series",
"      </td>",
"      <td class=\"subtitle1\" rowspan=\"2\">",
"       N",
"      </td>",
"      <td class=\"subtitle1\" colspan=\"2\">",
"       Tumor size, percent",
"      </td>",
"      <td class=\"subtitle1\" colspan=\"2\">",
"       Breast surgery, percent",
"      </td>",
"      <td class=\"subtitle1\" rowspan=\"2\">",
"       Clear margins, percent",
"      </td>",
"      <td class=\"subtitle1\" rowspan=\"2\">",
"       3-year survival",
"      </td>",
"      <td class=\"subtitle1\" rowspan=\"2\">",
"       Adjusted hazard rates for survival in surgery versus no surgery group",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2\">",
"       T &le;1-2",
"      </td>",
"      <td class=\"subtitle2\">",
"       T 3-4",
"      </td>",
"      <td class=\"subtitle2\">",
"       Total mastectomy",
"      </td>",
"      <td class=\"subtitle2\">",
"       Partial mastectomy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Khan, S; 2002 (National Cancer Database)",
"      </td>",
"      <td>",
"       16,024",
"      </td>",
"      <td>",
"       46",
"      </td>",
"      <td>",
"       43",
"      </td>",
"      <td>",
"       35",
"      </td>",
"      <td>",
"       22",
"      </td>",
"      <td>",
"       37",
"      </td>",
"      <td>",
"       25",
"      </td>",
"      <td>",
"       0.6 (0.58-0.65)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Rapiti, E; 2006 (Swiss)",
"      </td>",
"      <td>",
"       300",
"      </td>",
"      <td>",
"       31",
"      </td>",
"      <td>",
"       54",
"      </td>",
"      <td>",
"       29",
"      </td>",
"      <td>",
"       13",
"      </td>",
"      <td>",
"       48",
"      </td>",
"      <td>",
"       31",
"      </td>",
"      <td>",
"       0.6 (0.4-1.0)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Babiera, G; 2006 (MD Anderson)",
"      </td>",
"      <td>",
"       224",
"      </td>",
"      <td>",
"       38",
"      </td>",
"      <td>",
"       50",
"      </td>",
"      <td>",
"       19",
"      </td>",
"      <td>",
"       17",
"      </td>",
"      <td>",
"       62",
"      </td>",
"      <td>",
"       83",
"      </td>",
"      <td>",
"       NR",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Blanchard, D; 2008 (Baylor)",
"      </td>",
"      <td>",
"       395",
"      </td>",
"      <td>",
"       N/A",
"      </td>",
"      <td>",
"       N/A",
"      </td>",
"      <td>",
"       48",
"      </td>",
"      <td>",
"       13",
"      </td>",
"      <td>",
"       N/A",
"      </td>",
"      <td>",
"       27 versus 17 months*",
"      </td>",
"      <td>",
"       0.7 (p &lt;0.0001)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Gnerlich, J; 2007 (SEER)",
"      </td>",
"      <td>",
"       9734",
"      </td>",
"      <td>",
"       41",
"      </td>",
"      <td>",
"       29",
"      </td>",
"      <td>",
"       26",
"      </td>",
"      <td>",
"       19",
"      </td>",
"      <td>",
"       NR",
"      </td>",
"      <td>",
"       36 versus 21 months*",
"      </td>",
"      <td>",
"       0.63 (0.6-0.66)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Fields, K; 2007 (Washington University)",
"      </td>",
"      <td>",
"       409",
"      </td>",
"      <td>",
"       35",
"      </td>",
"      <td>",
"       51",
"      </td>",
"      <td>",
"       25",
"      </td>",
"      <td>",
"       21",
"      </td>",
"      <td>",
"       49",
"      </td>",
"      <td>",
"       32 versus 15 months*",
"      </td>",
"      <td>",
"       0.53 (0.42-0.67)",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     NR: not reported; N/A: not available.",
"     <br>",
"      * Median survival after diagnosis of stage IV disease.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_17_34076=[""].join("\n");
var outline_f33_17_34076=null;
var title_f33_17_34077="MVP complication and MR severity";
var content_f33_17_34077=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F57338&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F57338&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 477px\">",
"   <div class=\"ttl\">",
"    Complications in MVP related to mitral regurgitation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 457px; height: 319px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Among 229 patients with mitral valve prolapse (MVP), the incidence of complications was directly related to the severity of mitral regurgitation. Complications included atrial fibrillation, heart failure, chordal rupture, infective endocarditis, the need for mitral valve replacement, cerebral embolism, and cardiac death.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Kim S, Kuroda T, Nishinaga M, et al. Am Heart J 1996; 132:348.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_17_34077=[""].join("\n");
var outline_f33_17_34077=null;
var title_f33_17_34078="Bicycle helmet fit PI";
var content_f33_17_34078=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F59465&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F59465&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bicycle helmet fit",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 197px; height: 270px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A properly fitting bicycle helmet should rest just above the eyebrows and not slide around on the head. The straps of the helmet should be adjusted to form a \"Y\" just under the ear of the child. The chin strap should be snug enough to pull down on the helmet when the child opens the mouth wide.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_17_34078=[""].join("\n");
var outline_f33_17_34078=null;
var title_f33_17_34079="Interstitial keratitis Cogans";
var content_f33_17_34079=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F52648&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F52648&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Early interstitial keratitis in Cogan's syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 260px; height: 380px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The subtle stromal infiltrate&nbsp;(black arrow head) indicative of early interstitial keratitis in a patient with Cogan's syndrome is demonstrated by the narrow band of light in this slit lamp examination of the eye.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: McCallum RM, St.Clair EW, Haynes BF. Cogan's syndrome. In: Inflammatory Diseases of Blood Vessels. Hoffman GS, Weyand CM (Eds). Marcel Dekker, Inc, New York City, 2002. Copyright &copy; 2002 Marcel Dekker, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_17_34079=[""].join("\n");
var outline_f33_17_34079=null;
